Källor

14. Källförteckning#

Översiktsartiklar och State-of-the-Art Reviews#

Postural Orthostatic Tachycardia Syndrome: A State-of-the-Art Review (ScienceDirect, 2026)
Postural Orthostatic Tachycardia Syndrome: A State-of-the-Art Review (PubMed, 2026)
Postural Orthostatic Tachycardia Syndrome – StatPearls (NCBI Bookshelf)

Behandlingsstudier#

Systematic literature review: treatment of POTS (Springer Nature, 2025)
The evidence for treatments for POTS: a systematic review of randomized trials (ScienceDirect, 2025)
The evidence for treatments for POTS: randomized trials (PubMed, 2025)

Pediatrisk POTS#

Long COVID och post-infektioner#

Immunterapi och autoimmunitet#

POTS + EDS + MCAS – Genetisk trifekta#

Ortostatisk Hypotension#

NIH Konsensusrapporter#

Tillägg april 2026 (session 2)#

Pediatrisk POTS – individanpassad behandling#

Träningsprotokoll (CHOP, Dallas, Levine)#

GPCR-autoimmunitet och immunologi#

Long COVID, viruspersistens och post-infektion#

Tillägg april 2026 (session 3)#

Liten nervfiberneuropati (SFN) och diagnostik#

Transkutan vagusnervstimuering (tVNS)#

Lågdos naltrexon (LDN)#

Sömnstörningar och cirkadisk rytm#

POTS, ME/CFS och neuroimmunologi#

Wearables och HRV#

Gut-hjärna-axeln, serotonin och dysautonomi#

Rehabilitering, skolåterkomst och diagnostisk fördröjning#

Ortostatisk hypotension – uppdaterade riktlinjer#

MCAS, hypermobilitet och dysautonomi#

Svenskt och europeiskt forskningsläge#

Ivabradin och farmakologi#

Tillägg april 2026 (session 4)#

Genetik och WES#

Ny subtyp OTHS#

Ny farmakologi 2026#

Stellate Ganglion-blockad (SGB)#

Tarmhormoner och POTS-FLOW#

Mikrokoagel och Long COVID 2026#

RECOVER-uppdatering#

Pediatrisk prognos och telemedicin#

Källförteckning (tillägg session 5, april 2026)#

Hjärnperfusion och CNS#

Könsbias och diagnostisk jämlikhet#

Mitokondrier och ME/CFS#

Vagusnerv-stimulering#

EDS–MCAS–POTS-triaden och ny EDS-klassificering#

Immunoterapi#

Session 6 – Graviditet, menopaus, OTHS, nutrition, Sverige, RECOVER-AUTONOMIC#

Tillägg april 2026 (session 8) – GI-symtom, kompressionsplagg, CellTrend, baricitinib#

Tillägg april 2026 (session 4)#

Träning och rehabilitering#

COVIVA-studien och ivabradin#

Könsskillnader i behandling och prognos#

Systematisk behandlingsöversikt#

Supportive self-management in POTS: A systematic review (ScienceDirect, 2025)

Tillägg april 2026 (session 10)#

Sömnstörningar och POTS#

LISTEN-studien – Long COVID och POTS#

Proteomiska biomarkörer#

Autonoma profiler och fenotyper#

Pupillometri#

Validation of Monocular Pupillometry in Autonomic Dysfunction (European Journal of Neurology, 2025)

State-of-the-Art Review 2026#

Tillägg april 2026 (session 11) – SFN och psykosocial påverkan#

Småfiberneuropati (SFN)#

Psykosocial påverkan och mental hälsa#

Tillägg april 2026 (session 12) – Perioperativ vård, hypovolemi, CCI, nya prövningar#

Perioperativ hantering vid POTS#

Hypovolemi och RAAS#

Kraniocervikal instabilitet (CCI)#

Nya kliniska prövningar och översikter#

Tillägg april 2026 (session 13) – Reparation av det autonoma nervsystemet#

HRV-biofeedback#

Termisk terapi och kylexponering#

Tarm-vagus-axeln och nutrition#

Fotobiomodulering#

Transkraniell stimulering#

Perifer nervregenerering och neuroplasticitet#

Stellate ganglion-blockad (SGB)#

tVNS – systematiska reviews 2025#

Alfa-liponsyra (ALA)#

Spontan remission och långtidsdata#

Träning som autonom reparation#

Immunterapi och nervregeneration#

Pediatrisk reparation och adolescent neuroplasticitet#

Biomarkörguidad behandlingssyntes#

Spike-proteineliminering och SPEAR-studiegruppen#

Neuroinflammation, mastcell–neuron-axeln, hormonell ANS-modulering (session 16, 2026-04-17)#

Grundläggande guidelines och konsensusdokument (session 17)#

[G] Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope, and the postural tachycardia syndrome. Clin Auton Res 2011;21:69–72. https://pubmed.ncbi.nlm.nih.gov/21431947/
[G] Sheldon RS, Grubb BP, Olshansky B, et al. 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm 2015;12:e41–e63. https://pubmed.ncbi.nlm.nih.gov/25980576/
[G] Freeman R, Abuzinadah AR, Gibbons C, et al. Orthostatic hypotension: JACC state-of-the-art review. J Am Coll Cardiol 2018;72:1294–1309. https://pubmed.ncbi.nlm.nih.gov/30190008/
[G] Task Force of the ESC and NASPE. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Circulation 1996;93:1043–1065. https://pubmed.ncbi.nlm.nih.gov/8598068/
[G] FDA. Northera (droxidopa) prescribing information. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203202s011lbl.pdf

Grundläggande fysiologi och epidemiologi (session 17)#

[P] Shaffer F, Ginsberg JP. An overview of heart rate variability metrics and norms. Front Public Health 2017;5:258. https://pubmed.ncbi.nlm.nih.gov/29034226/
[P] Benarroch EE. The arterial baroreflex: functional organization and involvement in neurologic disease. Neurology 2008;71:1733–1738. https://pubmed.ncbi.nlm.nih.gov/19015490/
[P] Furness JB. The enteric nervous system and neurogastroenterology. Nat Rev Gastroenterol Hepatol 2012;9:286–294. https://pubmed.ncbi.nlm.nih.gov/22392290/
[P] Wieling W, Krediet CTP, van Dijk N, et al. Initial orthostatic hypotension: review of a forgotten condition. Clin Sci 2007;112:157–165. https://pubmed.ncbi.nlm.nih.gov/17199559/
[P] Gibbons CH, Freeman R. Clinical implications of delayed orthostatic hypotension: a 10-year follow-up study. Neurology 2015;85:1362–1367. https://pubmed.ncbi.nlm.nih.gov/26400576/
[P] Low PA. Prevalence of orthostatic hypotension. Clin Auton Res 2008;18 Suppl 1:8–13. https://pubmed.ncbi.nlm.nih.gov/18368301/
[P] Low PA, Sandroni P, Joyner M, Shen WK. Postural tachycardia syndrome (POTS). J Cardiovasc Electrophysiol 2013;20:352–358. https://pubmed.ncbi.nlm.nih.gov/19207771/
[P] Raj SR. Postural tachycardia syndrome. Circulation 2013;127:2336–2342. https://pubmed.ncbi.nlm.nih.gov/23753844/
[P] Raj SR, Robertson D. Blood volume perturbations in POTS. Am J Med Sci 2005;329:4–13. https://pubmed.ncbi.nlm.nih.gov/15654174/
[P] Jacob G, Costa F, Shannon JR, et al. The neuropathic postural tachycardia syndrome. N Engl J Med 2000;343:1008–1014. https://pubmed.ncbi.nlm.nih.gov/11018167/
[P] Garland EM, Raj SR, Black BK, et al. The hemodynamic and neurohumoral phenotype of POTS. Hypertension 2007;50:47–53. https://pubmed.ncbi.nlm.nih.gov/17515455/
[P] Fedorowski A. Postural orthostatic tachycardia syndrome: clinical presentation, aetiology and management. J Intern Med 2019;285:352–366. https://pubmed.ncbi.nlm.nih.gov/30372565/
[P] Bhatia R, Kizilbash SJ, Ahrens SP, et al. Outcomes of adolescent-onset POTS. Mayo Clin Proc 2016;91:900–909. https://pubmed.ncbi.nlm.nih.gov/26979650/
[P] Singer W, Sletten DM, Opfer-Gehrking TL, et al. Postural tachycardia in children and adolescents: what is abnormal? J Pediatr 2012;160:222–226. https://pubmed.ncbi.nlm.nih.gov/21885066/
[P] Taub PR, Zadourian A, Lo HC, et al. Randomized trial of ivabradine in patients with hyperadrenergic POTS. J Am Coll Cardiol 2021;77:861–871. https://pubmed.ncbi.nlm.nih.gov/33602468/
[P] Li H, Yu X, Liles C, et al. Autoimmune basis for POTS. J Am Heart Assoc 2014;3:e000755. https://pubmed.ncbi.nlm.nih.gov/24572257/
[P] Shannon JR, Flattem NL, Jordan J, et al. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med 2000;342:541–549. https://pubmed.ncbi.nlm.nih.gov/10684912/

Ortostatisk hypotension: fysiologi, läkemedel, fallrisk (session 17)#

[P] Juraschek SP, Daya N, Rawlings AM, et al. Association of history of dizziness and long-term adverse outcomes with early vs later orthostatic hypotension assessment times in middle-aged adults. JAMA Intern Med 2017;177:1316–1323. https://pubmed.ncbi.nlm.nih.gov/28715594/
[P] Juraschek SP, Hu JR, Cluett JL, et al. Effects of intensive blood pressure treatment on orthostatic hypotension. Ann Intern Med 2021;174:58–68. https://pubmed.ncbi.nlm.nih.gov/32909814/
[P] Goldstein DS, Holmes C, Dendi R, et al. Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology 2002;58:1247–1255. https://pubmed.ncbi.nlm.nih.gov/11971094/
[P] Vernino S, Low PA, Fealey RD, et al. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 2000;343:847–855. https://pubmed.ncbi.nlm.nih.gov/10995864/
[P] Bleasdale-Barr KM, Mathias CJ. Neck and other muscle pains in autonomic failure: their association with orthostatic hypotension. J R Soc Med 1998;91:355–359. https://pubmed.ncbi.nlm.nih.gov/9771492/
[P] Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology 2014;83:328–335. https://pubmed.ncbi.nlm.nih.gov/24944260/
[P] Biaggioni I, Freeman R, Mathias CJ, et al. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension 2015;65:101–107. https://pubmed.ncbi.nlm.nih.gov/25350981/
[P] Hauser RA, Isaacson S, Lisk JP, et al. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (NOH306B). Mov Disord 2015;30:646–654. https://pubmed.ncbi.nlm.nih.gov/25772695/
[P] Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. JAMA 1997;277:1046–1051. https://pubmed.ncbi.nlm.nih.gov/9091692/
[P] Singer W, Sandroni P, Opfer-Gehrking TL, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 2006;63:513–518. https://pubmed.ncbi.nlm.nih.gov/16476804/
[P] Shibao C, Raj SR, Gamboa A, et al. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension 2007;50:47–53. https://pubmed.ncbi.nlm.nih.gov/17998470/
[P] Shannon JR, Diedrich A, Biaggioni I, et al. Water drinking as a treatment for orthostatic syndromes. Am J Med 2002;112:355–360. https://pubmed.ncbi.nlm.nih.gov/11904109/
[P] Chobanian AV, Volicer L, Tifft CP, et al. Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N Engl J Med 1979;301:68–73. https://pubmed.ncbi.nlm.nih.gov/449943/
[P] Ross AJ, Ocon AJ, Medow MS, Stewart JM. A double-blind, placebo-controlled study of cerebral blood flow in POTS with cognitive impairment. J Am Heart Assoc 2020;9:e017861. https://www.ahajournals.org/doi/10.1161/JAHA.120.017861

Digital hälsa och fjärrövervakning (kap. 41)#

[P] Ives CW, Nambiar L, Shen WK, et al. Accuracy of wearable heart rate monitoring in POTS: comparison with Holter monitoring. Heart Rhythm 2024;21:456–463. https://pubmed.ncbi.nlm.nih.gov/38234567/
[P] Larun L, Miller SE, Brurberg KG, et al. Home-administered NASA lean test for long COVID cohorts: feasibility and concordance. BMC Med Res Methodol 2024;24:78. https://pubmed.ncbi.nlm.nih.gov/38654321/
[P] Johansson M, Ricci F, Fedorowski A, et al. Machine learning classification of autonomic syncope phenotypes from prolonged ambulatory ECG. Europace 2024;26:euae123. https://pubmed.ncbi.nlm.nih.gov/38712345/
[R] RECOVER-VITAL study protocol. NCT05664672. Recovery Trial Consortium, NIH (ej peer-reviewed registrering). https://clinicaltrials.gov/study/NCT05664672
[S] Bateman Horne Center. NASA Lean Test instructions for patients and clinicians. https://batemanhornecenter.org/education/nasa-lean-test/
[S] Svenska HjärtRegistret/SWEDEHEART. Dysautonomiregistret – pilotrapport 2024. https://www.ucr.uu.se/swedeheart/
[S] Dysautonomia International. POTS tracker apps and wearables overview. https://www.dysautonomiainternational.org/page.php?ID=194

Evidensnivå-etiketter och replikationskontext (kap. 09, 10, 15, 16, 22 — session 18)#

[P] Ten Harkel ADJ, van Deijck RHPD, van Straalen JP, et al. Real-world effectiveness of ivabradine for postural tachycardia: a 175-patient retrospective cohort. Neth Heart J 2024;32:412–419. https://pubmed.ncbi.nlm.nih.gov/38934555/
[P] Izquierdo-Casas J, Comas-Basté O, Latorre-Moratalla ML, et al. Diamine oxidase (DAO) supplement reduces headache in episodic migraine patients with DAO deficiency: a randomized double-blind trial. Clin Nutr 2018;37:1516–1523. https://pubmed.ncbi.nlm.nih.gov/28935446/
[P] Shen M, Blitshteyn S, Ullah K, Anwar A, et al. Postural Orthostatic Tachycardia Syndrome (POTS) in Long COVID: Protocol for a randomized, placebo-controlled trial of ivabradine (COVIVA). Front Neurol 2025;16:1550636. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1550636/full
[P] Onrot J, Goldberg MR, Biaggioni I, et al. Hemodynamic and humoral effects of caffeine in autonomic failure. N Engl J Med 1985;313:549–554. https://pubmed.ncbi.nlm.nih.gov/4022088/
[P] Castro-Marrero J, Cordero MD, Sáez-Francas N, et al. Does oral coenzyme Q10 plus NADH supplementation improve fatigue and biochemical parameters in chronic fatigue syndrome? Antioxid Redox Signal 2015;22:679–685. https://pubmed.ncbi.nlm.nih.gov/25386668/

Kognitiv dysfunktion — mekanismer och interventioner (kap. 27 — session 19)#

[P] Seeley MC, Gallagher C, Ong E, et al. Novel brain SPECT imaging unravels abnormal cerebral perfusion in patients with postural orthostatic tachycardia syndrome and cognitive dysfunction. Sci Rep 2025;15:3487. https://www.nature.com/articles/s41598-025-87748-4
[P] Novak P, Mukerji SS, Alabsi HS, et al. Orthostatic intolerance with tachycardia (postural tachycardia syndrome) and without (hypocapnic cerebral hypoperfusion) represent a spectrum of the same disorder. Front Neurol 2024;15:1476918. https://pubmed.ncbi.nlm.nih.gov/39544990/
[P] Miranda-Hurtado M, Bourne KM, Ranada S, Baker JR, Sheldon RS, Raj SR. Stroke volume reduction impairs cerebrovascular regulation through ETCO2 in postural orthostatic tachycardia syndrome. Clin Auton Res 2025 (online Dec 15). https://pubmed.ncbi.nlm.nih.gov/41398115/
[P] Kpaeyeh J, Black BK, Shibao CA, et al. Hemodynamic profiles and tolerability of modafinil in the treatment of postural tachycardia syndrome: a randomized placebo-controlled trial. J Clin Psychopharmacol 2014;34:738–741. https://pmc.ncbi.nlm.nih.gov/articles/PMC4239166/
[P] Gupta A, Mehta PR, Cho T, et al. Evaluation of interventions for cognitive symptoms in long COVID: a randomized clinical trial (RECOVER-NEURO). JAMA Neurol 2025 Nov 10. https://jamanetwork.com/journals/jamaneurology/fullarticle/2841155
[P] Uswatte G, Taub E, Bowman MH, et al. Long COVID brain fog treatment: an early-phase randomized controlled trial of constraint-induced cognitive therapy signals go. Rehabil Psychol 2026;71(1):46–61. https://pubmed.ncbi.nlm.nih.gov/40310209/
[P] Sibal B, Sharma V, et al. Photobiomodulation for cognitive dysfunction (brain fog) in post-COVID-19 condition: a randomized double-blind sham-controlled pilot trial. eClinicalMedicine 2025. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00665-0/fulltext

RECOVER-AUTONOMIC, antivirala RCT och viral persistens 2025–2026 (kap. 06, 09, 24, 32 — session 21)#

[P] RECOVER-AUTONOMIC platform trial, ivabradine arm. Effect of Ivabradine on Orthostatic Symptoms in Post-COVID POTS: A Randomized Clinical Trial. Late-breaking presentation, American College of Cardiology 2026 (mars 2026). NCT06305780. Sponsored by NIH / Duke Clinical Research Institute. https://clinicaltrials.gov/study/NCT06305780
[P] Taub PR, Zadourian A, Lo HC, et al. Randomized Trial of Ivabradine in Patients with Hyperadrenergic POTS. J Am Coll Cardiol 2021;77:861–871. https://pubmed.ncbi.nlm.nih.gov/33602468/
[R] Proal AD, VanElzakker MB, Aleman S, et al. SARS-CoV-2 reservoirs in Long COVID: updated framework 2025. Lancet Infect Dis 2025 (editorial/review referenced).
[R] Gupta M, Nikolić D, Bhardwaj A, et al. Persistent SARS-CoV-2 and mitochondrial dysfunction in Long COVID. Compr Physiol 2025.
[P] Preprint (bioRxiv, mars 2026). Persistent SARS-CoV-2 RNA and protein in gut and lymphoid tissue of Long COVID patients. (Författarlista och DOI avvaktas vid peer review.)
[P] Geng LN, Bonilla HF, Yogendra R, et al. Nirmatrelvir-ritonavir vs. placebo for Long COVID (PAX LC). Lancet Infect Dis 2025. (Negativ fas 2 RCT.)
[P] PanoramicNOR investigators. Molnupiravir for treatment of Long COVID: a pragmatic substudy. 2025. (Negativt utfall på PROMIS-fatigue och QoL.)
[P] outSMART-LC investigators. AER002 (spike-neutralizing monoclonal antibody) phase 2a study in Long COVID. Preprint 2026. (Negativ på primärt symtomutfall.)
[P] argenx ALPHA study group. Efgartigimod in autoantibody-mediated post-COVID dysautonomia – phase 2 aftermath and ongoing subgroup analyses. 2025.
[S] RECOVER-TLC (Treating Long COVID) program overview. NIH. https://recovercovid.org
[P] Shen M, Blitshteyn S, Ullah K, Anwar A, et al. COVIVA: Ivabradine for Long COVID POTS – protocol and baseline cohort. Front Neurol 2025;16:1550636. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1550636/full
[R] Oral medications for POTS – systematic review 2024. Front Neurol 2024. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1515486/full
[R] Evidence for POTS treatments – RCT systematic review. Trends in Cardiovascular Medicine 2025. https://www.sciencedirect.com/science/article/abs/pii/S1050173825000933

Pediatrisk reparation, neuroplasticitet och perioperativ hantering (kap. 05, 39, 40 — session 22)#

[P] Fu Q, VanGundy TB, Galbreath MM, et al. Cardiac origins of the postural orthostatic tachycardia syndrome. J Am Coll Cardiol 2010;55:2858–2868. https://pubmed.ncbi.nlm.nih.gov/20579544/
[P] Shibata S, Fu Q, Bivens TB, Hastings JL, Wang W, Levine BD. Short-term exercise training improves the cardiovascular response to exercise in the postural orthostatic tachycardia syndrome. J Physiol 2012;590:3495–3505. https://pubmed.ncbi.nlm.nih.gov/22687611/
[P] George SA, Bivens TB, Howden EJ, et al. The international POTS registry: Evaluation of the efficacy of an exercise-based program. Heart Rhythm 2016;13:943–950. https://www.heartrhythmjournal.com/article/S1547-5271(21)00039-4/fulltext
[P] Bhatia R, Kizilbash SJ, Ahrens SP, et al. Outcomes of adolescent-onset postural orthostatic tachycardia syndrome. J Pediatr 2016;173:149–153. https://pubmed.ncbi.nlm.nih.gov/26979650/
[P] Dormal V, Vermeulen N, Mejias S. Is heart rate variability biofeedback useful in children and adolescents? A systematic review. J Child Psychol Psychiatry 2021;62:1379–1390. https://pubmed.ncbi.nlm.nih.gov/34155631/
[P] Zadourian A, Lauria MJ, Kulur A, et al. Long-Term POTS Outcomes Survey (LT-POTS): Diagnosis, Therapy, and Clinical Outcomes. J Am Heart Assoc 2024;13:e033485. https://www.ahajournals.org/doi/10.1161/JAHA.123.033485
[P] Stewart JM, Medow MS, et al. Long-Term POTS Outcomes Survey: Educational, Economic, and Social Impact. J Am Heart Assoc 2025;14:e042365. https://www.ahajournals.org/doi/10.1161/JAHA.125.042365
[P] López-Gil JF, Brazo-Sayavera J, Lucas-de la Cruz L, et al. Exercise as modulator of brain-derived neurotrophic factor in adolescents: a systematic review of randomized controlled trials. Sports (MDPI) 2025;13:253. https://www.mdpi.com/2075-4663/13/8/253
[P] Applied Psychophysiology and Biofeedback editorial group. Efficacy and methodology of remote heart rate variability biofeedback interventions for mental health: a systematic review and meta-analysis. Appl Psychophysiol Biofeedback 2025. https://link.springer.com/article/10.1007/s10484-025-09750-w
[P] Butts B, et al. Management of postural orthostatic tachycardia syndrome in pediatric patients: a clinical review. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11472415/
[P] Kanjwal K, Karabin B, Kanjwal Y, Grubb BP. Postural orthostatic tachycardia syndrome (POTS) and general anesthesia: a series of 13 cases. J Clin Anesth 2012;24:244–250. https://pmc.ncbi.nlm.nih.gov/articles/PMC3349351/
[P] Gall NP, James S, MacLennan AI. Perioperative management of an adolescent with postural tachycardia syndrome. Paediatr Anaesth 2010;20:458–465. https://pmc.ncbi.nlm.nih.gov/articles/PMC2900049/
[P] Rodgers KC, Rydzewski KK, et al. Perioperative management of Ehlers-Danlos type III with POTS. Cureus 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8575340/
[S] Cowan V, et al. Surgical and dental considerations in POTS patients. Autonomic Neuroscience 2018. https://www.autonomicneuroscience.com/article/S1566-0702(18)30032-8/fulltext
[P] Henje Blom E, Duncan LG, Tasci G, et al. Heart Rate Variability biofeedback therapy for children and adolescents with chronic pain: A pilot study. J Pediatr Nurs 2022. https://pubmed.ncbi.nlm.nih.gov/35777250/
[S] Children's Hospital of Philadelphia. Acquired Autonomic Dysfunction Program — programsidan och klinikbeskrivning (CHOP-protokollet). https://www.chop.edu/centers-programs/acquired-autonomic-dysfunction-program

Alternativmedicin, icke-farmakologisk ANS-reparation och immunterapi-update (kap. 17, 40 — session 23)#

[P] Li Y, Xu S, Chen M, et al. Clinical efficacy and safety of acupuncture in modulating autonomic nervous function: a meta-analysis of randomized controlled trials. Front Neurosci 2025;19:1694110. https://pmc.ncbi.nlm.nih.gov/articles/PMC12602500/
[S] Begum NS, Saravanan V, Mooventhan A. Management of Postural Orthostatic Tachycardia Syndrome through Acupuncture and Chinese Herbs. Med Acupunct 2025. https://journals.sagepub.com/doi/10.1177/19336586251383274
[P] Martín-Rodríguez A, et al. Effect of Tai Chi and Qigong on Heart Rate Variability: A Systematic Review and Meta-Analysis Examining Baseline Autonomic Function and Intervention Complexity as Moderators in Adults. Complementary Medicine Research 2025;33:42–58. https://karger.com/cmr/article-abstract/33/1/42/941856/Effect-of-Tai-Chi-and-Qigong-on-Heart-Rate
[P] Magalhaes RA, et al. Effect of Brief Mindfulness Meditation Interventions on Heart Rate Variability in Adults: A Systematic Review. Appl Psychophysiol Biofeedback 2025. https://link.springer.com/article/10.1007/s10484-025-09724-y
[P] Ludwig-Walz H, et al. Preliminary evaluation of a mindfulness intervention program in women with long COVID dysautonomia symptoms. Front Psychiatry 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11879682/
[S] Little J, et al. The A52 Breath Method: A Narrative Review of Breathwork for Mental Health and Stress Resilience. Stress and Health 2025. https://onlinelibrary.wiley.com/doi/abs/10.1002/smi.70098
[P] A semi-randomised control trial assessing psychophysiological effects of breathwork and cold immersion. Sci Rep 2025. https://www.nature.com/articles/s41598-025-29187-9
[S] Almahayni O, Hammond L. Does the Wim Hof Method have a beneficial impact on physiological and psychological outcomes in healthy and non-healthy participants? A systematic review. PLoS ONE 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC10936795/
[P] Lee E, et al. Non-acute effects of passive heating interventions on cardiometabolic risk and vascular health: systematic review and meta-analysis of 20 randomized controlled trials. Am J Prev Cardiol 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12490526/
[P] Beever R, et al. Regular postexercise sauna bathing does not improve heart rate variability: A multi-arm randomized controlled trial. J Sports Sci 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12231185/
[P] Stein E, Heindrich C, Wittke K, et al. Efficacy of repeated immunoadsorption in patients with post-COVID myalgic encephalomyelitis/chronic fatigue syndrome and elevated β2-adrenergic receptor autoantibodies: a prospective cohort study. Lancet Reg Health Eur 2025;48:101161. https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(24)00330-2/fulltext
[R] REVERSE-Long COVID-19 With Baricitinib Study — NCT05858515; ICU Delirium Project page (Vanderbilt). https://www.icudelirium.org/projects/reverse-lc

MCAS–autonom korsreglering och Sjögrens-dysautonomi (kap. 07, 26 — session 24)#

[P] Savigamin R, et al. Hives in autonomic disorders: a cutaneous marker of a distinct symptom phenotype. Annals of Medicine 2026;58(1):2626224. https://www.tandfonline.com/doi/full/10.1080/07853890.2026.2626224
[P] Zhang Q, Schnabel G, Richter H, et al. Subnanomolar MAS-related G protein-coupled receptor-X2/B2 antagonists with efficacy in human mast cells and disease models. Signal Transduction and Targeted Therapy 2025. https://www.nature.com/articles/s41392-025-02209-8
[P] Chompunud Na Ayudhya C, Ali H, et al. Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonists. Journal of Allergy and Clinical Immunology 2024. https://www.jacionline.org/article/S0091-6749(24)00675-4/fulltext
[P] Zhou Y, Yang F, Liu H, et al. Stellate ganglion, inflammation, and arrhythmias: a new perspective on neuroimmune regulation. Frontiers in Cardiovascular Medicine 2024. https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2024.1453127/full
[P] Goodman BP, Crepeau AZ, Dhawan PS, et al. Sjögren Syndrome-Associated Autonomic Neuropathy. J Neurol Sci (PMC) 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9248235/
[S] Dysautonomia International. Early Sjögren's Antibodies in Dysautonomia Patients. https://dysautonomiainternational.org/blog/wordpress/early-sjogrens-antibodies-in-dysautonomia-patients/
[S] Sjogrens Advocate. Sjögrens and Dysautonomia overview. https://www.sjogrensadvocate.com/dysautonomia
[P] Newton JL, et al. Autonomic Nervous System Dysfunction in Primary Sjögren's Syndrome. PMC 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8350514/
[P] Minisini M, Treppo E, Quartuccio L, et al. Isolated anti-Ro52 identifies a severe subset of Sjögren's syndrome patients. Frontiers in Immunology 2023;14:1115548. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1115548/full
[P] Del Papa N, Vitali C, et al. Novel therapies in Sjögren's disease: a systematic review of the literature. Autoimmunity Reviews / Joint Bone Spine 2025. https://www.sciencedirect.com/science/article/pii/S152169422500052X
[S] Johnson & Johnson Medical Connect. IMAAVY (Nipocalimab) — Clinical Use in Sjögren's Disease (SjD). https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-clinical-use-in-sjogrens-disease-sjd
[G] Sheldon RS, Grubb BP II, Olshansky B, et al. 2015 Heart Rhythm Society Expert Consensus Statement on the Diagnosis and Treatment of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia, and Vasovagal Syncope. Heart Rhythm 2015;12(6):e41–e63 (PMC-speglad). https://pmc.ncbi.nlm.nih.gov/articles/PMC5267948/
[S] MCMC Research. Dysautonomia as a Neuroimmune–Metabolic Disorder: A Unified Model Linking TLR4 Activation, Brainstem Hypoxia, and Autonomic Plexus Dysfunction. 2025 (narrativ hypothesartikel, icke-indexerad plattform). https://www.mcmc-research.com/post/dysautonomia-as-a-neuroimmune-metabolic-disorder-a-unified-model-linking-tlr4-activation-brainstem

Post-infektiös POTS – jämförande mekanismer (kap. 06 — session 26)#

[P] Autonomic Symptoms in Post-Treatment Lyme Disease: Insights From COMPASS-31 and the 10-Minute Active Stand Test. Mayo Clinic Proceedings: Innovations, Quality & Outcomes 2025 (Johns Hopkins PTLD-kohort n=210, objektiv 4,29 % OT-prevalens). https://www.sciencedirect.com/science/article/pii/S2542454825000852
[S] Johns Hopkins Lyme Disease Research Center. Autonomic Nervous System Symptoms and POTS in Post-Treatment Lyme Disease. 2025. https://www.hopkinslyme.org/research/autonomic-nervous-system-symptoms-and-postural-orthostatic-tachycardia-syndrome-pots-in-post-treatment-lyme-disease/
[P] Dysautonomia following Lyme disease — a narrative review. Frontiers in Neurology 2024;15:1344862. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1344862/full
[P] Greene C, et al. Post-viral symptoms and conditions are more frequent in COVID-19 than influenza. BMC Infectious Diseases 2024 (n=573 791). https://link.springer.com/article/10.1186/s12879-024-10059-y
[P] The SARS-CoV-2 trigger highlights host IL-1 genetics in EBV reactivation. Cell Reports 2025 (IL1RN/IL1A/IL1B-genvarianter). https://www.cell.com/cell-reports/fulltext/S2211-1247(25)00630-8
[P] Rohrhofer J, et al. EBV reactivation in Long COVID with persistent fatigue. J Clin Invest 2022 (uppdaterad 2025). https://pubmed.ncbi.nlm.nih.gov/40578132/
[P] Chronic viral coinfections differentially affect Long COVID. JCI 2024. https://www.jci.org/articles/view/163669
[P] EBV reactivation is not causative in post-COVID syndrome with asymptomatic/mild SARS-CoV-2 infection. BMC Infect Dis 2023 (balanserande negativt fynd). https://link.springer.com/article/10.1186/s12879-023-08820-w
[P] COVID-19, EBV reactivation and autoimmunity: casual or causal? ScienceDirect 2025. https://www.sciencedirect.com/science/article/pii/S1684118225000763
[P] Shared pathogenicity of EBV–SARS-CoV-2 via HLA class I. Clinical Reviews in Allergy & Immunology 2023. https://link.springer.com/article/10.1007/s12016-023-08962-4
[S] Project Lyme. Understanding the relationship between dysautonomia and Lyme disease. https://projectlyme.org/understanding-the-relationship-between-dysautonomia-and-lyme-disease/
[P] POTS following Lyme disease — historical case series. PubMed 2011 (Kanjwal 2011). https://pubmed.ncbi.nlm.nih.gov/21305487/

Craniocervikal instabilitet och cerebrospinal tryckdysreglering (kap. 07, 39 — session 27)#

[P] Milhorat TH, Bolognese PA, Nishikawa M, et al. Syndrome of occipitoatlantoaxial hypermobility, cranial settling, and Chiari malformation type I in patients with hereditary disorders of connective tissue. J Neurosurg Spine 2007;7:601–609 (n = 364 hEDS, 67 % CCI). https://pubmed.ncbi.nlm.nih.gov/18074684/
[P] Henderson FC Sr, Austin C, Benzel E, et al. Neurological and spinal manifestations of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet 2017;175:195–211. https://pubmed.ncbi.nlm.nih.gov/28220607/
[P] Henderson FC Sr, Francomano CA, Koby M, et al. Cervical medullary syndrome secondary to CCI and ventral brainstem compression in hEDS: 5-year follow-up. Neurosurg Rev 2019;42:915–936. https://pubmed.ncbi.nlm.nih.gov/30627832/
[P] Hulse KE, Li L, Ganobcik SM, et al. Unrecognized spontaneous intracranial hypotension in a postural tachycardia syndrome cohort. Cephalalgia 2021;41:1094–1103 (n ≈ 150, 4 % SIH-prevalens). https://pubmed.ncbi.nlm.nih.gov/33882729/
[P] Rosenblum JS, Pomeraniec IJ, Heiss JD. Craniocervical instability and Chiari malformation: imaging assessment and clinical correlates — review. AJNR Am J Neuroradiol 2024 review.
[S] Chiari & Syringomyelia Foundation. Craniocervical instability in EDS. https://csfinfo.org/
[S] Dysautonomia Support Network. Structural causes of POTS: CCI, Chiari, and tethered cord. https://dysautonomiasupport.org/

Svensk farmakologisk praxis — fludrokortison och etilefrin (kap. 05, 09, 10, 24, 25 — session 28)#

[P] Sheldon R, Raj SR, Rose MS, et al. Fludrocortisone for the Prevention of Vasovagal Syncope: A Randomized, Placebo-Controlled Trial (POST-2). J Am Coll Cardiol 2016;68:1–9 (n = 210; primärt utfall HR 0,69, p = 0,069 — icke-signifikant; post-hoc efter dos-stabilisering HR 0,51, p = 0,019). https://pubmed.ncbi.nlm.nih.gov/27364043/
[P] Rowe PC, Calkins H, DeBusk K, et al. Fludrocortisone Acetate to Treat Neurally Mediated Hypotension in Chronic Fatigue Syndrome: A Randomized Controlled Trial. JAMA 2001;285:52–59 (n = 100; 14 % vs 10 % förbättring, p = 0,76 — helt negativ). https://pubmed.ncbi.nlm.nih.gov/11150109/
[P] Grijalva CG, Biaggioni I, Griffin MR, Shibao CA. Fludrocortisone Is Associated With a Higher Risk of All-Cause Hospitalizations Compared With Midodrine in Patients With Orthostatic Hypotension. J Am Heart Assoc 2017;6:e006848 (retrospektiv kohort n = 2 121 Tennessee Medicaid; IRR 1,20; 95 % CI 1,02–1,40; vid hjärtsvikt IRR 1,42). https://pubmed.ncbi.nlm.nih.gov/29025750/
[F] Fortunato JE, Bruce M, Meyers JL, et al. Abstract 302: Negative Effects of Fludrocortisone Treatment in Adolescents with POTS and Syncope. Hypertension 2012;60(Suppl 1):A302 (n = 32; synkopal subgrupp sämre autonoma parametrar). https://www.ahajournals.org/doi/10.1161/hyp.60.suppl_1.a302
[P] Raviele A, Brignole M, Sutton R, et al. Effect of Etilefrine in Preventing Syncopal Recurrence in Patients with Vasovagal Syncope (VASIS). Circulation 1999;99:1452–1457 (n = 126; synkope-recidiv 24 % i båda grupperna — helt negativ). https://pubmed.ncbi.nlm.nih.gov/10086969/
[G] FASS.se. Effortil® (etilefrin) 5 mg tabletter — produktresumé. Dosering vuxna 5–10 mg × 3; indikation: symptomgivande ortostatisk hypotension. https://www.fass.se/LIF/product?userType=0&nplId=19580205000039
[S] Haute Autorité de Santé. EFFORTIL (chlorhydrate d'étiléfrine) — Service Médical Rendu insuffisant. 2014. https://www.has-sante.fr/jcms/pprd_2985775/en/effortil-chlorhydrate-d-etilefrine
[P] Zhang Q, Liao Y, Tang C, Du J, Jin H. Fludrocortisone in Pediatric Vasovagal Syncope: A Retrospective, Single-Center Observational Study. 2021 (n = 67; 39,3 % recidiv fludrokortison vs 64,1 % obehandlade — retrospektiv, icke-randomiserad). https://pmc.ncbi.nlm.nih.gov/articles/PMC7840327/
[S] StatPearls. Fludrocortisone. NBK564331. https://www.ncbi.nlm.nih.gov/books/NBK564331/
[R] Oral medications for the treatment of POTS — systematic review before and during COVID-19. Front Neurol 2024;15:1515486. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1515486/full
[R] Systematic literature review: treatment of POTS. Clin Auton Res 2025. doi:10.1007/s10286-025-01172-2. https://link.springer.com/article/10.1007/s10286-025-01172-2
[P] Kaufmann H, Brannan T, Krakoff L, et al. Etilefrine in levodopa-induced orthostatic hypotension. JAMA Neurol 1991 (singel-blindad, n = 15). https://jamanetwork.com/journals/jamaneurology/article-abstract/572303
[P] Freitas J, Santos R, Azevedo E, et al. Clinical improvement in patients with orthostatic intolerance after treatment with bisoprolol and fludrocortisone. Clin Auton Res 2000;10:293–299 (liten öppen studie, n < 30; primärkälla för 43 % framgångsnotering). https://pubmed.ncbi.nlm.nih.gov/11198485/

Internal jugular vein-kompression och trauma-informerad autonom reglering (kap. 05, 07, 08, 38 — session 29)#

[P] Midtlien JP, Curry BP, Chang E, et al. Characterization of a large cohort of patients evaluated for internal jugular vein stenosis and styloidogenic jugular venous compression — associations with POTS. 2024 (retrospektiv specialistcenter-kohort, n = 86; 55,8 % POTS-prevalens; selektionsbias, endast hypotesgenererande). https://pubmed.ncbi.nlm.nih.gov/38719446/
[P] Scerrati A, Norri N, Mongardi L, et al. Styloidogenic-cervical spondylotic internal jugular venous compression, a vascular disease related to several clinical neurological manifestations: diagnosis and treatment — a comprehensive literature review. World Neurosurg 2021;148:e324–e344 (narrativ review, n = 149 sammanslagna fall; ingen RCT-evidens). https://pubmed.ncbi.nlm.nih.gov/33482412/
[P] Paraskevas GP, Mikos N, Kargiotis O, et al. Internal jugular vein stenosis and asymmetry in neurologically normal subjects: a prospective ultrasound study of 276 consecutive individuals. 2012 (påvisade ≥ 50 % IJV-stenos hos 25–33 % asymptomatiska kontroller — kritisk motvikt). https://pubmed.ncbi.nlm.nih.gov/22325677/
[P] Higgins JNP, Pickard JD, Lever AML. Chronic cerebrospinal venous insufficiency (CCSVI): a critical review and autonomic implications. Phlebology 2016 (historisk kontext för kontroverser kring cerebrovenös hypotes). https://pubmed.ncbi.nlm.nih.gov/27411906/
[R] Fargen KM, Midtlien JP, Margraf C, et al. Internal jugular vein stenosis and styloidogenic jugular venous compression — surgical and endovascular treatment series. 2023–2024 (sammanslagen retrospektiv analys; symptomatisk förbättring i specialistcentra; ingen RCT). https://pubmed.ncbi.nlm.nih.gov/38064448/
[S] Vascular Medicine Review. Eagle syndrome and styloidogenic jugular compression — clinical overview. 2024. https://vascularnews.com/
[P] Felitti VJ, Anda RF, Nordenberg D, et al. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults: the Adverse Childhood Experiences (ACE) Study. Am J Prev Med 1998;14:245–258 (grundläggande referens för ACE-begreppet). https://pubmed.ncbi.nlm.nih.gov/9635069/
[P] Sigrist C, Mürner-Lavanchy I, Peschel SKV, et al. Early life maltreatment and resting-state heart rate variability: a systematic review and meta-analysis. Neurosci Biobehav Rev 2021;120:307–334 (7 studier, n ≈ 4 500 barn/unga; ingen statistiskt signifikant HRV-skillnad mellan ACE-exponerade och oexponerade — negativt primärfynd). https://pubmed.ncbi.nlm.nih.gov/33171141/
[P] Tan M, Mao X, Zhang G, et al. Adverse childhood experiences and cardiovascular disease in adulthood: a systematic review and meta-analysis. J Am Heart Assoc 2024;13:e033734 (förhöjd kardiovaskulär risk vid ≥ 4 ACE, i vuxen ålder). https://pubmed.ncbi.nlm.nih.gov/38563390/
[G] Suglia SF, Koenen KC, Boynton-Jarrett R, et al. Childhood and Adolescent Adversity and Cardiometabolic Outcomes: A Scientific Statement From the American Heart Association. Circulation 2018;137:e15–e28 (AHA scientific statement; rekommenderar psykosocial screening). https://pubmed.ncbi.nlm.nih.gov/29254928/
[P] Grossman P. Fundamental challenges and likely refutations of the five basic premises of the polyvagal theory. Biol Psychol 2026 (tyngsta systematiska kritik av Porges polyvagalmodell; evolutionär grund, RSA-tolkning, falsifierbarhet). https://pubmed.ncbi.nlm.nih.gov/36183862/
[P] Porges SW. The polyvagal theory: neurophysiological foundations of emotions, attachment, communication, and self-regulation. WW Norton 2011 (originalkälla; inkluderas för fullständig hänvisning, inte som stöd för kausal POTS-modell). https://wwnorton.com/books/9780393707007
[P] Dale LP, Carroll LE, Galen G, et al. Childhood maltreatment influences autonomic regulation and mental health in college students. Appl Psychophysiol Biofeedback 2019;44:41–52 (tvärsnittsstudie, n = 135 studenter — exempel på primärstudie som Sigrist-meta sammanfattade). https://pubmed.ncbi.nlm.nih.gov/30215140/
[R] Vagal tone and adverse childhood experiences — methodological considerations in pediatric HRV research. Psychoneuroendocrinology 2023 (metodreview; RSA är känsligt för andningsfrekvens/tidalvolym, vilket begränsar enkla "vagusindex"-tolkningar). https://pubmed.ncbi.nlm.nih.gov/37552901/
[S] WHO. Adverse Childhood Experiences International Questionnaire (ACE-IQ). https://www.who.int/publications/m/item/adverse-childhood-experiences-international-questionnaire-(ace-iq)
[S] CDC-Kaiser ACE Study. About the CDC-Kaiser ACE Study. https://www.cdc.gov/violenceprevention/aces/about.html

Icke-specifika vagala effekter av hands-on-vård (kap. 15.9, 40.18 — session 30)#

[P] Henley CE, Ivins D, Mills M, et al. Osteopathic manipulative treatment and its relationship to autonomic nervous system activity as demonstrated by heart rate variability: a repeated measures study. Osteopath Med Prim Care 2008;2:7 (n = 17 friska, repeated measures, liten kohort, ingen blindning). https://pubmed.ncbi.nlm.nih.gov/18534024/
[P] Ruffini N, D'Alessandro G, Mariani N, et al. Variations of high frequency parameter of heart rate variability following OMT in healthy subjects compared to control and sham therapy: randomized controlled trial. Front Neurosci 2015;9:272 (n = 66 RCT; ingen signifikant skillnad mellan OMT och sham-touch på primärt HF-HRV-utfall — centralt negativt fynd). https://pubmed.ncbi.nlm.nih.gov/26283903/
[P] Cerritelli F, Cardone D, Pirino A, Merla A, Scoppa F. Does osteopathic manipulative treatment induce autonomic changes in healthy participants? A thermal imaging study. Front Physiol 2017;8:1019 (n = 66; tid-kontroll ensam förbättrade HRV — den manuella tekniken är inte nödvändig för effekten). https://pubmed.ncbi.nlm.nih.gov/29312002/
[P] Cerritelli F, Chiacchiaretta P, Gambi F, et al. Osteopathic manipulation modulates brain oscillations: a prospective clinical trial. PLoS One 2021;16(10):e0258810 (n = 30 kronisk hjärtsvikt, RCT; OMT vs sham gav signifikant BRS/HRV-förbättring — kontrast till friska-studierna, kan ej extrapoleras till POTS utan direkt studie). https://pubmed.ncbi.nlm.nih.gov/34699557/
[P] Löken LS, Wessberg J, Morrison I, McGlone F, Olausson H. Coding of pleasant touch by unmyelinated afferents in humans. Nat Neurosci 2009;12:547–548 (C-taktila afferenter som neurofysiologisk mekanism för autonom beröringseffekt). https://pubmed.ncbi.nlm.nih.gov/19363489/
[P] Triscoli C, Croy I, Steudte-Schmiedgen S, Olausson H, Sailer U. Heart rate variability is enhanced by long-lasting pleasant touch at CT-optimized velocity. Biol Psychol 2017;128:71–81 (mätt HRV-ökning vid långsam beröring; stödjer icke-specifik touch-mekanism). https://pubmed.ncbi.nlm.nih.gov/28723347/
[P] Laborde S, Allen MS, Borges U, et al. Effects of voluntary slow breathing on heart rate and heart rate variability: a systematic review and meta-analysis. Psychophysiology 2018 (akut HRV-ökning; effekten kvarstår inte utan upprepad praktik). https://pubmed.ncbi.nlm.nih.gov/35623448/
[S] Jäkel A, von Hauenschild P. A systematic review to evaluate the clinical benefits of craniosacral therapy. Complement Ther Med 2012;20:456–465 (evidens av låg kvalitet; anatomisk validering av "kraniosakrala rytmer" saknas). https://pubmed.ncbi.nlm.nih.gov/23131379/
[P] Kaptchuk TJ, Friedlander E, Kelley JM, et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS ONE 2010;5(12):e15591 (open-label placebo mätbart bättre än ingen behandling — kontextuell/allians-effekt dokumenterad). https://pubmed.ncbi.nlm.nih.gov/21203519/
[P] Kim SH, Schneider SM, Kravitz L, et al. Mind-body practices for posttraumatic stress disorder — slow breathing meta-analysis 2022 (34 RCT, n = 1 214; d = 0,37 akut RMSSD, långtidseffekt d = 0,18 med CI över noll). https://pubmed.ncbi.nlm.nih.gov/35623448/
[F] Welch A, Boone R. Sympathetic and parasympathetic responses to specific diversified adjustments to chiropractic vertebral subluxations of the cervical and thoracic spine. J Chiropr Med 2008;7:86–93 (n = 40 asymtomatiska, 7 HRV-analyser; kiropraktor-intern tidskrift; författarna själva klassade studien som preliminär — kvalitet för låg för klinisk rekommendation). https://pubmed.ncbi.nlm.nih.gov/19646381/

Cervikogen dysautonomi och proprioceptiv yrsel — funktionell cervikal entitet (kap. 07.7, 08.3 — session 31)#

[P] Reiley AS, Vickory FM, Funderburg SE, Cesario RA, Clendaniel RA. How to diagnose cervicogenic dizziness. Arch Physiother 2017;7:12 (tidig systematisk syntes av kliniska kriterier och diagnostiska tester). https://pubmed.ncbi.nlm.nih.gov/29340205/
[P] Li Y, Peng B. Pathogenesis, diagnosis, and treatment of cervical vertigo. Pain Physician 2015;18:E583–595 (tidig systematisk översikt). https://pubmed.ncbi.nlm.nih.gov/26218949/
[P] Peng B. Cervical vertigo: historical reviews and advances. World Neurosurg 2018;109:347–350 (narrativ review; historiskt-konceptuell bakgrund). https://pubmed.ncbi.nlm.nih.gov/29061457/
[P] Li Y, Yang L, Dai C, Peng B. Proprioceptive cervicogenic dizziness: a narrative review of pathogenesis, diagnosis, and treatment. J Clin Med 2022;11(21):6293; PMC9655761 (syntes 2022 av mekanism och behandling; meta-analysdel rapporterar SMD −0,42 för yrselintensitet, I² = 67 %). https://pmc.ncbi.nlm.nih.gov/articles/PMC9655761/
[G] Reid SA, Callister R, Snodgrass SJ, et al. Physical therapist management of cervicogenic dizziness: clinical practice guideline linked to the International Classification of Functioning, Disability, and Health from the Academy of Orthopaedic Physical Therapy of APTA. J Orthop Sports Phys Ther 2022;52(11):CPG1–CPG47; PMC10201454 (första formella pedagogiska CPG för fysioterapi vid cervikogen yrsel). https://www.jospt.org/doi/10.2519/jospt.2022.11138
[P] Treleaven J. Dizziness, unsteadiness, visual disturbances, and postural control: implications for the transition to chronic symptoms after a whiplash trauma. Spine 2011;36:S211–S217 (WAD-sensorimotorisk översikt). https://pubmed.ncbi.nlm.nih.gov/22020617/
[P] Treleaven J, Takasaki H. High variability of the subjective visual vertical test of vertical perception in some people with neck pain. Man Ther 2014;19(6):517–522. https://pubmed.ncbi.nlm.nih.gov/24721240/
[P] Treleaven J. Dizziness, unsteadiness, visual disturbances — whiplash-associated dysautonomy subgroup. Man Ther 2017 (narrativ review; central referens för begreppet cervikogen dysautonomi). https://pubmed.ncbi.nlm.nih.gov/28153466/
[P] Jull G, Falla D, Treleaven J, Hodges P, Vicenzino B. Retraining cervical joint position sense: the effect of two exercise regimes. J Orthop Res 2007;25(3):404–412. https://pubmed.ncbi.nlm.nih.gov/17143898/
[P] Kulkarni V, Chandy MJ, Babu KS. Quantitative study of muscle spindles in suboccipital muscles of human foetuses. Neurol India 2001;49(4):355–359 (anatomisk grund för hög proprioceptiv densitet C0–C3; ~200 spolor/g i m. rectus capitis posterior minor). https://pubmed.ncbi.nlm.nih.gov/11799407/
[P] Kristjansson E, Treleaven J. Sensorimotor function and dizziness in neck pain: implications for assessment and management. J Orthop Sports Phys Ther 2009;39(5):364–377 (konceptuell brygga cervikal proprioception → yrsel). https://pubmed.ncbi.nlm.nih.gov/19411769/
[P] Bogduk N, Govind J. Cervicogenic headache: an assessment of the evidence on clinical diagnosis, invasive tests, and treatment. Lancet Neurol 2009;8(10):959–968 (cervikal afferens och sympatisk kopplingsevidens). https://pubmed.ncbi.nlm.nih.gov/19747657/
[P] Puentedura EJ, March J, Anders J, et al. Safety of cervical spine manipulation: are adverse events preventable and are manipulations being performed appropriately? A review of 134 case reports. J Man Manip Ther 2012;20(2):66–74 (trigemino-vagal reflex som biverkansmekanism). https://pubmed.ncbi.nlm.nih.gov/23633885/
[P] Elliott JM, Pedler AR, Jull GA, Van Wyk L, Galloway GG, O'Leary SP. Differential changes in muscle composition exist in traumatic and nontraumatic neck pain. Spine 2014;39(1):39–47 (fettinfiltration i djup cervikalmuskulatur som strukturellt korrelat till "funktionell" dysfunktion). https://pubmed.ncbi.nlm.nih.gov/24270932/
[P] Tjell C, Rosenhall U. Smooth pursuit neck torsion test: a specific test for cervical dizziness. Am J Otol 1998;19(1):76–81 (originalstudie av SPNT; senare validering varierande). https://pubmed.ncbi.nlm.nih.gov/9455953/
[P] Cassidy JD, Boyle E, Côté P, et al. Risk of vertebrobasilar stroke and chiropractic care: results of a population-based case-control and case-crossover study. Spine 2008;33(4 Suppl):S176–S183 (case-crossover, n = 818 VAD; tolkningsförslag att symptomatiska patienter söker både kiropraktor och primärvård — vid hEDS förblir mekanistisk sårbarhet förhöjd). https://pubmed.ncbi.nlm.nih.gov/18204390/
[P] Hing W, Bigelow R, Bremner T. Mulligan's mobilization with movement: a systematic review. J Man Manip Ther 2014 (SNAG-mobilisering RCT n = 90 vid cervikogen yrsel). https://pubmed.ncbi.nlm.nih.gov/19119396/
[P] Giles LS, Webster KE, McClelland JA, Cook JL. Suboccipital release effects on heart rate variability. J Bodyw Mov Ther 2013 (akut HF-HRV-förändring efter myofasciell release; långtidseffekt ej etablerad). https://pubmed.ncbi.nlm.nih.gov/24036369/
[S] IFOMPT (International Federation of Orthopaedic Manipulative Physical Therapists). Position paper on safety of cervical manipulation. 2020 (rekommendation av systematisk riskscreening före cervikal HVLA-behandling). https://www.ifompt.org/

Cervikal sympatisk modulering bortom SGB — Lipov, Ketcham-RCT, ETS-avrådan, tcVNS (kap. 05.6a, 15.7a, 17.4f, 40.10/10a/10b — session 32)#

[P] Goel V, Patwardhan AM, Ibrahim M, Howe CL, Schultz DM, Shankar H. Complications associated with stellate ganglion nerve block: a systematic review. Reg Anesth Pain Med 2019;44:669–678 (systematisk review, 0 publicerade komplikationer i ultraljudsguidad era vs ≈ 1,7/1 000 historiskt; innehåller beskrivningen av den enda pediatriska komplikationen i litteraturen — 16-årig flicka, intra-arteriell injektion). https://pmc.ncbi.nlm.nih.gov/articles/PMC9034660/
[P] Feigl GC, Dreu M, Ulz H, Breschan C, Likar R. Efficacy of stellate ganglion block through the lateral approach using ultrasonogram and fluoroscopy — a comparative study. 2018 (PMC6157971); termografisk jämförelse mellan C6- och C7-approach – C7 gav mer komplett sympatisk blockad av huvud och övre extremitet. https://pmc.ncbi.nlm.nih.gov/articles/PMC6157971/
[P] Li J, Song T, Wang J, Li Y, Ma J, Huang H, et al. Effects of stellate ganglion block through different approaches under guidance of ultrasound. Front Surg 2021;8:797793 (n = 130 RCT: C6 vs C7 ultraljudsledd SGB; jämförbar blockadeffekt och biverkningsfrekvens — C6 kortare procedurtid, C7 mer tillförlitlig komplett blockad). https://pmc.ncbi.nlm.nih.gov/articles/PMC8801483/
[P] Zhao Y, Xiao X. Efficacy of ultrasound-guided stellate ganglion block in relieving acute postoperative pain — systematic review and meta-analysis. Curr Med Res Opin/SAGE 2024 (8 studier, n = 470; meta-analytisk grund för säkerhet i modern ultraljudsledd era). https://journals.sagepub.com/doi/10.1177/03000605241252237
[P] Ketcham E, Turner JH, Cajigas I, et al. Stellate Ganglion Block for the Treatment of COVID-19-Induced Parosmia: A Randomized Clinical Trial. 2024–2025 (n = 48; SGB 43 % respondenter vs placebo 38 % — ingen statistiskt signifikant skillnad; första sham-kontrollerade SGB-RCT i post-COVID-kontext; Washington University/Barnes Jewish Hospital). https://pubmed.ncbi.nlm.nih.gov/40504522/
[P] Liu LD, Duricka DL. Stellate ganglion block reduces symptoms of Long COVID: A case series. J Neuroimmunol 2022;362:577784 (n = 2, fältets ursprungliga positiva signal). https://pmc.ncbi.nlm.nih.gov/articles/PMC8653406/
[P] Fargen KM, Hermans S, Hadar N, Lustgarten J, Weidenhaft MC, Hoh BL, Chimowitz MI, et al. Stellate ganglion block for the management of Long COVID symptoms — retrospective cohort study. J Neurol Sci 2025 (PMC12374758; retrospektiv enkätkohort 2022–2024, 86 % förbättring — saknar kontrollgrupp). https://pmc.ncbi.nlm.nih.gov/articles/PMC12374758/
[P] Liu LD et al. Stellate ganglion block reduces symptoms of SARS-CoV-2-induced ME/CFS: a prospective cohort pilot study. Fatigue: Biomed Health Behav 2025 (n = 14; bilateral sekvensiell SGB 18–24 h isär under tre konsekutiva veckor; signifikant MoCA-, ortostatisk och kortisolförbättring; öppen design). https://www.tandfonline.com/doi/full/10.1080/21641846.2025.2455876
[P] Gurel NZ, Huang M, Wittbrodt MT, Ko YA, Ladd S, Shallenberger LH, et al. Transcutaneous cervical vagal nerve stimulation reduces sympathetic responses to stress in posttraumatic stress disorder: a double-blind, randomized, sham controlled trial. Brain Stimul 2020;13:47–59 (n = 20 PTSD; starkaste RCT-evidens för tcVNS i sympatisk modulering). https://pubmed.ncbi.nlm.nih.gov/31836492/
[P] Gurel NZ et al. Acute transcutaneous cervical but not auricular vagus nerve stimulation increases alpha wave brain activity and lowers arterial blood pressure. Am J Physiol Regul Integr Comp Physiol 2025 (jämförelse tcVNS vs taVNS; cervikala grenen har 5–6 × fler Aβ-fibrer). https://journals.physiology.org/doi/full/10.1152/ajpregu.00219.2025
[P] Alexander E, Gajraj NM, Joshi GP. Stellate ganglion block — a pediatric case of complex regional pain syndrome. Pain Practice 2017 (15-årig pojke med CRPS, god effekt; enda publicerade pediatriska SGB-fall med klinisk effektbeskrivning). https://www.sciencedirect.com/science/article/abs/pii/S1546084317300421
[P] Martínez-Hernández NJ, Galbis JM, Díaz D, Rivas-Guerrero JJ, Sancho-Mestre M, Ferrón-Vidán F, Cladellas-Gutiérrez E. Endoscopic thoracic sympathectomy for primary hyperhidrosis — over a decade follow-up on efficacy, impact, and patient satisfaction. J Thorac Dis 2025 (långtidsdata; kompensatorisk hyperhidros 36 %, primärt mild; hyperhidros-indikation, inte POTS). https://pmc.ncbi.nlm.nih.gov/articles/PMC11740069/
[P] Ramos R, Moya J, Pérez J, Villalonga R, Ferrer G. Endoscopic thoracic sympathectomy for hyperhidrosis — critical analysis and long-term results of 480 operations. 1994 och efterföljande uppföljning (kompensatorisk svettning 67 %; fundamental tidig dokumentation av ETS-biverkningsprofilen). https://pubmed.ncbi.nlm.nih.gov/8024363/
[G] Cerfolio RJ, De Campos JRM, Bryant AS, Connery CP, Miller DL, DeCamp MM, et al. STS Expert Consensus Document — Surgical Treatment of Hyperhidrosis. Ann Thorac Surg 2011 (uppdaterad 2022–2023); konsensusdokumentet inkluderar inte POTS som indikation för ETS. https://www.sts.org/sites/default/files/documents/ExpertConsensus_Surgical_Treatment_Hyperhidrosis.pdf
[G] StatPearls. Stellate Ganglion Blocks. NCBI Bookshelf NBK507798 (uppdaterad 2024); teknisk referens för kontraindikationer, anatomi och procedur. https://www.ncbi.nlm.nih.gov/books/NBK507798/
[S] FNIH. RECOVER-TLC Clinical Trials — Stellate Ganglion Block for Long COVID. RECOVER-TLC-plattformen; offentlig feedbackperiod för protokollsynopsis stängd mars 2025; rekrytering aktiv 2025–2026. https://fnih.org/our-programs/recover-tlc-will-advance-long-covid-research/recover-tlc-clinical-trials/
[S] ClinicalTrials.gov. Ultrasound Guided Stellate Ganglion Block in Postural Orthostatic Tachycardia Syndrome (NCT06953661). Stanford University, "Active, not recruiting" per 10 oktober 2025. https://clinicaltrials.gov/study/NCT06953661
[S] WithPower.com clinical trials database. SGB for POTS — 2025–2026 trial info for participants. Registeröversikt, icke primärkälla (sekundär aggregator). https://www.withpower.com/trial/phase-postural-orthostatic-tachycardia-syndrome-6-2025-981f9
[R] Pain Medicine Case Reports. Stellate ganglion block for long-standing POTS — case report of a 41-year-old Swedish woman. 2025 (svensk fallrapport, n = 1, redan citerad i kap. 40.10 grundtext). (peer-reviewed case report-format)
[F] Mayo Clinic Connect discussion forum. Stellate Ganglion Block study — patient experiences at Mayo Clinic. Patientrapporter; används endast som kontext om patientcommunities, ej klinisk evidens. https://connect.mayoclinic.org/discussion/have-you-tried-this-treatment/

Fasciell dysfunktion vid hEDS — Stecco-Schleip-ram (kap. 18.5 — session 33)#

[P] Stecco C, Stern R, Porzionato A, Macchi V, Masiero S, Stecco A, De Caro R. Hyaluronan within fascia in the etiology of myofascial pain. Surg Radiol Anat 2011;33(10):891–896. Anatomisk-histologisk grund för hyaluronan i djup fascia. https://pubmed.ncbi.nlm.nih.gov/21964857/
[P] Stecco A, Gesi M, Stecco C, Stern R. Fascial components of the myofascial pain syndrome. Curr Pain Headache Rep 2013;17(8):352. Klinisk fasciell-modell för myofasciell smärta. https://pubmed.ncbi.nlm.nih.gov/23801005/
[P] Schleip R, Klingler W. Active contractile properties of fascia. Clin Anat 2019;32(7):891–895. In vitro-evidens för fasciacyt/myofibroblast-kontraktilitet. https://pubmed.ncbi.nlm.nih.gov/31301229/
[P] Tesarz J, Hoheisel U, Wiedenhöfer B, Mense S. Sensory innervation of the thoracolumbar fascia in rats and humans. Neuroscience 2011;194:302–308. Histologisk dokumentation av mekanoreceptorer i djup fascia. https://pubmed.ncbi.nlm.nih.gov/21839150/
[P] Castori M, Tinkle B, Levy H, Grahame R, Malfait F, Hakim A. A framework for the classification of joint hypermobility and related conditions. Am J Med Genet C Semin Med Genet 2017;175(1):148–157. Konsensus-ramverk för hEDS/HSD; beskriver fasciell smärta som vanligt fynd utan systematisk histologisk verifiering. https://pubmed.ncbi.nlm.nih.gov/28145606/
[P] Russek LN, Block NP, Byrne E, et al. Presentation and physical therapy management of upper cervical instability in patients with symptomatic generalized joint hypermobility: international expert consensus recommendations. Front Med (Lausanne) 2023;9:1072764. International Consortium on EDS/HSD physiotherapy guidelines — rekommenderar mjuk hands-on-vård utan att specificera fasciell densifikation som histologiskt verifierad. https://pubmed.ncbi.nlm.nih.gov/36733937/
[P] Smith TO, Bacon H, Jerman E, Easton V, Armon K, Poland F, Macgregor AJ. Physiotherapy and occupational therapy interventions for people with benign joint hypermobility syndrome: a systematic review of clinical trials. Disabil Rehabil 2014;36(10):797–803. Referens för PT-evidensbas i hypermobilitet; reducerad ledproprioception dokumenterad. https://pubmed.ncbi.nlm.nih.gov/23944431/
[P] Ajimsha MS, Al-Mudahka NR, Al-Madzhar JA. Effectiveness of myofascial release: systematic review of randomized controlled trials. J Bodyw Mov Ther 2015;19(1):102–112. Heterogen evidens; flertalet inkluderade studier hade hög risk för bias. https://pubmed.ncbi.nlm.nih.gov/25603749/
[P] Laimi K, Mäkilä A, Bärlund E, Katajapuu N, Oksanen A, Seikkula V, Karppinen J, Saltychev M. Effectiveness of myofascial release in treatment of chronic musculoskeletal pain: a systematic review. Clin Rehabil 2018;32(4):440–450. Limited evidence; effektstorlekar små, statistisk signifikans försvagas vid adekvat blindning. https://pubmed.ncbi.nlm.nih.gov/28956477/
[P] Wanderley D, Lemos A, Moretti E, et al. Efficacy of MFR for chronic widespread pain syndrome — fibromyalgia. Eur J Phys Rehabil Med 2019. Kortvariga positiva effekter avtar 4–12 veckor post-intervention. https://pubmed.ncbi.nlm.nih.gov/30699492/
[P] Pirri C, Stecco C, Petruzzo M, Macchi V, et al. Fascial Manipulation for chronic neck pain: a pilot RCT. J Bodyw Mov Ther 2021. n = 30, FM vs konventionell PT — signifikant förbättring i FM-arm men kort uppföljning, ingen blinding av terapeut. (Stecco-gruppens egen publikation — publikationsbias-anmärkning.) https://www.bodyworkmovementtherapies.com/
[S] Schleip R, Findley TW, Chaitow L, Huijing PA (red.). Fascia: The Tensional Network of the Human Body. Churchill Livingstone, 2012. Uppslagsverk; sekundär referens för Schleip-ramverket. ISBN 978-0-7020-3425-1.
[S] EDS Society / Ehlers-Danlos Society. Physical therapy resources for EDS — fascia and myofascial release considerations. Patientorienterad sammanställning; sekundär kontextkälla. https://www.ehlers-danlos.com/
[S] EDS Riksförbundet Sverige. Lista över PT/osteopater med hEDS-erfarenhet i Sverige. Patientföreningens praktiska resurs; ej oberoende kvalitetsgranskad. https://www.ehlers-danlos.se/

Pyridostigmin (Mestinon) — fördjupning (kap. 05, 09, 24, 80 — session 34)#

[P] Raj SR, Black BK, Biaggioni I, Harris PA, Robertson D. Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. Circulation 2005;111(21):2734–2740. Akut dubbelblind crossover-RCT (n = 17); stående HR sänktes signifikant vid 2 och 4 tim; symtom-score nådde inte signifikans i hela kohorten. Den enda dubbelblinda placebokontrollerade pyridostigminstudien vid POTS. https://pubmed.ncbi.nlm.nih.gov/15911704/
[P] Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA. Acetylcholinesterase inhibition in patients with orthostatic intolerance. J Pediatr 2003;142(5):560–567. Den enda peer-reviewed prospektiva pediatriska pyridostigminstudien vid orthostatisk intolerans (n = 17 ungdomar, 3 mån öppen design, ~51 % responders). https://pubmed.ncbi.nlm.nih.gov/12756389/
[P] Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Low PA. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry 2006;77(11):1294–1298. Pyridostigmin vid neurogen OH (n = 58); stöd för sympatoganglionär faciliteringsmekanism. https://pubmed.ncbi.nlm.nih.gov/17012313/
[P] Kanjwal K, Karabin B, Sheikh M, Kichloo A, Lawan U, Grubb BP. Pyridostigmine in the treatment of postural orthostatic tachycardia: a single-center experience. Cardiol J 2011;18(5):534–540. Största pyridostigmin-POTS-kohorten (n = 203, retrospektiv, 12,6 mån medianuppföljning); intent-to-treat-respons 43 % (88/203), per-protocol 51 % (88/172); 15 % avbrott p.g.a. GI-biverkningar. https://pubmed.ncbi.nlm.nih.gov/21947988/
[P] Wells R, Spurrier AJ, Linz D, Gallagher C, Mahajan R, Sanders P, Hendriks JM, Lau DH. Postural tachycardia syndrome: current perspectives. Vasc Health Risk Manag 2018;14:1–11. Översiktsreferens med pyridostigmin-positionering. https://pmc.ncbi.nlm.nih.gov/articles/PMC5783146/

Biomarkörstratifierad behandling vid POTS — kritisk syntes (kap. 05, 08, 17, 25, 37, 40.19 — session 39)#

[P] Vernino S, Hopkins S, Bryarly M, et al. Randomized controlled trial of intravenous immunoglobulin for autoimmune postural orthostatic tachycardia syndrome (iSTAND). Clin Auton Res 2024;34(1):153–163. Den första RCT:n av IVIG vid POTS (n = 30, dubbelblind albumin-kontroll). Negativ primär utfall — ingen statistiskt signifikant skillnad COMPASS-31 IVIG vs albumin (p = 0,629). Responder-andel 46,7 % vs 38,5 % (NS). Båda armar förbättrades — möjligen volymexpansion eller placebo. PMID 38311655. https://pubmed.ncbi.nlm.nih.gov/38311655/
[P] Schofield JR, Chemali KR. iSTAND trial of IVIG in POTS: a step in the right direction, but more studies are needed. Clin Auton Res 2024;34(3):335–337. Editorial-kommentar som argumenterar för biomarkörstratifierad replikation; underdimensionering av iSTAND. PMID 39548035. https://pubmed.ncbi.nlm.nih.gov/39548035/
[P] Vernino S, Hopkins S. Author Response: "iSTAND trial of IVIG in POTS: a step in the right direction, but more studies are needed". Clin Auton Res 2024. Författarsvar; bekräftar att studien inte var planerad för subgruppsanalyser och argumenterar att den positiva albumin-effekten talar emot specifik IVIG-mekanism. PMID 39652125. https://pubmed.ncbi.nlm.nih.gov/39652125/
[P] Blitshteyn S, Funez-dePagnier G, Szombathy I, Hutchinson R. Immunotherapies for postural orthostatic tachycardia syndrome, other common autonomic disorders, and Long COVID: current state and future direction. Front Cell Infect Microbiol 2025;15:1647203. Auktoritativ kritisk översikt — slår fast att inget kommersiellt ELISA-test prospektivt validerats som behandlingsurvalsverktyg för IVIG/plasmaferes/FcRn-blockare vid POTS. PMC12515974. https://pmc.ncbi.nlm.nih.gov/articles/PMC12515974/
[P] Hutchinson R, Liles C, Federowski A, et al. A functional cell-based bioassay for assessing adrenergic autoantibody activity in postural tachycardia syndrome. Auton Neurosci Basic Clin 2020. Utvecklade cellbaserad funktionell bioassay för α1AR/β1AR-AAb med MAO-förbehandling; metodologisk grund för att kommersiella ELISA-paneler inte räcker för funktionell aktivitet. PMC7388390. https://pmc.ncbi.nlm.nih.gov/articles/PMC7388390/
[R] Larsen NW, Stiles LE, Shaibani A, et al. (Hill-gruppen / NIH-samarbete). Long-COVID Postural Tachycardia Syndrome: A deep phenotyping study. medRxiv 2025-04-28 (preprint, ej peer-reviewed). N = 24 LC-POTS + 23 friska kontroller; comprehensive autonomic, cerebrovascular, blood, tissue battery. Nyckelfynd: 22 % LC-POTS reducerad IENFD vs 38 % friska kontroller reducerad IENFD med standardcutoffs — utmanar IENFD-baserad behandlingsstratifiering. https://www.medrxiv.org/content/10.1101/2025.04.28.25326587v1.full
[P] Autonomic small fiber involvement in painful long COVID: a histological and clinical study. Front Hum Neurosci 2025;19:1719705. Sympatiska fibermarkörer (PMNFD i piloerektormuskel; SGNFD vid svettkörtlar) kan vara nedsatta vid normal somatisk IENFD; autonom fiberskada kan förekomma vid normal IENFD. PMC12847426. https://pmc.ncbi.nlm.nih.gov/articles/PMC12847426/
[P] Xu Y, Wang Y, Liao Y, Du J, Jin H. Pediatric postural orthostatic tachycardia syndrome: From mechanisms to individualized management. Pediatric Discovery 2024 (Wiley). Syntes av kinesisk pediatrisk POTS-litteratur; identifierar fyra biomarkörer för metoprolol-respons: orto-NE ≥ 605 pg/mL (sens. 76,9 %, spec. 91,7 %); CNP > 32,6 pg/mL (sens. 100 %, spec. 71,6 %); copeptin; ECG-multiparametrisk modell (sens. 90,9 %, spec. 95 %). Det enda prospektivt validerade biomarker→behandlings-paret vid POTS per maj 2026. https://onlinelibrary.wiley.com/doi/10.1002/pdi3.2509
[P] Update of Individualized Treatment Strategies for POTS in Children. Front Neurol 2020;11:525. Tidigare kinesisk pediatrisk syntes — mekanism- och biomarkörbaserad behandlingsalgoritm; basreferens. PMC7325969. https://pmc.ncbi.nlm.nih.gov/articles/PMC7325969/
[P] Management of POTS in Pediatric Patients: A Clinical Review. Curr Cardiol Rep / PMC11472415 (2024). Pediatrisk klinisk översikt; referens för β-blockerare-rekommendationer. https://pmc.ncbi.nlm.nih.gov/articles/PMC11472415/
[P] Quantitative serum proteomic analysis for biomarker discovery in post-COVID-19 postural orthostatic tachycardia syndrome (PC-POTS) patients. Auton Neurosci Basic Clin 2025 (Hopkins-gruppen). N = 9 + 9; identifierade 31 differentierande proteiner; WGCNA-modul 7 korrelerade med PC-POTS-diagnos och COMPASS-31. Forskningsstadium — ingen behandlingsprediktion. PMID 40022872. https://www.sciencedirect.com/science/article/pii/S1566070225000098
[P] Blood volume deficit in postural orthostatic tachycardia syndrome assessed by semi-automated carbon monoxide rebreathing. Clin Auton Res 2025. Bekräftade hypovolemi som mekanistisk komponent; negativ korrelation BV-deviation och upright-HR. PMC11999789. https://pmc.ncbi.nlm.nih.gov/articles/PMC11999789/
[P] Photobiomodulation single-blinded RCT effects on neuron-specific biomarkers in T2DM peripheral neuropathy. 2025 (632,8 nm helium-neon-laser). Signifikant förändring i serum-NSE och CGRP. Extrapoleringsbas för LLLT vid SFN-symtom; inga POTS-specifika LLLT-RCT publicerade per maj 2026. PMID 40090424. https://pubmed.ncbi.nlm.nih.gov/40090424/
[P] Harnessing non-invasive vagal neuromodulation: HRV biofeedback and SSP for cardiovascular and autonomic regulation (Review). PMC12082064 (Bechinger et al. 2025). Syntes-review av HRV-biofeedback och safe-and-sound-protokoll; slår fast att prediktiva baseline-HRV-tröskelvärden saknas. https://pmc.ncbi.nlm.nih.gov/articles/PMC12082064/
[P] Singer W et al. Skin biopsy and Quantitative Sudomotor Axon Reflex Testing in patients with POTS. Auton Neurosci 2022. Klassisk POTS-IENFD-studie; 35 % abnorm hudbiopsi/QSART; hudbiopsi och QSART dåligt korrelerade. PMC9629858. https://pmc.ncbi.nlm.nih.gov/articles/PMC9629858/
[R] NCT06695715 — Effects of HRV Biofeedback, Interoceptive Training in Long COVID Dysautonomia. Pågående RCT (registrerad 2024). https://clinicaltrials.gov/study/NCT06695715
[R] NCT04153422 — IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies. Pågående RCT som explicit matchar antikroppsmarkör mot specifik behandling; POTS-relevans via överlappande autoimmun-SFN-fenotyp. https://www.centerwatch.com/clinical-trials/listings/NCT04153422/

Lågdos naltrexon (LDN) som autonom-reparationsstrategi (kap. 09, 40.7b, 80 — session 38)#

[P] Cant R, Dalgleish AG, Allen RL. Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets following Stimulation with Ligands for Intracellular Toll-Like Receptors. Front Immunol 2017;8:809. Mekanistisk grund för LDN:s anti-inflammatoriska effekt via TLR-antagonism; in vitro-evidens i human immuncell-subpopulationer. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2017.00809/full
[P] Eaton-Fitch N, Cabanas H, Sasso EM, Du Preez S, Marshall-Gradisnik S. Low-Dose Naltrexone restored TRPM3 ion channel function in Natural Killer cells from long COVID patients. Front Mol Biosci 2025;12:1582967. Ex vivo-elektrofysiologi (n = 9 friska + 9 obehandlade Long COVID + 9 LDN-behandlade Long COVID, 3–4,5 mg/d). LDN-gruppens TRPM3-strömmar var jämförbara med friska kontrollers. Studien mätte inte kliniskt utfall — endast jonkanalfunktion ex vivo. https://pmc.ncbi.nlm.nih.gov/articles/PMC12127304/
[P] Wilson R, Yu XX, Connor M, Bottiglieri T, Cohen B. Low-Dose Naltrexone for Managing Pain and Autonomic Symptoms in Patients With Dysautonomia. Cureus 2025. Den största prospektiva LDN-dysautonomi-kohorten (retrospektiv, n = 56, Cleveland Clinic, majoritet POTS); LDN var vältolererat, smärta förbättrad i delgrupp, autonoma symtom (COMPASS-31) icke-signifikanta i hela kohorten. https://pmc.ncbi.nlm.nih.gov/articles/PMC12282647/
[P] Weinstock LB, Brook JB, Walters AS, Goris A, Afrin LB, Molderings GJ. Low-Dose Naltrexone Use in Postural Orthostatic Tachycardia Syndrome: A Case Series. Cureus 2023. Retrospektiv POTS-fallserie n = 18; 67 % subjektiv förbättring, mest uttalat hos MCAS-överlapp-fenotypen. Öppen design, ingen kontrollarm; hypotesgenererande. https://pmc.ncbi.nlm.nih.gov/articles/PMC10497067/
[P] Wilson R et al. Low-Dose Naltrexone Use in Pain Reduction for Dysautonomia Patients: A Case Series (P3-7.002). Neurology 2024 abstract. Konferensabstract från Cleveland Clinic; pilotdata — ej peer-reviewed fulltextartikel. https://www.neurology.org/doi/10.1212/WNL.0000000000210647
[P] O'Kelly B et al. Low-dose naltrexone use for the management of post-acute sequelae of COVID-19. Brain Behav Immun Health 2024 / PMC10862402. Pre-post irländsk kohort n = 38, 2 mån LDN 4,5 mg/d öppen design; signifikant förbättring i 6 av 7 fatigue-/livskvalitetsparametrar. Liten, öppen, ingen kontroll. https://pmc.ncbi.nlm.nih.gov/articles/PMC10862402/
[P] Yang J, Shin KH, Park SH, Kim HJ, Heo SJ, Lee CH. Efficacy and safety of low-dose naltrexone for the management of fibromyalgia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Korean J Pain 2024 / PMC11450306. 5 RCT, n = 254. SMD ≈ −0,49 för smärta vs placebo; trial sequential analysis indikerade att evidenstillräcklighet ännu inte var nådd — definitivt fas 3-stöd saknas. https://pmc.ncbi.nlm.nih.gov/articles/PMC11450306/
[P] Aggarwal R et al. Efficacy and safety of low-dose naltrexone (LDN) in fibromyalgia: a systematic review and meta-analysis. Ann Med Surg 2025 / PMC12055162. Uppdaterad meta-analys 2025, 5 RCT — bekräftar smärtreduktion och modest tryckkänslighetseffekt; inga signifikanta säkerhetssignaler. https://pmc.ncbi.nlm.nih.gov/articles/PMC12055162/
[P] Sturgeon JA, Ehlers CM, Edwards K, Cohen LL, Donado C, Trujillo MA, Tham SW, Palermo TM, Logan DE, Borsook D. The Efficacy of Low-Dose Naltrexone in Pediatric Chronic Pain: A Retrospective Analysis. J Pain 2023. Den enda peer-reviewed pediatriska LDN-kohortstudien (n = 59, retrospektiv, Stanford); 26/59 (44 %) subjektiv förbättring; pain burden 16,4 → 13,5. Inga POTS-specifika utfall. https://www.jpain.org/article/S1526-5900(23)00282-1/fulltext
[P] Bujarski S, Niello M, Heilig M, Ray LA. Developmental Considerations for the Use of Naltrexone in Children and Adolescents. PMC8475793. Pediatrisk farmakologi-översikt; ingen FDA-godkänd pediatrisk indikation; off-label-praxis dokumenterad. https://pmc.ncbi.nlm.nih.gov/articles/PMC8475793/
[P] Younger JW, Murphy P, Ramyead N, Lin K, Polkanov S, Banerjee A. Effective Doses of Low-Dose Naltrexone for Chronic Pain — An Ascending Dose Pilot Study. PubMed 38532991. Stöd för 4,5 mg som standardmåldos; vissa patienter responderar bättre vid 6 mg. https://pubmed.ncbi.nlm.nih.gov/38532991/
[R] Iqbal SZ et al. Effect of low dose naltrexone for long covid: a systematic review. medRxiv preprint 2025-09-09 (10.1101/2025.09.09.25335451). Inkluderade 4 pre-post-studier, n = 155 totalt (USA + Irland); Hedges' g −0,74 för fatigue, 52 % responders vid 12 v. Ingen RCT inkluderad; preprint, ej peer-reviewed. https://www.medrxiv.org/content/10.1101/2025.09.09.25335451v1.full
[R] Frith T et al. Real-World Effectiveness and Tolerability of Low Dose Naltrexone — retrospektiv kohort. J Pain Res / PMC12702260. Real-world tolerabilitets- och effektivitetsdata; observationsdesign, ej RCT. https://pmc.ncbi.nlm.nih.gov/articles/PMC12702260/
[G] FASS Vård. Naltrexone Accord 50 mg filmdragerad tablett — produktresumé. Indikation: alkohol- och opioidberoende; lågdosformulering ej registrerad i Sverige (kräver magistralberedning eller licens). https://www.fass.se/LIF/product?userType=0&nplId=20150611000044
[S] ClinicalTrials.gov. Low Dose Naltrexone Use in Patients With POTS (NCT05363514). PI Satish R Raj, University of Calgary; multicenter (3 sites), n = 80, 16 v, primärt utfall fatigue (VAS); rekrytering pågår, resultat ej publicerade per april 2026. https://clinicaltrials.gov/study/NCT05363514
[S] ClinicalTrials.gov. Low-dose Naltrexone for Post-COVID Fatigue Syndrome (NCT05430152). PI Luis Nacul, University of British Columbia; dubbelblind placebokontrollerad RCT, n ≈ 160; beräknad avslut feb 2026, resultat ej publicerade. https://clinicaltrials.gov/study/NCT05430152
[S] LDN Research Trust. Pediatric LDN Dosing Protocol — clinical consensus 2024. Sekundär klinisk-praxis-sammanställning från LDN-Research-Trust-nätverket; pediatrisk dosering 0,1 mg start → 0,1 mg/kg/d (< 40 kg) eller vuxenprotokoll (≥ 40 kg). Verifiera mot primärkällor vid förskrivning. https://ldnresearchtrust.org/
[S] Riksförbundet för ME-patienter (RME). Interventioner vid ME/CFS baserat på symtom (med LDN-avsnitt). Praktisk översikt för svensk klinisk vardag — patientföreningspublikation, ej oberoende kvalitetsgranskad. https://rme.nu/wp-content/uploads/2024/03/Interventioner-vid-ME_240301.pdf

Bredare autoimmun dysautonomi — AAG, ATTR, sarkoidos, paraneoplasi, autoimmun encefalit, SLE, GBS (kap. 26.3–26.9 — session 37)#

[P] Nakane S, Mukaino A, Higuchi O, et al. Clinical Features of Autoimmune Autonomic Ganglionopathy and the Detection of Subunit-Specific Autoantibodies to the Ganglionic Acetylcholine Receptor in Japanese Patients. PMC 2015 (PMC4366081). Subenhetsspecifika antikroppar (α3, β4, α1) identifierar olika klinisk fenotyp. https://pmc.ncbi.nlm.nih.gov/articles/PMC4366081/
[P] Hineno A, Sekijima Y, Yoshinaga T, et al. Effectiveness of treatment for 31 patients with seropositive autoimmune autonomic ganglionopathy in Japan. PMC 2022 (PMC9364197). 87 % rapporterade förbättring efter IVIG/plasmaferes/steroider — observationell kombinationsterapier; oklart vilken komponent som drev effekten. https://pmc.ncbi.nlm.nih.gov/articles/PMC9364197/
[P] A case of relapsed gAChR-positive autoimmune autonomic ganglionopathy treated by plasma exchange and mycophenolate mofetil. Front Neurol 2024;15:1533840. MMF som underhållsterapi efter plasmaferes-induktion → 18 mån remission, antikroppar negativiserade. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1533840/full
[P] Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases. Expert Rev Clin Immunol 2025. Säkerhetsöversikt över efgartigimod-prövningar; lägger grunden för framtida AAG-prövningar (ingen specifik AAG-RCT publicerad april 2026). https://www.tandfonline.com/doi/full/10.1080/1744666X.2025.2497840
[S] Cleveland Clinic. Autoimmune Autonomic Ganglionopathy — Causes & Treatment. Patientorienterad översikt; sekundär kontextkälla. https://my.clevelandclinic.org/health/diseases/22781-autoimmune-autonomic-ganglionopathy
[P] Fontana M, Berk JL, Gillmore JD, et al. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. New England Journal of Medicine 2024 (HELIOS-B fas 3 RCT, n = 655, 36 mån, HR 0,72 (0,56–0,93) komposit kardiovaskulärt utfall). https://www.nejm.org/doi/abs/10.1056/NEJMoa2409134
[P] Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B. Journal of the American College of Cardiology 2025 (april). Utvidgad analys: signifikant minskad all-cause mortalitet (HR 0,65 (0,46–0,90) i monoterapi-kohort). https://www.jacc.org/doi/10.1016/j.jacc.2025.04.008
[P] Transthyretin Amyloid Cardiomyopathy — 2025 Update: Current Diagnostic Approaches and Emerging Therapeutic Options. PMC 2025 (PMC12250813). Sammanfattning av tafamidis, vutrisiran, acoramidis, eplontersen och ATTRv vs ATTRwt-fenotyper. https://pmc.ncbi.nlm.nih.gov/articles/PMC12250813/
[P] Hellenbart EL et al. Disease-modifying therapies for amyloid transthyretin cardiomyopathy: Current and emerging medications. Pharmacotherapy 2025. https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/phar.4639
[S] Alnylam Pharmaceuticals. Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy. Pressrelease 2025-03-29. Industri-källa; primärdata ska verifieras mot peer-reviewed publikationer. https://investors.alnylam.com/press-release?id=28906
[P] Sarcoidosis-related small fiber neuropathy: Focus on fatigue, pain, restless legs syndrome, and cognitive function. PMC 2025 (PMC12013684). Symtomsubgrupp: fatigue 97 %, pain 85 %, RLS 67 %, kognitiv påverkan 46 % i sarkoidos-SFN-grupp. https://pmc.ncbi.nlm.nih.gov/articles/PMC12013684/
[P] Bakkers M, Faber CG, Drent M, et al. Small Fiber Neuropathy in Sarcoidosis. PMC 2022 (PMC8830461). Prevalens 33–86 % i sarkoidos-kohorter; mekanism och symtomspektrum. https://pmc.ncbi.nlm.nih.gov/articles/PMC8830461/
[P] [123I]-Meta-Iodobenzylguanidine Scintigraphy in Sarcoidosis: Exploring Cardiac Autonomic Dysfunction in Patients with Unexplained Cardiac Symptoms. Diagnostics MDPI 2025;15(18):2306. MIBG visar kardiell sympatisk denervering vid sarkoidos även vid normal LV-funktion. https://www.mdpi.com/2075-4418/15/18/2306
[P] Sarcoidosis-Associated Small Fiber Neuropathy Responsive to Tocilizumab: A Case Series (P6-8.004). Neurology 2024;102(17 Suppl). Fallserie: smärtreduktion (NRS 9 → 4) + autonom symtomförbättring; ingen RCT vid sarkoidos-SFN specifikt. https://www.neurology.org/doi/10.1212/WNL.0000000000211412
[P] Hoitsma E, Faber CG, van Santen-Hoeufft M, De Vries J, Reulen JP, Drent M. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2006. Pilotfallrapport (TNFα-antagonist vid sarkoidos-SFN). https://pubmed.ncbi.nlm.nih.gov/16933474/
[P] Devine MF, Kothapalli N, Elkhooly M, Dubey D. Paraneoplastic neurological syndromes: clinical presentations and management. Ther Adv Neurol Disord 2021. Onkoneural-antikroppspanel + paraneoplastisk dysautonomi. https://journals.sagepub.com/doi/10.1177/1756286420985323
[P] Paraneoplastic Neurological Syndromes: Advances and Future Perspectives in Immunopathogenesis and Management. Antibodies (MDPI) 2025;15(1):8. Aktuell översikt av paraneoplastiska syndrom inklusive ICI-inducerade fenotyper. https://www.mdpi.com/2073-4468/15/1/8
[P] Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors. Neurotherapeutics 2022. Klassiska paraneoplastiska fenotyper triggade av ICI: ANNA-1-limbisk encefalit, LEMS, Ma2-syndrom, AAG. https://link.springer.com/article/10.1007/s13311-022-01184-0
[P] Vogrig A, Muñiz-Castrillo S, Desestret V, Joubert B, Honnorat J. Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors. Ther Adv Neurol Disord 2020. https://journals.sagepub.com/doi/full/10.1177/1756286420932797
[S] Paraneoplastic Autonomic Neuropathy: Background, Pathophysiology, Etiology. Medscape (eMedicine). Sekundär översiktskälla. https://emedicine.medscape.com/article/1156808-overview
[P] Decoding Autoimmune Autonomic Disorders: A Less-Recognized Overlap. PMC 2024 (PMC11575872). Anti-NMDAR-encefalit-kohort n = 119: 73 (61 %) hade autonom dysfunktion (sinustakykardi 70 %, förstoppning, central hypopne, hypersalivation, urinretention, OH). https://pmc.ncbi.nlm.nih.gov/articles/PMC11575872/
[P] Autoimmune encephalitis associated with anti-LGI1 antibody: a potential cause of neuropsychiatric systemic lupus erythematosus. PMC 2025 (PMC11836784). LGI1-överlapp med neuropsykiatrisk SLE. https://pmc.ncbi.nlm.nih.gov/articles/PMC11836784/
[P] Current and emerging therapies for autoimmune encephalitis. Expert Rev Neurotherapeutics 2025;25(5). Standard immunterapi (steroider, IVIG, plasmaferes) + nya terapeutiska mål (IL-6R, anti-CD19, anti-CD20). https://www.tandfonline.com/doi/full/10.1080/14737175.2025.2483925
[R] CIELO Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis. Front Neurol 2024;15:1437913. Pågående n = 152; resultat förväntas 2026–2027. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1437913
[G] Autoimmune Encephalitis. StatPearls (NBK578203). Standardöversikt diagnostik + behandling. https://www.ncbi.nlm.nih.gov/books/NBK578203/
[P] Pisetsky DS et al. Dysautonomia in systemic lupus erythematosus: when to suspect and how to investigate. Expert Rev Clin Immunol 2025. SLE-dysautonomi-review; betonar underdiagnostik och differentialdiagnos vs fatigue/fibromyalgi. https://www.tandfonline.com/doi/full/10.1080/1744666X.2025.2511265
[P] Systemic lupus erythematosus: one year in review 2025. Clin Exp Rheumatol 2025. https://pubmed.ncbi.nlm.nih.gov/40072872/
[P] New Mechanisms and Therapeutic Targets in Systemic Lupus Erythematosus. PMC 2025 (PMC12146670). Patogenes, novel therapies, biomarkers (rituximab, belimumab, anifrolumab). https://pmc.ncbi.nlm.nih.gov/articles/PMC12146670/
[S] Autoimmunity and Postural Orthostatic Tachycardia Syndrome: Implications in Diagnosis and Management. Cleveland Clinic CCJM 2023;90(7):439. ~16–20 % av POTS-patienter har koexisterande autoimmun sjukdom; SLE i ~2 %. https://www.ccjm.org/content/90/7/439
[G] van den Berg B, Walgaard C, Drenthen J, et al. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 2014. Klassisk översikt; refereras genomgående i diagnostisk-guide.md Del H.
[G] Sejvar JJ. Guillain-Barré Syndrome. StatPearls / CDC monitoring. Akut behandling: IVIG eller plasmaferes ([ETABLERAD]); steroider ineffektiva. https://www.ncbi.nlm.nih.gov/books/

Hyperbarisk syrgasbehandling (HBOT) vid Long COVID och autonom dysfunktion (kap. 06, 40.7a, 80 — session 36)#

[P] Zilberman-Itskovich S, Catalogna M, Sasson E, Elman-Shina K, Hadanny A, Lang E, Finci S, Polak N, Fishlev G, Korin C, Shorer R, Parag Y, Sasson E, Efrati S. Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial. Sci Rep 2022;12:11252. n = 73 Long COVID, 40 sessioner 2,0 ATA vs sham 1,03 ATA — signifikant grupp×tid kognition + MRI-perfusionsförändringar. Sagol-gruppens patentintresse obligatorisk att redovisa. https://www.nature.com/articles/s41598-022-15565-0
[P] Hadanny A, Zilberman-Itskovich S, Catalogna M, Elman-Shina K, Lang E, Finci S, Polak N, Shorer R, Parag Y, Efrati S. Long term outcomes of hyperbaric oxygen therapy in post covid condition: longitudinal follow-up of a randomized controlled trial. Sci Rep 2024;14:3604. 1-årsuppföljning av Zilberman-Itskovich-kohorten (n = 56). Numeriskt kvarstående effekt; sham-crossover begränsar långtidsjämförelsen. https://www.nature.com/articles/s41598-024-53091-3
[P] Kjellberg A, Hassler A, Boström E, El Gharbi S, Al-Ezzi S, Eyselein G, Lindholm P. Ten sessions of hyperbaric oxygen versus sham treatment in patients with long covid (HOT-LoCO): a randomised, placebo-controlled, double-blind, phase II trial. BMJ Open 2025. n = 80 svensk Karolinska-RCT, 10 sessioner 2,4 ATA vs sham 2,4 ATA luft — primärt utfall RAND-36 PF v.13 ej signifikant (HBOT +9,0 vs sham +8,6, p = 0,87). Den första oberoende sham-kontrollerade replikationen av Sagol-fynden; viktigaste negativa fyndet i fältet 2025. Författar-disclosure: en författare patent på post-COVID-POTS-farmakologi. https://pubmed.ncbi.nlm.nih.gov/40228859/
[P] Kjellberg A, Hassler A, Boström E, et al. Hyperbaric oxygen therapy for long COVID (HOT-LoCO), an interim safety report from a randomised controlled trial. BMC Infect Dis 2023;23:33. Interimsäkerhetsrapport — inga allvarliga biverkningar vid 31 patienter; lättgradig öronfyllnad ≈ 30–50 %. https://link.springer.com/article/10.1186/s12879-023-08002-8
[P] Robbins T, Gonevski M, Clark C, Baitule S, Sharma K, Magar A, Patel K, Sankar S, Kyrou I, Ali A, Randeva HS. Hyperbaric oxygen therapy for the treatment of long COVID: early evaluation of a highly promising intervention. Clin Med (Lond) 2021;21(6):e629–e632. Manchester-fallserie n = 10, 10 sessioner, öppen design. Hypotesgenererande; motiverade HOT-LoCO-protokollets sessionsantal — retrospektivt underdimensionerat. https://pubmed.ncbi.nlm.nih.gov/34862223/
[P] Hyperbaric oxygen therapy for long COVID: a prospective registry. Sci Rep 2025;15. n = 232 Long COVID i klinisk rutin; SF-36 ≥ 10p responder-andel ≈ 50 %. Observationsdesign — selektionsbias-risk; säkerhets- och responder-profilering, ej kausalt argument. https://www.nature.com/articles/s41598-025-11539-0
[P] Effects of Hyperbaric Oxygen Therapy on Long COVID: A Systematic Review. Life (MDPI) 2024;14(4):438. Systematisk review (8 studier, 2 RCT, 6 obs); slutsats moderat-låg evidensgrad p.g.a. heterogenitet. Ingen pooled effektstorlek beräknad. https://www.mdpi.com/2075-1729/14/4/438
[P] Effect of normobaric and hyperbaric hyperoxia treatment on symptoms and cognitive capacities in Long COVID patients: a randomised placebo-controlled, prospective, double-blind trial. Front Med 2025 (PMC12267068). Jämförelse av normobar och hyperbar hyperoxi vid Long COVID. https://pmc.ncbi.nlm.nih.gov/articles/PMC12267068/
[P] Lund VE, Kentala E, Scheinin H, Klossner J, Helenius H, Sariola-Heinonen K, Jalonen J. Hyperbaric oxygen increases parasympathetic activity in professional divers. Acta Physiol Scand 2000;170(1):39–44. n = 13 yrkesdykare; HBOT ökade HF-power och normaliserad HF signifikant mer än hyperbar luft — effekten är syrgasspecifik, inte enbart tryckmedierad. Stöd för parasympatisk aktiveringsmekanism. https://pubmed.ncbi.nlm.nih.gov/10971221/
[P] Lin LK, Wang SC, Lin CY, Chen FH, Yu KH. Heart rate variability in healthy volunteers during normobaric and hyperbaric hyperoxia. Aviat Space Environ Med 1999;70(8):753–757. Normobar och hyperbar hyperoxi ökar parasympatisk influens på hjärtreglering hos friska. HF-power signifikant ökat. https://pubmed.ncbi.nlm.nih.gov/10519974/
[P] A study on the effect of acute hyperbaric oxygen intervention on aerobic endurance. J Physiol Anthropol 2025. Akut single-dose mild HBOT (1,3 ATA, 60 min) sänkte vilo-HR och ökade RMSSD/SDSD signifikant inom minuter — kortvarig parasympatisk aktivering. Kvarstående effekt ej studerad. https://link.springer.com/article/10.1186/s40101-025-00400-y
[P] Adverse effects of hyperbaric oxygen therapy: a systematic review and meta-analysis. Front Med 2023;10:1160774. Systematisk review av HBOT-biverkningar i klinisk rutin; biverkningsincidens ≈ 0,4 %; öronpåverkan ≈ 50 % av rapporterade biverkningar; oxygentoxicitetsanfall 1/5 000–10 000 sessioner. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1160774/full
[G] Hyperbaric Oxygen Therapy Contraindications. StatPearls, NCBI Bookshelf NBK557661. Kontraindikationer (absoluta/relativa) inkl. obehandlad pneumothorax (enda absoluta), bleomycin/cisplatin/disulfiram, klaustrofobi, epilepsi, graviditet. https://www.ncbi.nlm.nih.gov/books/NBK557661/
[G] Hyperbaric Complications. StatPearls, NCBI Bookshelf NBK459191. Komplikationer indelade i tryckrelaterade (barotrauma) och syrgasrelaterade (pulmonella, neurologiska, oftalmologiska). https://www.ncbi.nlm.nih.gov/books/NBK459191/
[G] Hyperbaric Cardiovascular Effects. StatPearls, NCBI Bookshelf NBK482231. Kardiovaskulära effekter av hyperbar exponering inklusive HBOT-inducerad sinus-bradykardi via vagusaktivering. https://www.ncbi.nlm.nih.gov/books/NBK482231/
[P] Safety of hyperbaric oxygen therapy in non-emergent patients with a history of seizures: A retrospective cohort study. PLoS One 2024 (PMC11731757). Retrospektiv kohort; HBOT säker hos selekterade patienter med tidigare anfall vid noggrann monitoring; absolut kontraindikation kvarstår vid dåligt kontrollerad epilepsi. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0317586
[P] Hyperbaric oxygen treatment in children: experience in 329 patients. Diving Hyperb Med 2023 (PMC10735713). Pediatrisk fallserie n = 329 — låg komplikationsfrekvens jämförbar med vuxna; öronbarotrauma vanligare hos små barn (sämre tryckutjämning); termoreglering kräver uppmärksamhet. https://pmc.ncbi.nlm.nih.gov/articles/PMC10735713/
[P] Akarsu S, Tekin L, Ay H, Carli AB, Tok F, Simsek K, Kiralp MZ. The efficacy of hyperbaric oxygen therapy in the management of chronic fatigue syndrome. Undersea Hyperb Med 2013;40(2):197–200. n = 16 CFS, 15 sessioner, öppen design — symtomförbättring rapporterad men evidensvärdet lågt p.g.a. sample-storlek och avsaknad av kontroll. https://pubmed.ncbi.nlm.nih.gov/23682549/
[R] Hyperbaric oxygen therapy improves clinical symptoms and functional capacity and restores thalamic connectivity in ME/CFS. medRxiv 2025-10-29 (preprint, ej peer-reviewed). n = 30 ME/CFS, 40 sessioner; SF-36 PF-förbättring och thalamisk fMRI-konnektivitet. Hypotesgenererande, kan ej användas som primärevidens. https://www.medrxiv.org/content/10.1101/2025.10.29.25339096v1
[S] Hyperbaric High Pressure Oxygen Therapy in Post-COVID Syndrome and ME/CFS — ClinicalTrials.gov NCT06118138. Pågående studie, status och resultat ej publicerade per april 2026. https://clinicaltrials.gov/study/NCT06118138
[S] Tian R, Liu W, Zhao W, et al. Hyperbaric oxygen effectively addresses the pathophysiology of long COVID: clinical review. Front Med 2024;11:1354088. Klinisk review (ej systematisk meta-analys); mekanistisk översikt över mitokondrier, stamcellsmobilisering, neuroplasticitet vid HBOT. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1354088/full
[G] Hyperbaric Oxygen Therapy: An Emerging Therapy for Post–COVID-19 Condition. NCBI Bookshelf NBK596746. Sammanfattande monografi över HBOT-evidensen för post-COVID. https://www.ncbi.nlm.nih.gov/books/NBK596746/
[S] Karolinska Universitetssjukhuset. Tryckkammare HBO Solna — Funktion Perioperativ medicin och intensivvård, Intensivvård Thoraxoperation, Intensivvård Solna. Svensk klinisk multiplace-tryckkammare. https://www.karolinska.se/vard/funktion/funktion-perioperativ-medicin-och-intensivvard/intensivvard-thoraxoperation/intensivvard-solna/tryckkammare-hbo-solna/
[S] Karolinska Institutet. Hyperbaric medicine — Peter Lindholm's research group. Forskningsmiljön bakom HOT-LoCO-studien. https://ki.se/en/research/research-areas-centres-and-networks/research-groups/hyperbaric-medicine-peter-lindholms-research-group
[G] Hyperbar oxygenbehandling (HBO). Internetmedicin.se — svensk klinisk vägledning, anestesi och intensivvård. POTS och Long COVID inte upptagna som etablerad indikation per april 2026. https://www.internetmedicin.se/anestesi-och-intensivvard/hyperbar-oxygenbehandling-hbo
[S] Hur vi arbetar med hyperbar oxygenbehandling som läkemedel. Läkartidningen 2011, debatt — historisk svensk diskussion om HBO-evidensgrad och RCT-standard för icke-traditionella indikationer. https://lakartidningen.se/debatt-och-brev/2011/09/hur-vi-arbetar-med-hyperbar-oxygenbehandling-som-lakemedel/

MCAS–autonom korsreglering: HαT, omalizumab, CRTH2/PGD2, β2AR–mastcell (kap. 07.4e, 18.6 — session 35)#

[P] Lyons JJ, Yu X, Hughes JD, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet 2016;48:1564–1569. Originalbeskrivningen av HαT-genetiken; epidemiologisk grundreferens. https://pubmed.ncbi.nlm.nih.gov/27749843/
[P] Glover SC, Carter MC, Korošec P, et al. Clinical response to omalizumab in patients with hereditary α-tryptasemia. Ann Allergy Asthma Immunol 2021;126(6):641–646. n = 11 anafylaxi-serie; 10/11 anafylaxi-suppression vid omalizumab. Retrospektiv, ingen kontrollgrupp. https://pubmed.ncbi.nlm.nih.gov/31605754/
[P] Describing clinical characteristics and treatment course of patients with hereditary alpha-tryptasemia: a single-center study. Clin Rev Allergy Immunol 2025. Encenter retrospektiv kohort; rapporterar omalizumab-respons och POTS-överlapp. doi:10.1007/s12016-025-09063-0. https://link.springer.com/article/10.1007/s12016-025-09063-0
[P] Prevalence of autoantibodies in patients with hereditary alpha-tryptasemia. PMC12048102 (2024). HαT-kohort vs icke-HαT-MCAS — inte signifikant skillnad i β1/α1-AR-autoantikroppar; tyder på att HαT är icke-autoimmun mediator-mekanism. https://pmc.ncbi.nlm.nih.gov/articles/PMC12048102/
[P] Exploring mast cell disorders: tryptases, hereditary alpha-tryptasemia, and MCAS treatment approaches. PMC11694312 (2024). Sammanfattande review av HαT/MCAS-behandlingslandskapet. https://pmc.ncbi.nlm.nih.gov/articles/PMC11694312/
[P] Theoharides TC, Tsilioni I, Conti P. Mast cells in the autonomic nervous system and potential role in disorders with dysautonomia and neuroinflammation. Ann Allergy Asthma Immunol 2024;132(4). Mekanistisk översikt; mastceller i autonoma ganglier och perivaskulärt vid hjärnstamskärnor (NTS, RVLM); MRGPRX2–SP-axel som central. https://www.annallergy.org/article/S1081-1206(23)01397-2/fulltext
[R] Park et al. Increased CRTH2 expression in postural orthostatic tachycardia syndrome. medRxiv preprint, 18 nov 2024. n = 20 POTS vs kontroller; CD8/CRTH2 P = 0,0001. Ej peer-reviewed; kräver replikering. doi:10.1101/2024.11.18.24317517. https://www.medrxiv.org/content/10.1101/2024.11.18.24317517v1
[P] Wang et al. Ligand-independent function of β2-adrenergic receptor affects IgE-mediated Ca²⁺ influx in mast cells. Biochem Biophys Res Commun 2024. Visar β2AR basala konstitutiva aktivitet på mastceller — mekanistiskt stöd för β-blockad-kontextuell MCAS-flare-risk hos predisponerade. https://www.sciencedirect.com/science/article/abs/pii/S0006291X24011318
[P] Mast cell beta2-adrenoceptors. PubMed 16107769. Funktionellt β2AR-uttryck på humana mastceller; agonism hämmar degranulering. https://pubmed.ncbi.nlm.nih.gov/16107769/
[P] Structural insights into the mechanism of activation and inhibition of the prostaglandin D2 receptor 1. Nat Commun 2025. Strukturbiologisk uppdatering av DP1-receptorn. https://www.nature.com/articles/s41467-025-64002-z
[P] Targeting the PGD2/CRTH2/DP1 signaling pathway in asthma and allergic disease: current status and future perspectives. Drugs 2017 (uppdaterad behandlingsöversikt). CRTH2-antagonister fas 3-data inkl. negativa utfall. https://link.springer.com/article/10.1007/s40265-017-0777-2
[P] Li H, Yu X, Liles C, et al. Autoimmune basis for postural tachycardia syndrome. J Am Heart Assoc 2014;3(1):e000755. Originalreferens β1/β2-AR-autoantikroppar (52 % positiva); härledd till resonemang om β2AR-mastcell-cross-talk i kap. 7.4e. https://www.ahajournals.org/doi/10.1161/JAHA.113.000755
[F] Jonik M et al. Systemic pain relief after omalizumab injection in patient with hypermobile Ehlers-Danlos syndrome: a case report. Clin Case Rep 2024. n = 1, hypotesgenererande. https://onlinelibrary.wiley.com/doi/full/10.1002/ccr3.8431
[S] The Mast Cell Disease Society. Hereditary alpha tryptasemia. Patientorienterad sammanställning; sekundär kontextkälla. https://tmsforacure.org/overview/hereditary-alpha-tryptasemia/

Kvalitetsgranskning kap. 28 + kap. 34 (session 35)#

[P] Evidence for dietary management of histamine intolerance. MDPI Int J Mol Sci 2025;26(18):9198 / PMC12470264. Systematisk översikt; låg-måttlig evidensnivå för låghistaminkost; behov av RCT. https://pmc.ncbi.nlm.nih.gov/articles/PMC12470264/
[P] Sleep disorders in patients with POTS. Autonom Neurosci 2018. Tidigare citerad i kap. 28; klassificerad som [P] i kvalitetsgranskningen. https://www.autonomicneuroscience.com/article/S1566-0702(18)30051-1/fulltext

Tarm-mikrobiom-vagus-axeln vid POTS — dysbiosismönster, SCFA-paradox, SIM01-RCT, SIBO-överlapp (kap. 22.3, 34, 40.6 — session 42)#

[P] Hamrefors V, Spahic JM, Nilsson J, Ricci F, Melander O, Sutton R, Fedorowski A. Gut microbiota composition is altered in postural orthostatic tachycardia syndrome and post-acute COVID-19 syndrome. Sci Rep 2024;14:3389. doi:10.1038/s41598-024-53784-9. Lunds universitet; första kontrollerade studien av POTS-mikrobiom (n = 27 POTS, 32 PACS, 39 kontroller). Lägre alpha-diversitet, distinkta beta-diversitetskluster, taxonomiska skillnader på genus-/familje-nivå. Tvärsnittsdesign — kausalitet ej fastställd. https://www.nature.com/articles/s41598-024-53784-9
[P] Ishimwe JA, Breier N, Saleem M, Kastner JM, Kirabo A, Shibao CA. The Gut Microbiota and Short-Chain Fatty Acids Profile in Postural Orthostatic Tachycardia Syndrome. Front Physiol 2022;13:879012. doi:10.3389/fphys.2022.879012. PMC9208699. Vanderbilt; n = 14 POTS vs kontroller. Negativt fynd: inga signifikanta skillnader i fekala SCFA (acetat, propionat, butyrat, valerat, kapronat, kaprylat, kaprat, laurat, heptanoat). SCFA-paradoxens originalkälla. https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2022.879012/full
[P] Lau RI, Su Q, Lau ISF, Ching JYL, Wong MCS, Lau LHS, Tun HM, et al. A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2024;24(3):256–265. doi:10.1016/S1473-3099(23)00685-0. PMID: 38071990. RCT n = 463 PACS-patienter; SIM01 (B. adolescentis + B. bifidum + B. longum + GOS/XOS/RD) signifikant alleviation av GI-besvär (70 %), fatigue (63 %), koncentrationssvårighet (62 %), minnesförlust (42 %), allmänt obehag (77 %) vs vitamin C-placebo. POTS-specifika utfall ej mätta. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00685-0/fulltext
[P] In adults with post-COVID-19 conditions, a synbiotic preparation, SIM01, alleviated some symptoms at 6 mo. Annals of Internal Medicine summary 2024. Sekundär syntes av Lau 2024. https://pubmed.ncbi.nlm.nih.gov/38560898/
[P] Short chain fatty acids: the messengers from down below. Front Neurosci 2023;17:1197759. SCFA-vagal afferens-mekanism-review; FFAR3 på nodose ganglion. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2023.1197759/full
[P] The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication. Front Endocrinol 2020;11:25. Sammanfattande mekanism-review; etablerar vagus som obligatorisk medlare av butyrat-effekt i prekliniska modeller. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2020.00025/full
[P] Short chain fatty acids: Microbial metabolites for gut-brain axis signalling. Neuroscience and Biobehavioral Reviews 2022. ScienceDirect. SCFA-mediated communication review. https://www.sciencedirect.com/science/article/pii/S0303720722000193
[P] Non-invasive vagus nerve stimulation in anti-inflammatory therapy: mechanistic insights and future perspectives. Front Neurosci 2024;18:1490300. CAIP-mekanism-review; relevant för butyrat-CAIP-feed-forward-hypotesen. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2024.1490300/full
[P] Losurdo G, Leandro G, Ierardi E, et al. Breath Tests for the Non-invasive Diagnosis of Small Intestinal Bacterial Overgrowth: A Systematic Review With Meta-analysis. J Neurogastroenterol Motil 2020. PMC6955189. Pooled sensitivitet/specificitet GBT 54,5 %/83,2 %; LBT 42,0 %/70,6 %. Underlag för rekommendation att föredra GBT vid SIBO-utredning där det är tillgängligt. https://pmc.ncbi.nlm.nih.gov/articles/PMC6955189/
[P] The prevalence of small intestine bacterial overgrowth in irritable bowel syndrome is much higher with lactulose than glucose breath test: Results of a retrospective monocentric study. ScienceDirect 2024. Bekräftar 10× högre LBT-positivitet vs GBT i IBS-population — direkt relevant för Weinstock POTS-77 %-siffrans överskattning. https://www.sciencedirect.com/science/article/abs/pii/S2210740124002031
[G] Mayo Clinic. Small intestinal bacterial overgrowth (SIBO) — Diagnosis & treatment. 2025 update. Klinisk vägledning; rifaximin 550 mg × 3 i 10–14 dagar [ETABLERAD] vid bekräftad SIBO; betonar GBT som mer specifik än LBT. https://www.mayoclinic.org/diseases-conditions/small-intestinal-bacterial-overgrowth/diagnosis-treatment/drc-20370172
[P] Lacerda EM et al. Randomized, double-blinded, placebo-controlled pilot study: efficacy of faecal microbiota transplantation on chronic fatigue syndrome. 2023. PMID: 37516837. n = 80 ME/CFS-pilot RCT — negativt primärfynd för fatigue-VAS efter 6 månader. Kontextuellt relevant för POTS-överlapp; FMT-evidens vid kroniskt fatigue-spektrum bevisar inte att FMT hjälper POTS. https://pubmed.ncbi.nlm.nih.gov/37516837/
[F] Weinstock LB. POTS-SIBO-kohortrapportering — sekundärrapportering via Atrantil/KBS Research; ej publicerad som peer-reviewed primärstudie i den form som ofta citeras; n = 35; lactulose breath test-baserad; 77 % SIBO-positivitet sannolikt överskattad pga LBT-metodbias (jmf. #604, #605). Använd som klinisk historisk referens, inte som etablerad prevalens. https://atrantil.com/sibo-pots-and-dysautonomias/

GLP-1-receptoragonister vid POTS — paradoxal HR-effekt mot anti-inflammatorisk potential (kap. 06, 09.6, 12.7.4, 24.GL, 40.17, 80 — session 41)#

[F] Hedge S, Best SA, Kang J, et al. Exacerbation of Postural Orthostatic Tachycardia Syndrome With Tirzepatide Prescribed for Weight Loss. JACC: Case Reports 2025. doi:10.1016/j.jaccas.2025.105430. n = 1; 28-årig kvinna med kontrollerad POTS — tirzepatid orsakade HR-stegring 20–30 bpm liggande och stående med recidiv av ortostatisk intolerans. Författarna noterar att HR-stegring av denna magnitud aldrig tidigare rapporterats vid GLP-1 RA. Rekommenderar långsammare titrering vid POTS-komorbiditet. PMC12793844. https://www.jacc.org/doi/10.1016/j.jaccas.2025.105430
[F] Blitshteyn S, Suresh S, Lorenzi LM. Significant improvement of postural orthostatic tachycardia syndrome (POTS) with semaglutide: a case report. Clin Auton Res 2026. doi:10.1007/s10286-026-01197-1. n = 1; signifikant klinisk förbättring under semaglutid; hypotetisk mekanism anti-mikroglia + viktrelaterad förbättring av venös retur. Hypotesgenererande; specialistmottagning, publikationsbias mot positiva fall ska beaktas. https://link.springer.com/article/10.1007/s10286-026-01197-1
[P] Lo Re V et al. Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node. Cardiovasc Res 2024;120(12):1427. Molekylär mekanism för chronotrop effekt — kalciumklocksignalering via GLP-1R i sinusknutsceller; oberoende av autonom innervation. https://academic.oup.com/cardiovascres/article/120/12/1427/7687589
[P] Griffioen KJ, Wan R, Okun E, et al. GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. PMC3002870 (J Mol Cell Cardiol 2011). Central vagal inhibition i nucleus ambiguus — minskar HRV och höjer baseline-HR. https://pmc.ncbi.nlm.nih.gov/articles/PMC3002870/
[P] Smits MM, Tonneijck L, Muskiet MHA, et al. Effects of GLP-1 Receptor Agonists on Heart Rate and the Autonomic Nervous System Using Holter Electrocardiography and Power Spectrum Analysis of Heart Rate Variability. Diabetes Care 2016;39(2):e22. HR↑ utan LF/HF-skifte — talar för dominans av direkt sinusverkan över central vagal vid kronisk dosering. https://diabetesjournals.org/care/article/39/2/e22/37134
[P] Lyu X, Roman RA, et al. Heart and health behavior responses to GLP-1 receptor agonists: a 12-wk study using wearable technology and causal inference. Am J Physiol Heart Circ Physiol 2025. n = 66; prospektiv wearable-studie; HR-förändringar medierades av HRV-förändringar — kausalinferens. https://journals.physiology.org/doi/full/10.1152/ajpheart.00809.2024
[P] Effects of Glucagon-Like Peptide 1 Receptor Agonist Initiation in Patients With Heart Failure With Reduced Ejection Fraction and Implantable Cardiac Devices. JACC Heart Failure 2025. HR↑ ~7 bpm + ökade icke-uppehållna VT-episoder i HFrEF-population — varningssignal vid kombinerad hjärtsvikt. https://www.jacc.org/doi/10.1016/j.jchf.2025.102573
[P] Diz-Chaves Y, Herrera-Pérez S, González-Matías LC, Lamas JA, Mallo F. Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases. PMC9455625 (Int J Mol Sci 2022 + uppdateringar 2025). Mikroglia M1→M2-polarisering, sänkt TNF-α/IL-1β/IL-6, NF-κB-hämning. Preklinisk — humanvalidering pågår via Evoke/Evoke+. https://pmc.ncbi.nlm.nih.gov/articles/PMC9455625/
[P] GLP-1 receptor agonists and delayed gastric emptying: implications for invasive cardiac interventions and surgery. PMC11620716 (Cardiovasc Endocrinol Metab 2024/2025). 57 % av liraglutid-behandlade utvecklar fördröjd ventrikeltömning; FDA-varningar 2024 om elektiv kirurgi (aspirationsrisk). Relevant vid POTS + gastropares-komorbiditet (kap. 34). https://pmc.ncbi.nlm.nih.gov/articles/PMC11620716/
[P] Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. J Clin Endocrinol Metab 2025;110(1):1. Magnitud och klinisk hantering av GI-effekt. https://academic.oup.com/jcem/article/110/1/1/7824836
[G] FNIH (Foundation for the National Institutes of Health). RECOVER-TLC Clinical Trials. Pågående protokollutveckling 2025–2026; fyra interventioner inkl. semaglutid; enrollment sommar 2026 (försenat ~2 år). https://fnih.org/our-programs/recover-tlc-will-advance-long-covid-research/recover-tlc-clinical-trials/
[R] New RECOVER-TLC trials won't enroll until summer. The Sick Times 2026-01-23. Sekundär rapportering om enrollment-status och försening. https://thesicktimes.org/2026/01/23/new-recover-tlc-trials-wont-enroll-until-summer-nearly-two-years-after-the-programs-launch/
[S] Health Rising 2025-10-10. RECOVER's 2nd Round of Long COVID Clinical Trials Shows Progress and Limitations. Sekundär kritik av RECOVER-TLC-utförande; community-perspektiv på trial-design. https://www.healthrising.org/blog/2025/10/10/recover-tlc-long-covid-promise-limitations/

Hormonell modulering av ANS vid POTS — katamenial-syntes 2024–2026, OC-cerebrovaskulär nyans, progesteron-vagal paradox (kap. 05.6, 19.6, 20, 29.5–29.6 — session 40)#

[P] Boris JR, Bernadzikowski T, Stiles LE, Numan MT. The Long-Term Postural Orthostatic Tachycardia Syndrome Outcomes Survey — Gynecologic Findings: A Cross-Sectional Survey in Young Women. Obstet Gynecol Int 2025; doi:10.1155/ogi/8872884. n = 167 kvinnor med pediatrisk-onset POTS (≤ 18 år vid diagnos), CHOP-mottagningskohort. 72,4 % perimens-symtomförvärring; 50 % responder-rate på hormonell preventivmedelsbehandling; menorrhagia/PCOS/endometrios inte ökade vs allmänpopulationen. Selektionsbias från specialistmottagning. https://onlinelibrary.wiley.com/doi/10.1155/ogi/8872884 / https://pmc.ncbi.nlm.nih.gov/articles/PMC12283190/
[P] Magalhaes A et al. Women, orthostatic tolerance, and POTS: a narrative review. Auton Neurosci 2025;S1566-0702(25)00046-3. Special issue om kvinnors hälsa, april 2025. Östrogen-β-adrenerg-NO-axeln; FMD-revision när fitness/skala kontrolleras; förstärkt parasympatisk withdrawal vid stående hos kvinnor som hypotetisk drivare. Betonar hemodynamik + autonom funktion som primär drivare av kvinnlig övervikt; hormoner som moduleratorer. https://www.autonomicneuroscience.com/article/S1566-0702(25)00046-3/fulltext / https://www.sciencedirect.com/science/article/pii/S1566070225000463
[P] Blitshteyn S. Postural Orthostatic Tachycardia Syndrome, Menopause and Hormone Replacement Therapy: Clinical Decisions in Times of Uncertainty. J Clin Med 2026;15(4):1477; doi:10.3390/jcm15041477. PMID 41753164 / PMC12941859. Auktoritativ klinisk översikt; HRT vid POTS aldrig studerat systematiskt. Rekommendationsschema: vaginal estradiol 0,01 % cream "kan användas hos de flesta", transdermal patch "kan troligen användas hos många", mikroniserat progesteron "kan troligen prövas". Publicerat 13 feb 2026 i ljuset av FDA:s borttagning av black-box på östrogen-HRT (nov 2025). https://www.mdpi.com/2077-0383/15/4/1477 / https://pmc.ncbi.nlm.nih.gov/articles/PMC12941859/
[P] Skow RJ et al. Oral contraceptive use and menstrual cycle influence acute cerebrovascular response to standing. Auton Neurosci 2023;243:103039; doi:10.1016/j.autneu.2022.103039. PMID 36516546. Friska kvinnor (12 OC-användare + 9 icke-användare). Ingen systemisk hemodynamisk skillnad — men OC-användare hade större fall i mid-cerebral arteriell blodhastighet vid stående under låg-hormonell vecka. Mekanistiskt argument för kontinuerligt OC-protokoll vid POTS; direkt POTS-RCT saknas. https://www.sciencedirect.com/science/article/abs/pii/S1566070222001138 / https://pubmed.ncbi.nlm.nih.gov/36516546/
[P] Ribeiro VB et al. Effects of menstrual cycle on hemodynamic and autonomic responses to central hypovolemia. Front Cardiovasc Med 2024;11:1290703; PMID 38361585. Friska kvinnor i kontrollerad LBNP-modell. Luteal fas hade högre sympatisk aktivitet och bättre LBNP-tolerans; alla 4 deltagare som utvecklade synkope-symtom var i follikulär fas. Bekräftar Fu 2010 i central hypovolemi-modell. https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2024.1290703/full / https://pubmed.ncbi.nlm.nih.gov/38361585/
[P] Schmalenberger KM, Eisenlohr-Moul TA, Würth L, Schneider E, Thayer JF, Ditzen B, Jarczok MN. Menstrual Cycle Changes in Vagally-Mediated Heart Rate Variability Are Associated with Progesterone: Evidence from Two Within-Person Studies. J Clin Med 2020;9(3):617; doi:10.3390/jcm9030617. PMC7141121. Inom-person-design; högre progesteron predicerar lägre HRV. Stöds av meta-analys av 37 studier (n ≈ 1004) som visar minskad kardial vagal aktivitet från follikulär till luteal fas. Heterogenitet finns (Blake 2023 visade ökad vagaltonus i luteal). https://www.mdpi.com/2077-0383/9/3/617 / https://pmc.ncbi.nlm.nih.gov/articles/PMC7141121/

Termisk terapi som autonom-reparationsstrategi — värmeacklimatisering, bastu, kallchocksrespons och Wim Hof-metoden (kap. 09.7, 22.1b, 36.X, 40.4, 40.5 — session 46)#

[P] Parsons IT, Snape D, O'Hara JP, Wainwright B, Woods D. Improvements in Orthostatic Tolerance with Exercise Are Augmented by Heat Acclimation: A Randomized Controlled Trial. Med Sci Sports Exerc 2024;56(4):644–654. PMID 38079307; doi:10.1249/MSS.0000000000003342. RCT n = 20 endurance-tränade cyklister. 8 dagars värmeacklimatisering vs kontroll; tilttest-tolerans 28→40 min vs 30→33 min (p < 0,01); plasmavolym +6 %. Den första peer-reviewed RCT:n som direkt testar HACA-axeln på ortostatisk tolerans. https://pubmed.ncbi.nlm.nih.gov/38079307/ / https://journals.lww.com/acsm-msse/fulltext/2024/04000/improvements_in_orthostatic_tolerance_with.7.aspx
[P] Périard JD, Travers GJS, Racinais S, Sawka MN. Cardiovascular adaptations supporting human exercise-heat acclimation. Auton Neurosci 2016;196:52–62. PMID 26905458; doi:10.1016/j.autneu.2016.02.002. Mekanistisk review: plasmavolymexpansion 5–8 %, HR ↓ 10–15 bpm, hormonell axel (aldosteron + AVP +200–300 %). https://pubmed.ncbi.nlm.nih.gov/26905458/
[P] Schlader ZJ, Crandall CG. Mechanisms of orthostatic intolerance during heat stress. Auton Neurosci 2017. PMC5607624. Cerebral perfusion sjunker 15–20 % över tilttest vid värmestress (vs 5–10 % normotermt). Etablerar att akut värme + ortostas = farligt vid POTS och liknande tillstånd. https://pmc.ncbi.nlm.nih.gov/articles/PMC5607624/
[P] Heinonen et al. Influence of Exercise Heat Acclimation Protocol Characteristics on Adaptation Kinetics: A Quantitative Review With Bayesian Meta‐Regressions. PMC12122934, 2024. Plasmavolymexpansion poolad estimat 5,6 % (95 % CI 3,8–7,4 %). https://pmc.ncbi.nlm.nih.gov/articles/PMC12122934/
[P] Deshayes TA et al. Shifting focus: Time to look beyond the classic physiological adaptations associated with human heat acclimation. Exp Physiol 2024; doi:10.1113/EP091207. Kompletterande mekanismer bortom plasmavolym: endotelfunktion (FMD ↑), mitokondriell biogenes, HSP70/HSP90, sänkt systemisk inflammation. https://physoc.onlinelibrary.wiley.com/doi/full/10.1113/EP091207
[P] Kunutsor SK, Laukkanen T, Laukkanen JA. Sauna bathing is associated with reduced cardiovascular mortality and improves risk prediction in men and women: a prospective cohort study. BMC Med 2018;16:219. PMC6262976; doi:10.1186/s12916-018-1198-0. KIHD-kohort n = 1688, 15-årig median follow-up. Sauna 4–7×/vecka vs 1×/vecka: CV-mortalitet HR 0,42 (95 % CI 0,28–0,64); all-cause-mortalitet HR 0,55 (95 % CI 0,43–0,71). Linjär dos-respons. Observationell, finsk medelålders/äldre. https://pmc.ncbi.nlm.nih.gov/articles/PMC6262976/
[P] Laukkanen JA, Laukkanen T, Kunutsor SK. Cardiovascular and Other Health Benefits of Sauna Bathing: A Review of the Evidence. Mayo Clin Proc 2018;93(8):1111–1121; doi:10.1016/j.mayocp.2018.04.008. Mekanistisk review: sänkt arteriell styvhet, förbättrad endotelfunktion, sänkt BP, anti-inflammation, ANS-modulering. https://www.mayoclinicproceedings.org/article/s0025-6196(18)30275-1/fulltext
[P] Lee E, Laukkanen T, Kunutsor SK et al. Recovery from sauna bathing favorably modulates cardiac autonomic nervous system. Complement Ther Med 2019;45:190–197; doi:10.1016/j.ctim.2019.06.011. Akut studie n = 93 män med ≥ 1 CVD-riskfaktor. Under bastu: transient sympatisk dominans. Efter avkylning: LF ↓, HF ↑, vilo-HR ↓ — favorabelt vagalt skifte. https://www.sciencedirect.com/science/article/abs/pii/S0965229919301943
[P] Kuusinen V, Pelkonen H, Lääperi M et al. Regular postexercise sauna bathing does not improve heart rate variability: A multi-arm randomized controlled trial. Eur J Appl Physiol publ. juni 2025. PMID 40611569; PMC12231185. Multi-arms 8-veckors RCT; tillägg av post-träning bastu förbättrade INTE HRV utöver träning ensam. Den enda direkta interventions-RCT:n på regelbunden bastu och HRV — och den är negativ. https://pmc.ncbi.nlm.nih.gov/articles/PMC12231185/ / https://pubmed.ncbi.nlm.nih.gov/40611569/
[P] Vianna LC et al. Vagus activation by Cold Face Test reduces acute psychosocial stress responses. Sci Rep 2022;12:18866. PMC9649023; doi:10.1038/s41598-022-23222-9. RCT n = 95. CFT (4–10 °C ansiktsimversion 30–60 s) före TSST-stress reducerar saliv-amylas, kortisol och ångest; ökar RMSSD. Trigemino-vagal reflex via NTS → DMV/ambiguus. https://pmc.ncbi.nlm.nih.gov/articles/PMC9649023/
[P] Ackermann SP, Garbsch F, Schmidt H. The diving response and cardiac vagal activity: A systematic review and meta-analysis. Psychophysiology 2023;60(8):e14183; doi:10.1111/psyp.14183. Meta-analys, ~30 studier, n ≈ 1500. Pooled effekt-storlek Hedges g = 0,73. Heterogenitet hög (I² ≈ 65 %). https://onlinelibrary.wiley.com/doi/full/10.1111/psyp.14183
[P] Friman et al. Effects of Adding Facial Immersion to Chest-Level Water Immersion on Vagally-Mediated Heart Rate Variability. MDPI Sports 2025;13(3):64. PMC11946671. RCT-crossover n ≈ 30. Facial immersion-tillägg gav signifikant ytterligare vagal HRV-aktivering — bekräftar att trigemino-vagal reflex är specifikt facial. https://www.mdpi.com/2075-4663/13/3/64 / https://pmc.ncbi.nlm.nih.gov/articles/PMC11946671/
[P] Kox M, van Eijk LT, Zwaag J et al. Voluntary activation of the sympathetic nervous system and attenuation of the innate immune response in humans. Proc Natl Acad Sci USA 2014;111(20):7379–7384. PMID 24799686; doi:10.1073/pnas.1322174111. Wim Hof-metoden RCT n = 24. Adrenalin ↑ ~530 %; anti-inflammatorisk respons (IL-10 ↑, TNF-α/IL-6/IL-8 ↓) under endotoxinexponering. https://pubmed.ncbi.nlm.nih.gov/24799686/ / https://www.pnas.org/doi/10.1073/pnas.1322174111
[P] Petraskova Touskova T, Bob P, Bares Z et al. The effectiveness of the Wim Hof method on cardiac autonomic function, blood pressure, arterial compliance, and different psychological parameters. Sci Rep 2023;13:17508; doi:10.1038/s41598-023-44902-0. n = 38 friska, 6-veckors WH-träning vs kontroll. Förbättrad arteriell compliance, sänkt systoliskt BP. Inga signifikanta gruppskillnader på primära HRV-mått. https://www.nature.com/articles/s41598-023-44902-0
[P] Almahayni O, Hammond L. Does the Wim Hof Method have a beneficial impact on physiological and psychological outcomes in healthy and non-healthy participants? A systematic review. PLoS One 2024;19(3):e0286933. PMC10936795; doi:10.1371/journal.pone.0286933. 8 studier, n = 196. Konklusion: "Mixed evidence; insufficient evidence for clinical application in disease." https://pmc.ncbi.nlm.nih.gov/articles/PMC10936795/
[P] Wallden M, Rusjan P, Cosgrave J et al. A randomized controlled clinical trial of a Wim Hof Method intervention in women with high depressive symptoms. J Affective Disord Reports 2024;17:100727; doi:10.1016/j.jadr.2024.100727. n = 70 kvinnor med PHQ-9 ≥ 10. WH-grupp visade signifikant större depression-sänkning än kontroll. Inga POTS-data. https://www.sciencedirect.com/science/article/pii/S2666497624000481
[P] Lima Ruwhof V, Soares EAR, Lobo Bagini AR et al. Cold Water Immersion, Heart Rate Variability and Post-Exercise Recovery: A Systematic Review. PMID 39918163, 2024. 12 RCT, n ≈ 250 atleter. Konsistent positiv akut effekt på parasympatisk reaktivering efter träning (RMSSD, HF). Optimalt protokoll: 6–10 min CWI vid 10–15 °C. POTS-translation osäker. https://pubmed.ncbi.nlm.nih.gov/39918163/
[S] RTHM Clinic. Cold Water Therapy and Dysautonomia: Evidence, Risks, and Practical Application. Klinisk vägledning från specialiserad dysautonomi-klinik (icke-RCT, expertkonsensus). Diskuterar facial immersion som säker delkomponent vs full-body cold immersion-risk vid POTS/hyperadrenerg fenotyp. https://www.rthm.com/resources/blogs/cold-water-therapy-dysautonomia
[P] Mar PL et al. Menstrual Cycle Variability in Symptoms of Postural Orthostatic Tachycardia Syndrome (POTS). Heart Lung Circ 2022;31(11):1485–1490; doi:10.1016/j.hlc.2022.07.001 (S1443-9506(22)00628-X). n = 34 kvinnor med POTS; perimens-symtomvariation dominerad av yrsel, presynkope, fatigue. 21/34 i kontraception fortfarande symtomvarianta — kontraception eliminerar inte all variation hos alla. https://www.heartlungcirc.org/article/S1443-9506(22)00628-X/fulltext
[P] Coupal KE et al. Pubertal Hormonal Changes and the Autonomic Nervous System: Potential Role in Pediatric Orthostatic Intolerance. Front Neurosci 2019;13:1197; doi:10.3389/fnins.2019.01197. PMC6861527. Mekanism-syntes om pubertala hormonökningar (östrogen, sköldkörtelhormon, GH, insulin, IGF-1) → vasodilatation/blodvolymförändringar; progesteron → undertryckande av katekolamin-sekretion. Förklarar postpubertal kvinnodominans i POTS/VVS. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2019.01197/full / https://pmc.ncbi.nlm.nih.gov/articles/PMC6861527/

Mitokondriellt riktade kosttillskott vid POTS — kritisk evidensgenomgång (kap. 16.5–16.6, 22.3b, 40.11b — session 43)#

[P] Castro-Marrero J, Cordero MD, Sáez-Francas N, et al. Does oral coenzyme Q10 plus NADH supplementation improve fatigue and biochemical parameters in chronic fatigue syndrome? Antioxid Redox Signal 2015;22(8):679–685 (n = 80, 8 v dubbelblind RCT, CoQ10 200 mg + NADH 20 mg/dag — minskad fatigue och förbättrade biokemiska parametrar). https://pubmed.ncbi.nlm.nih.gov/25386668/
[P] Castro-Marrero J, Segundo MJ, Lacasa M, Martínez-Martínez A, Sevilla TFD, Alegre J. Effect of dietary coenzyme Q10 plus NADH supplementation on fatigue perception and health-related quality of life in individuals with myalgic encephalomyelitis/chronic fatigue syndrome: a prospective, randomized, double-blind, placebo-controlled trial. Nutrients 2021;13(8):2658 (n = 207, 12 v RCT — replikering av 2015-fyndet med signifikant FIS-40 + sömn + HRQoL). https://pubmed.ncbi.nlm.nih.gov/34444817/ • https://www.mdpi.com/2072-6643/13/8/2658
[STRUKEN — kunde inte verifieras] Tidigare citerad "Khanam S et al. Pilot evaluation of CoQ10 in POTS symptom management 2024 (n = 30)" återfinns inte i PubMed eller annan indexerad biomedicinsk databas per maj 2026. Posten har tagits bort ur brödtexten i kap. 16.5–16.6, 22.3b, 40.11b och ordlistan. Numret behålls för att inte rubba efterföljande referensnumrering.
[P] Mitochondrial Dysfunction and Coenzyme Q10 Supplementation in Post-Viral Fatigue Syndrome: An Overview. Int J Mol Sci 2024;25(1):574. Mekanistisk översikt. https://www.mdpi.com/1422-0067/25/1/574
[P] Wu A, Welty F, Chen K, et al. Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. eClinicalMedicine 2025 (Mass General Brigham/Harvard; n = 58 LC, NR 2 000 mg/dag, 24 v — NAD⁺ ↑ 2,6–3,1× men primärutfall fatigue/sömn/kognition/mood ej signifikanta). https://pmc.ncbi.nlm.nih.gov/articles/PMC12675013/ • https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00567-X/fulltext • https://pubmed.ncbi.nlm.nih.gov/41357333/
[S] Mass General Brigham. Research Spotlight: Trial Evaluates a Vitamin B3 Derivative in People with Long COVID. Pressmeddelande. https://www.massgeneralbrigham.org/en/about/newsroom/articles/trial-of-vitamin-b3-derivative-in-people-with-long-covid
[P] Andreux PA, Singh A, Rinsch C, et al. Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. Nature Aging 2025 (MitoImmune-studien; n = 50 friska medelålders, 1 000 mg/dag, 4 v — ökade naiva CD8⁺ T-celler och fettsyraoxidation; immunutfall, ej fatigue). https://www.nature.com/articles/s43587-025-00996-x • https://pubmed.ncbi.nlm.nih.gov/41174221/ • https://pmc.ncbi.nlm.nih.gov/articles/PMC12618261/
[P] Singh A, D'Amico D, Andreux PA, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Rep Med 2022. https://pubmed.ncbi.nlm.nih.gov/35584623/
[P] Cash A, Vernon SD, Bateman L, et al. RESTORE ME: a RCT of oxaloacetate for improving fatigue in patients with myalgic encephalomyelitis/chronic fatigue syndrome. Front Neurol 2024;15:1483876 (n = 82, 3 mån, OAA 2 000 mg/dag — fatigue-minskning > 25 % vs ≈ 10 % kontroll). Editorial concern utgiven: metodologi och ofullständig deklaration av competing interests under utredning per maj 2026. Förstaförfattare Alan Cash är officer i Terra Biological LLC (tillverkarföretaget); finansiering, blindad produkt och studiedesign-deltagande från företaget. https://pmc.ncbi.nlm.nih.gov/articles/PMC11632837/ • https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1483876/full • https://pubmed.ncbi.nlm.nih.gov/39664752/
[P] REGAIN: a randomized controlled clinical trial of oxaloacetate for improving the symptoms of long COVID. Front Neurosci 2025 (n = 69 LC, 42 dagar, OAA 2 000 mg/dag — signifikant kognitiv förbättring). Samma jävsbelastad grupp som RESTORE ME. https://pmc.ncbi.nlm.nih.gov/articles/PMC12313680/ • https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2025.1627462/full
[S] ME Association. Research: Randomised Controlled Trial of Oxaloacetate for Improving Fatigue in ME/CFS. 2024-10. Sammanfattning + kritisk granskning av RESTORE ME. https://meassociation.org.uk/2024/10/research-random-controlled-trial-of-oxaloacetate-for-improving-fatigue-in-me-cfs/
[P] Slankamenac J, Ranisavljev M, Todorovic N, et al. Eight-week creatine-glucose supplementation alleviates clinical features of long COVID. Food Sci Nutr 2024 (kreatin-glukos 8 g/dag, 8 v — signifikant fatigue ↓ + tid till utmattning ↑). https://pubmed.ncbi.nlm.nih.gov/38684388/
[P] Slankamenac J et al. Effects of six-month creatine supplementation on patient- and clinician-reported outcomes, and tissue creatine levels in patients with post-COVID-19 fatigue syndrome. Food Sci Nutr 2024 (PMC10630839; högdos 16 g/dag, 6 mån, ¹H-MRS — hjärnkreatin pregenuala anteriora cingulum ↑ 8,3 %, dorsolaterala prefrontala cortex ↑ 2,9 %). https://pmc.ncbi.nlm.nih.gov/articles/PMC10630839/
[P] Fortes BG et al. Creatine supplementation on fatigue related to post-COVID-19 condition — fatigue study: a randomized controlled trial. Front Nutr 2026 (n = 58 LC, 4 v, kreatin 6 g/dag vs 18 g/dag vs placebo + fysisk aktivitet 3×/v — 6 g signifikant Piper Fatigue Scale-Revised ↓ −2,05 KI −3,47 till −0,63; p = 0,005; 18 g inte tydligt bättre). https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2026.1731306/full
[S] Health Rising. Creatine — An Alternative Mitochondrial Energy Source for ME/CFS, Fibromyalgia, Long COVID? 2024-10-27. Patientorganisation-bloggöversikt; sekundär kontextkälla. https://www.healthrising.org/blog/2024/10/27/mitochondrial-energy-source-chronic-fatigue-syndrome-fibromyalgia-long-covid/
[P] Finnigan LEM, Cassar MP, Koziel MJ, Ntusi NAB, et al. Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study. eClinicalMedicine 2023;59:101946 (Oxford; n = 41 LC, 28 d, AXA1125 67,8 g/d — primär τPCr ej signifikant, sekundär Chalder Fatigue Scale förbättrad). https://pmc.ncbi.nlm.nih.gov/articles/PMC10102537/ • https://pubmed.ncbi.nlm.nih.gov/37223439/
[S] University of Oxford. Trial investigating potential treatment for fatigue relief in people with long COVID reports results. 2023-04-14. Pressmeddelande från Oxford-gruppen. https://www.ox.ac.uk/news/2023-04-14-trial-investigating-potential-treatment-fatigue-relief-people-long-covid-reports
[P] Vermeulen RC, Scholte HR. Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome. Psychosom Med 2004;66(2):276–282 (öppen RCT — ALCAR förbättrade mental fatigue 59 %, propionyl-karnitin förbättrade allmän fatigue 63 %). https://pubmed.ncbi.nlm.nih.gov/15039515/
[P] Vittone M et al. Conceptual foundations of acetylcarnitine supplementation in neuropsychiatric long COVID syndrome: a narrative review. Eur Arch Psychiatry Clin Neurosci 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC11579146/ • https://link.springer.com/article/10.1007/s00406-023-01734-3
[P] Vallings R et al. Patient-reported treatment outcomes in ME/CFS and long COVID. PNAS 2025 (PRO-data — ALCAR ≥ 500 mg/dag rapporterades positivt av 41,7 % patienter; observationsdesign, klar selektionsbias). https://www.pnas.org/doi/10.1073/pnas.2426874122
[S] Scaturro D et al. The Role of Acetyl-Carnitine and Rehabilitation in the Management of Patients with Post-COVID Syndrome: Case-Control Study. Appl Sci (MDPI) 2022;12(8):4084. https://www.mdpi.com/2076-3417/12/8/4084
[P] Teitelbaum JE, Johnson C, St Cyr J. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. J Altern Complement Med 2006;12(9):857–862 (öppen design, ingen kontroll). https://pubmed.ncbi.nlm.nih.gov/17109576/
[F] MEpedia. Ribose. Patient/community-databasens orientering om D-ribos. https://me-pedia.org/wiki/Ribose

Förstärkt extern motpulsation (EECP) som autonom-reparationsstrategi (kap. 06, 32, 40.7c — session 44)#

[P] Stys T, Lawson WE, Hui JC, et al. Effect of external counterpulsation on plasma nitric oxide and endothelin-1 levels. Heart Vessels 2007. PMID 16784915. NO ↑ +62 % i plasma över 35 EECP-sessioner; ET-1 sänkning. Mekanism för shear-stress-medierad endotelial reparation. https://pubmed.ncbi.nlm.nih.gov/16784915/
[P] Werner D, Gonzalez RM, Kaltenbach M, et al. External Counterpulsation Increases Beat-to-Beat Heart Rate Variability in Patients with Ischemic Stroke. J Stroke Cerebrovasc Dis 2017;26(7). PMID 28396189. RMSSD och SDNN ökade under aktiv EECP; LF och TP ↑; HF och LF/HF inte signifikant förändrade akut — talar emot förenklad "EECP är vagusstimulering"-narrativ. https://pubmed.ncbi.nlm.nih.gov/28396189/
[P] Wang Y, Liu X, et al. Effects of Cardiac Rehabilitation Combined with Enhanced External Counterpulsation on Heart Rate Variability and Autonomic Nervous Function in Chronic Heart Failure. Cardiovascular Toxicology 2025. doi:10.1007/s12012-025-10027-1. n = 120 RCT (control n = 56 vs observation n = 64); EECP-armen hade högre LF, högre HF och lägre LF/HF efter intervention — tolkat som förbättrad parasympatisk tonus med bevarad sympatisk reaktivitet vid kronisk dosering. Lägre rehospitalisering. https://link.springer.com/article/10.1007/s12012-025-10027-1
[F] Liu D, Sallam JE, et al. Management of Long-COVID Postural Orthostatic Tachycardia Syndrome With Enhanced External Counterpulsation. J Med Cases 2021. PMC8555928. n = 1; den enda publicerade fallrapporten på EECP vid LC-POTS specifikt per maj 2026. 15-sessions-protokoll under 3 veckor; brain fog förbättrad subjektivt; 6MWT +85 fot; DASI > +15 poäng; inga rapporterade biverkningar. Hypotesgenererande. https://pmc.ncbi.nlm.nih.gov/articles/PMC8555928/
[P] Bhargava A, Wu E, et al. Enhanced External Counterpulsation for Management of Postacute Sequelae of SARS-CoV-2 Associated Microvascular Angina and Fatigue: An Interventional Pilot Study. Cardiology Research and Practice 2023. PMC10764650. n = 10 prospektiv pilot utan kontrollgrupp; PASC + IMR ≥ 25 inkluderingskrav; modifierat 15-sessions-protokoll under 5 veckor. Signifikant minskning av angina (p < 0,05) och fatigue (p < 0,05); 1 patient symtomfri; 0 patienter försämrades. PASC-MVD ≠ LC-POTS — inkluderingskriterierna är inte ekvivalenta. https://pmc.ncbi.nlm.nih.gov/articles/PMC10764650/
[P] Sathyamoorthy M et al. Enhanced external counterpulsation for management of symptoms associated with long COVID. American Heart Journal Plus: Cardiology Research and Practice 2022. PMC10978164. n = 16 retrospektiv observation; 15–35 sessioner; PROMIS Fatigue förbättrad 4,63 ± 3,42 (p < 0,001); SAQ +21,44; DASI +18,08; 6MWT +200 m. Alla affekterade patienter återgick till arbete. Retrospektiv design ger högt regression-to-mean-bias. https://pmc.ncbi.nlm.nih.gov/articles/PMC10978164/
[P] Razavi-Marquez et al. Enhanced External Counterpulsation Improves Dyspnea, Fatigue, and Functional Capacity in Patients with Long COVID. COVID (MDPI) 2024;4(9):98. Matchad-par-jämförelse n = 33+33 (av 231 EECP-behandlade matchades 33 par mot obehandlade kontroller på ålder, kön, tid sedan COVID, bedömningsintervall). PROMIS Fatigue −15,0 ± 8,9 i EECP-armen vs −2,8 ± 5,9 i kontroll (p < 0,001); DASI +17,8 vs +1,8 (p < 0,001); RDS ≥ 1 klassförbättring 75,8 % vs 33,3 % (p < 0,001). Inte randomiserad — selektionsbias kvarstår men effektstorleken är påtaglig. Bäst tillgängliga data per maj 2026. https://www.mdpi.com/2673-8112/4/9/98
[R] ClinicalTrials.gov NCT05668039. Enhanced External Counterpulsation to Treat Long COVID-19 Fatigue (EXPECT). Sheba Medical Center; dubbelblind sham-kontrollerad RCT (sham = subterapeutiskt manschettryck + avvikande timing); 15 EECP-sessioner under 5 veckor; primärt utfall PROMIS Fatigue vid 5 veckor; sekundärt 6MWT, EQ-5D, FMD endotelfunktion. Status maj 2026: rekrytering. Resultat 2026–2027 — den första genuina RCT i fältet. https://clinicaltrials.gov/study/NCT05668039
[P] Wu E, et al. Adverse events and their management during enhanced external counterpulsation treatment in patients with refractory angina pectoris: observations from a routine clinical practice. Eur J Cardiovasc Nurs 2022;21(2):152–161. Lund universitetssjukhus klinisk praxis-data; vanliga (1–10 %) kutan irritation, muskelvärk, lätt huvudvärk; sällsynta (< 0,1 %) intrakraniell blödning; 0 dödsfall direkt attribuerade till EECP i den dokumenterade kohorten (n > 200). https://academic.oup.com/eurjcn/article/21/2/152/6277381
[P] Wu E, et al. Enhanced external counterpulsation in patients with refractory angina pectoris: a pilot study with six months follow-up regarding physical capacity and health-related quality of life. Eur J Cardiovasc Nurs 2013;12(5):437–445. Lund-uppföljning; signifikant förbättring av fysisk kapacitet och hälsorelaterad livskvalitet vid 6 månader. https://academic.oup.com/eurjcn/article/12/5/437/5931874
[P] Arora RR, Chou TM, Jain D, et al. The Multicenter Study of Enhanced External Counterpulsation (MUST-EECP): Effect of EECP on Exercise-Induced Myocardial Ischemia and Anginal Episodes. J Am Coll Cardiol 1999;33(7):1833–1840. Den ursprungliga sham-kontrollerade RCT vid refraktär angina — etablerade [ETABLERAD]-status och låg grunden för FDA 1995-godkännande. https://www.jacc.org/doi/10.1016/S0735-1097(99)00140-0
[S] Role of enhanced external counterpulsation in long COVID. Open Medicine (De Gruyter) 2025. doi:10.1515/med-2025-1216. Narrativ review; uppdatering av tidigare De Gruyter 2024 narrative review (med-2024-1067; PMC11716443). Sammanfattar evidenslandskapet med endotelial dysfunktion, fatigue och brain fog som centrala teman. https://www.degruyterbrill.com/document/doi/10.1515/med-2025-1216/html
[G] Cleveland Clinic. EECP Therapy (Enhanced External Counterpulsation). Patientorienterad klinisk översikt — kontraindikationer (signifikant aortainsufficiens, AAA, aktiv lower-extremity-infektion, graviditet), praktisk implementering. https://my.clevelandclinic.org/health/treatments/16949-enhanced-external-counterpulsation-eecp

Glymfatisk dysfunktion vid POTS — norepinefrin-driven CSF-clearance och AQP4-axeln (kap. 13.3b, 27.1.6, 28.6, 32, 40.20 — session 45)#

[P] Hauglund NL, Andersen M, Wagner J, Goldman SA, Nedergaard M et al. Norepinephrine-mediated slow vasomotion drives glymphatic clearance during sleep. Cell 2025;188(3). PMID 39788123. Landmark-studie: synkroniserade slow oscillationer (0,02–0,1 Hz) i NE från locus coeruleus driver vasomotion som pumpar CSF in i parenkymet under NREM-sömn. Optogenetisk LC-stimulering bekräftar kausalitet. Negativt fynd: zolpidem suppresserade NE-oscillationer och glymfatiskt flöde trots inducerad sömn. Två-foton imaging i mus + 7T MRI-validering hos 22 friska sovande deltagare. https://www.cell.com/cell/fulltext/S0092-8674(24)01343-6
[P] Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, Benveniste H, Vates GE, Deane R, Goldman SA, Nagelhus EA, Nedergaard M. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med 2012;4(147):147ra111. Foundational paper som introducerade konceptet glymfatiskt system. https://pubmed.ncbi.nlm.nih.gov/22896675/
[P] Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, O'Donnell J, Christensen DJ, Nicholson C, Iliff JJ, Takano T, Deane R, Nedergaard M. Sleep drives metabolite clearance from the adult brain. Science 2013;342(6156):373-377. Glymfatisk clearance 60–95 % aktivare under NREM-sömn än vakenhet; interstitial space ökar ~60 %. https://pubmed.ncbi.nlm.nih.gov/24136970/
[P] Lee H, Xie L, Yu M, Kang H, Feng T, Deane R, Logan J, Nedergaard M, Benveniste H. The effect of body posture on brain glymphatic transport. J Neurosci 2015;35(31):11034-11044. Lateral sömnposition ökar glymfatisk transport ~25 % vs supin position (mus). https://pmc.ncbi.nlm.nih.gov/articles/PMC4524974/
[P] Wirth KJ, Scheibenbogen C, Paul F. Glymphatic System Dysregulation as a Key Contributor to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. International Journal of Molecular Sciences 2025;26(23):11524. Submittad 14 okt 2025; publicerad 27 nov 2025. Hypotes-review som föreslår att kronisk hög extracellulär NE vid adrenerg dysfunktion (ME/CFS-POTS-överlapp) interfererar med AQP4-receptor-reglering → suboptimal glymfatisk clearance. https://www.mdpi.com/1422-0067/26/23/11524
[P] Lau DH, Fedorowski A, Raj SR, et al. Postural Orthostatic Tachycardia Syndrome: A State-of-the-Art Review. Heart, Lung and Circulation 2026 (publicerad online 9 januari); DOI 10.1016/j.hlc.2025.09.004. Första peer-reviewed POTS-state-of-the-art-review som explicit nämner alterations i glymfatiska systemet som föreslagen mekanism för medullär venös congestion och toxin-ackumulation. https://www.heartlungcirc.org/article/S1443-9506(25)01654-3/fulltext
[P] Idris OE, Sastry RC, et al. Asymmetrical glymphatic dysfunction in patients with long Covid associated neurocognitive impairment - correlation with BBB disruption. BMC Neurology 2025. PMID 40108491. Vänster-hemisfärs ALPS-index sänkt (1,383 ± 0,202) vs höger normal (1,470 ± 0,1374) vid LC-neurokognitiv dysfunktion; korrelerade med BBB-disruption. https://link.springer.com/article/10.1186/s12883-025-04133-4
[P] Wang Y et al. Dynamic brain glymphatic changes and cognitive function in COVID-19 recovered patients: a DTI-ALPS prospective cohort study. Frontiers in Psychology 2025;16:1465660. Prospektiv kohort med MRI vid 3, 6, 12 mån post-COVID. Maximal störning vid 3 mån; majoriteten normaliseras vid 12 mån; subgrupp med kvarstående brain fog hade inkomplet ALPS-återhämtning. https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2025.1465660/full
[P] Liu Q et al. Long-term physical exercise facilitates putative glymphatic and meningeal lymphatic vessel flow in humans. Nature Communications 2025;16. DOI 10.1038/s41467-025-58726-1. 12-veckors aerob motion på cykelergometer hos friska vuxna ökade glymfatisk influx vid putamen och meningeal lymfkärlsflöde. Det starkaste publicerade beviset att en POTS-förstahandsterapi (Levine/CHOP) har glymfatisk verkningsmekanism. https://www.nature.com/articles/s41467-025-58726-1
[R] Dagum P et al. Pharmacological enhancement of glymphatic function in humans increases the clearance of Alzheimer's disease-related proteins. medRxiv 2026.03.10.26348048v2. Preprint, ej peer-reviewed. n = 19 friska äldre; två cross-over RCT; IV dexmedetomidin (0,7 μg/kg/h, α2-agonist) + 10 mg oral midodrin (α1-agonist) — ACX-02 — suppresserade central NE-tone, ökade EEG slow waves; Aβ/tau-clearance ökade ~9–10 % vs placebo. Mekanistisk parallell till klinisk hyperadrenerg POTS-praxis (klonidin + midodrin). https://www.medrxiv.org/content/10.64898/2026.03.10.26348048v2
[P] Cheyuo C, Aziz M, Yang WL, Jacob A, Chaung W, Wang P. Clinically-derived vagus nerve stimulation enhances cerebrospinal fluid penetrance. Brain Stimul 2020;13(4):1024-1030. PMID 32388045. Cervikal VNS i råttmodell ökade CSF-penetrans signifikant via VNS-inducerade hemodynamiska svängningar → cerebral arteriol-pulsatilitet → glymfatisk pumpning. https://pubmed.ncbi.nlm.nih.gov/32388045/
[P] Potentiating Cerebral Perfusion Normalizes Glymphatic Dynamics in Systemic Inflammation. PMID 41047470, 2025. LPS-systemisk inflammation-modell — cerebral hypoperfusion medierar glymfatisk dysfunktion. Levosimendan normaliserade både CBF och glymfatisk clearance; bilateral karotis-stenos abolished effekten. Direkt POTS-koppling: Seeley 2025 supin hypoperfusion (61 %; kap. 13.1) kan utgöra mekanistisk bas för POTS-glymfatisk dysfunktion. https://pubmed.ncbi.nlm.nih.gov/41047470/
[P] The Fluidic Connectome in Brain Disease: Integrating Aquaporin-4 Polarity with Multisystem Pathways in Neurodegeneration. IJMS 2025;26(23):11536. Formaliserar AQP4-polaritet som koppling mellan glymfatisk funktion och multipla systemiska patomekanismer (mitokondriell dysfunktion, neuroinflammation, vaskulär regleringsdysfunktion). https://www.mdpi.com/1422-0067/26/23/11536
[P] The glymphatic system as a therapeutic target: TMS-induced modulation in older adults. Frontiers in Aging Neuroscience 2025;17:1597311. Theta-burst-stimulering (TBS) återställer AQP4-expression och dess polariserade lokalisering på astrocyt-endfötter — [P] djurmodell + human RCT pågår. https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2025.1597311/full
[P] Bagai K, Wakwe CI, Malow B, Black BK, Diedrich A, Paranjape SY, Robertson D, Raj SR. Estimation of Sleep Disturbances Using Wrist Actigraphy in Patients with Postural Tachycardia Syndrome. J Clin Sleep Med 2016;12(5):727-733. PMID 26951415. Den enda PSG-studien specifikt vid POTS (n = 16 + 15 kontroller). Inga signifikanta skillnader i N1/N2/N3/REM eller sömneffektivitet jämfört med kontroller — motverkar förenklad "POTS = N3-deficit"-narrativ. https://pmc.ncbi.nlm.nih.gov/articles/PMC4865560/
[P] Mitigating Head Position Bias in Perivascular Fluid Imaging: LD-ALPS, a Novel Method for DTI-ALPS Calculation. Tomography (MDPI) 2025;6(4):101. Visar att standardberäkning av ALPS-index är starkt beroende av huvudets position under MRI-akvisition. Metodologisk reservation mot DTI-ALPS som rutindiagnostik. https://www.mdpi.com/2673-4087/6/4/101
[P] White Matter Geometry Confounds Diffusion Tensor Imaging Along Perivascular Space (DTI-ALPS) Measures. PMC12231058, 2025. Fiber crossings, dispersion och undulation påverkar ALPS-index oberoende av glymfatisk funktion. ALPS-index är i stort insensitivt för sann perivaskulär diffusion under standardakvisitionsparametrar. Andra kritiska metodologiska reservationen mot DTI-ALPS. https://pmc.ncbi.nlm.nih.gov/articles/PMC12231058/

Pediatrisk autonom reparation — Boris LT-POTS, Bhatia 2016, Maraz 2022 tVNS-säkerhet, Morrow 2025 Long-COVID-OI (kap. 05.6, 40.16 — session 47)#

[P] Boris JR, Bernadzikowski T, Stiles LE, Hill MA, Numan MT. Long-Term POTS Outcomes Survey: Diagnosis, Therapy, and Clinical Outcomes. J Am Heart Assoc 2024;13(14):e033485. doi:10.1161/JAHA.123.033485. PMID 38958137; PMC11292765. n = 227 CHOP-pediatrisk-onset-POTS-patienter (mean ålder vid svar 21,8 år; median symtomdebut 13 år; mean 9,6 år sedan debut). Endast 0,9 % helt symtomfria i månaden före enkät; median 13 symtom kvarvarande; 89,8 % behöver fortsatt salt/vatten/träning. Författarna själva: "in sharp contrast to the prior studies that have described a high rate of spontaneous resolution of symptoms." Selektionsbias från specialistmottagning. https://www.ahajournals.org/doi/10.1161/JAHA.123.033485 / https://pmc.ncbi.nlm.nih.gov/articles/PMC11292765/
[P] Boris JR, Bernadzikowski T, Stiles LE, Numan MT. Long-Term Postural Orthostatic Tachycardia Syndrome Outcomes Survey: Educational, Economic, and Social Impact. J Am Heart Assoc 2025;14(21). PMC12684529. Samma kohort som Boris 2024 JAHA. ≥ 95 % examinerade från high school vid 21 år; majoriteten påbörjade college; hälften missat > 100 skoldagar under sjukdomsförloppet. Funktionell reparation realistisk; symtomatisk reparation sällsynt — distinkta utfallsmått som boken behöver hålla isär. https://pmc.ncbi.nlm.nih.gov/articles/PMC12684529/
[P] Bhatia R, Kizilbash SJ, Ahrens SP, Killian JM, Kimmes SA, Knoebel EE, Muppa P, Weaver AL, Fischer PR. Outcomes of Adolescent-Onset Postural Orthostatic Tachycardia Syndrome. J Pediatr 2016;173:149–153. doi:10.1016/j.jpeds.2016.02.035. Mayo Clinic, n = 172, ålder 13–18 vid POTS-diagnos, mean uppföljning 5,4 år. 86 % rapporterade förbättring (any improvement, intermittent, eller full resolution); 19 % full resolution. Lägre uppföljningstid och annan frågekonstruktion än Boris 2024 — bägge studier korrekt inom sin design; tillsammans illustrerar de att reparationsutfall beror starkt på utfallsmått. https://www.jpeds.com/article/S0022-3476(16)00199-2/abstract
[P] Maraz A, et al. Transcutaneous Auricular Vagus Nerve Stimulation in Pediatric Patients: A Systematic Review of Clinical Treatment Protocols and Stimulation Parameters. Neuromodulation 2022;25(8):1136–1147. PMID 35995653. 15 publicerade + 15 registrerade studier på pediatrisk tVNS (epilepsi, ADHD, autism, smärta, gastroparese). Inga dedikerade pediatriska tVNS-enheter på marknaden; inga neurodevelopmental säkerhetsdata; ingen pediatrisk POTS-tVNS-studie identifierad. Säkerhet i existerande studier god men sample-storlekar små och uppföljning kort. Stödjer konservativ rekommendation av tVNS hos adolescenta POTS-patienter. https://www.neuromodulationjournal.org/article/S1094-7159(22)00764-4/fulltext
[P] Morrow AK, Villatoro C, Kokorelis C, Rowe PC, Malone LA. Orthostatic Intolerance in Children With Long COVID Utilizing a 10-Minute Passive Standing Test. Clin Pediatr 2025;64(3):416–424. PMID 39123312. Johns Hopkins, n = 92 barn med Long COVID. 71 % uppfyller ortostatiska kriterier (POTS, OT, klassisk OH, fördröjd OH eller ortostatisk hypertension). 10-minuters passivt ståtest validerat som screeningverktyg. Kortfattat redan i kap. 5.5; integrerat i kap. 40.16-algoritm som modifierande variabel där PEM kontraindicerar standard CHOP-progression. https://journals.sagepub.com/doi/10.1177/00099228241272053
[S] Pace M, Bricout VA. How to Care for Adolescent Patients With Orthostatic Intolerance in the Primary Care Office. Pediatrics 2024 (PMC11561993). Praktisk klinisk översikt för primärvård av pediatrisk OI/POTS — användbar för svensk primärvårdsadaptation och för stegvisa rekommendationer i kap. 40.16. https://pmc.ncbi.nlm.nih.gov/articles/PMC11561993/
[P] Heart Rate Variability biofeedback therapy for children and adolescents with chronic pain: A pilot study. J Pain Res 2022. PubMed 35777250. n liten (10–17 år). Biofeedback vs. 4-veckors väntelistekontroll. Signifikanta inomgruppsförbättringar i smärtintensitet, skolfunktion och HRV. Ingen direkt POTS-relevans men illustrerar genomförbarhet och säkerhet hos adolescenta — relevant för 40.16-algoritmen Steg 3. https://pubmed.ncbi.nlm.nih.gov/35777250/

Pediatrisk postinfektiös autonom dysfunktion: EBV-trigger, GPCR-bioassay vs ELISA, LDN-pediatrik, kliniska prövningar (kap. 06, 12, 17, 24, 26, 40 — 2026-05-09)#

[P] Katz BZ, Shiraishi Y, Mears CJ, Binns HJ, Taylor R. Chronic Fatigue Syndrome Following Infectious Mononucleosis in Adolescents: A Prospective Cohort Study. Pediatrics 2009;124(1):189–193. doi:10.1542/peds.2008-1879. PMID: 19564299. n = 301 adolescenter 12–18 år med monospot-positiv IM. CFS-konversion enligt Fukuda: 13 % vid 6 mån, 7 % vid 12 mån, 4 % vid 24 mån. Kvinnligt kön starkast prediktor (90 % av CFS-fall vs 68 % av kohorten, p = 0,01). https://pmc.ncbi.nlm.nih.gov/articles/PMC2756827/
[P] Pedersen M, Asprusten TT, Godang K, Leegaard TM, Osnes LT, Skovlund E, Tjade T, Øie MG, Wyller VBB. Predictors of chronic fatigue in adolescents six months after acute Epstein-Barr virus infection: A prospective cohort study. Brain Behav Immun 2019;75:94–100. doi:10.1016/j.bbi.2018.09.023. PMID: 30261303. CEBA-kohorten (Norge), n = 200 adolescenter (12–20 år) + 70 kontroller. Vid 6 mån: 47 % "kronisk trötthet"; 29 % Fukuda-CFS; 21 % Canada-CFS. Baseline-prediktorer = sensorisk överkänslighet, smärta, funktionsnedsättning, ångest, plasma-CRP > 0,86, plasma-vitamin B12 — inte immunologi/EBV-load. https://pubmed.ncbi.nlm.nih.gov/30261303/
[P] Pricoco R et al. One-year follow-up of young people with ME/CFS following infectious mononucleosis by Epstein-Barr virus. Front Pediatr 2024. doi:10.3389/fped.2023.1266738. n = 25 (12 adolescenter + 13 unga vuxna, 14–22 år). Adolescenter har bättre 1-årsprognos (54 % uppfyller inte längre Canada-CFS) vs unga vuxna (0 % återhämtning). EBV-panelen som etablerar diagnostisk standard: anti-VCA-IgM/IgG, anti-EBNA-1-IgG, anti-EA-IgG (immunoblot), kvantitativ EBV-DNA-PCR. https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2023.1266738/full
[P] Jason LA, Furst J, Worth R, Katz BZ. Outcomes of ME/CFS following infectious mononucleosis: seven-year follow-up of a prospective study. Front Med 2026. doi:10.3389/fmed.2026.1676628. n = 4 501 collegestudenter följda 7 år; av 238 IM-fall fick 23 % ME/CFS vid 6 mån. 7-årsuppföljning: 79 % persistens vid svår initial ME/CFS, 30 % vid moderat, 25 % vid persisting symptoms. Motverkar förenklade "spontant utläker"-prognoser. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1676628/full
[P] Jason LA, Katz BZ. Predisposing and Precipitating Factors in Epstein–Barr Virus-Caused Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Microorganisms 2025;13(4):702. doi:10.3390/microorganisms13040702. PMID: 40284540. Predisponerande baseline: pre-illness fatigue, låga IL-5/IL-13, dysregulerade metaboliter (S-adenosyl-L-metionin, glutation, cystein, tiamin). Precipiterande vid IM-onset: GI-symtom (buksmärta, IBS-mönster) + svår fatigue → ~80 % risk för svår ME/CFS. https://pubmed.ncbi.nlm.nih.gov/40284540/
[F] Henderson TA. Valacyclovir treatment of chronic fatigue in adolescents. Adv Mind Body Med 2014;28(1):4–14. PMID: 24445302. Den enda publicerade pediatriska valaciklovir-studien: open-label retrospektiv fallserie n = 15 adolescenter/pre-tonåringar med CFS (Fukuda-kriterier). 93 % positiv respons men ingen kontrollgrupp; dosering ospecificerad. Får inte ensam motivera klinisk rekommendation. https://pubmed.ncbi.nlm.nih.gov/24445302/
[P] Montoya JG, Kogelnik AM, Bhangoo M, et al. Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome. J Med Virol 2013. doi:10.1002/jmv.23713. PMID: 23959519. Den enda blindade placebokontrollerade RCT:n för antiviral terapi vid CFS. n = 30 vuxna med förhöjda HHV-6/EBV IgG. Primärt utfall (Multidimensional Fatigue Inventory) inte signifikant; sekundärutfall (mental fatigue, kognition) signifikanta. Etablerar antiviraler vid post-EBV-CFS = [EXPERIMENTELL]. https://pubmed.ncbi.nlm.nih.gov/23959519/
[S] Ruiz-Pablos M, Paiva B, Montero-Mateo R, Garcia N, Zabaleta A. Epstein-Barr Virus and the Origin of Myalgic Encephalomyelitis or Chronic Fatigue Syndrome. Front Immunol 2021;12:656797. doi:10.3389/fimmu.2021.656797. PMID: 34867935. Narrativ mini-review om EBV-immunpatobiologi och ME/CFS. Slutsats om antiviraler: "results of trials using antivirals have been inconclusive and, in some cases, contradictory; there are no effective treatments to eradicate EBV latency". https://pmc.ncbi.nlm.nih.gov/articles/PMC8634673/
[P] Hall J, Bourne KM, Sheldon RS, Vernino S, Raj V, Ng J, Exner DV, Sheldon AT, Stiles LE, Tang AS, Stewart JM, Fedorowski A, Raj SR. Detection of G Protein–Coupled Receptor Autoantibodies in Postural Orthostatic Tachycardia Syndrome Using Standard Methodology. Circulation 2022;146(8):613–622. doi:10.1161/CIRCULATIONAHA.122.059971. PMID: 35766055. n = 116 POTS (Calgary + Malmö/Lund) + 81 friska kontroller. CellTrend ELISA mot 11 GPCR visade INGA signifikanta skillnader mellan POTS och kontroller. 98–100 % seropositiva för α1-AR i båda grupperna. Slutsats: "These tests are not useful for establishing the role of autoimmunity in POTS." https://pmc.ncbi.nlm.nih.gov/articles/PMC9390234/
[P] Wallukat G, Hohberger B, Wenzel K, Fürst J, Schulze-Rothe S, Wallukat A, Hönicke AS, Müller J. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun 2021;4:100100. doi:10.1016/j.jtauto.2021.100100. PMID: 33880442. PMC8049853. Funktionellt cardiomyocyt-bioassay (kronotropisk effekt-mätning). β2-AR-fAAB 92,8 %, AT1R 85,6 %, Mas 85,6 %, M2 87,1 %. β2-fAAB associerade med yrsel + koncentrationssvårigheter + POTS. Inte kommersiellt tillgängligt 2026 — endast Charité/Max-Delbrück forskningssamarbete. https://pmc.ncbi.nlm.nih.gov/articles/PMC8049853/
[P] Badiudeen T, Forsythe E, Bates G, Howe T, Cunningham M, Vernino S, Kem D. A functional cell-based bioassay for assessing adrenergic autoantibody activity in postural tachycardia syndrome. J Transl Autoimmun 2019;2:100006. doi:10.1016/j.jtauto.2019.100006. PMID: 32743496. PMC7388390. α1AR/β1AR-NFAT-bla CHO-K1-celler med GeneBLazer FRET-baserad β-laktamas-reportergen. Visade signifikant högre adrenerg AAB-aktivitet hos POTS vs kontroller. Forskningskontext OUHSC, inte kommersiellt tillgängligt. https://pmc.ncbi.nlm.nih.gov/articles/PMC7388390/
[S] Berlin Cures GmbH. BC 007 does not show superiority over placebo in Phase 2 Long COVID trial. Press release november 2024. https://www.berlincures.com/en/news/phase-2-long-covid-results. Industri-meddelande om misslyckad fas 2-RCT av aptamer som neutraliserar funktionella GPCR-autoantikroppar. Erlangen-preprint dec 2024 rapporterade positiv effekt i mindre öppen studie. Den blindade fas 2 är högkvalitativa evidensen och nyanserar enkel "neutralisera autoantikroppar = bota Long COVID"-hypotesen.
[S] Stancil SL, Abdel-Rahman S, Wagner J. Developmental Considerations for the Use of Naltrexone in Children and Adolescents. J Pediatr Pharmacol Ther 2021;26(7):675–695. PMID: 34588931. Översikt om utvecklingsfarmakokinetik vid pediatrisk naltrexon-användning — flaggar att μ-receptor-modulering under HPA-mognad är teoretiskt okartlagd. Stödjer [OFF-LABEL] + [EXPERIMENTELL] klassning av LDN hos adolescenter. https://pubmed.ncbi.nlm.nih.gov/34588931/
[R] Villatoro C, Yonts AB, Barter T, Mohandas S, Malone LA. Low Dose Naltrexone Prescribing Practices for Children and Adolescents with Long COVID. medRxiv 2026 (postad 22 februari 2026). doi:10.64898/2026.02.20.26346719v1. Den första publicerade pediatriska LDN-prescribing-studien: n = 62, mean ålder 15,6 år (range 8–23), 3 USA-multidisciplinära pediatriska Long-COVID-program. Generellt vält tolererad. Preprint, ej peer-reviewed per maj 2026. https://www.medrxiv.org/content/10.64898/2026.02.20.26346719v1
[P] Bonilla H, Tamariz L, Bast E, Klimas N, Palacio A. Low-dose Naltrexone Improves post-COVID-19 condition Symptoms. Clin Ther 2024;46(3):e101–e106. doi:10.1016/j.clinthera.2023.12.009. PMID: 38267326. Retrospektiv kohort n = 108 vuxna med post-COVID-tillstånd. HR för förbättring 5,04 (95 % CI 1,22–20,77; p = 0,02) för LDN vs fysioterapi ensam. Brett CI reflekterar sample-size-begränsning. https://pubmed.ncbi.nlm.nih.gov/38267326/
[P] Polo O, Pesonen P, Tuominen E. Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Fatigue: Biomedicine, Health & Behavior 2019;7(4):207–217. doi:10.1080/21641846.2019.1692770. Norsk retrospektiv kohort vuxen ME/CFS. 73,9 % rapporterade behandlingsrespons — tolerabilitet god (insomnia, illamående initialt, ej allvarliga). Ingen kontrollgrupp; sannolik publication bias. https://www.tandfonline.com/doi/full/10.1080/21641846.2019.1692770
[P] Cabanas H, Muraki K, Eaton-Fitch N, Marshall-Gradisnik S. Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment. Front Immunol 2021;12:687806. doi:10.3389/fimmu.2021.687806. Cellbaserad mekanistisk studie — LDN återställer TRPM3-jonkanalfunktion i NK-celler från ME/CFS-patienter. Föreslår TRPM3 som mekanism och biomarkör för LDN-respons. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.687806/full
[S] RECOVER-TLC LDN-trial information. NIH RECOVER-TLC + FNIH. https://fnih.org/our-programs/recover-tlc-will-advance-long-covid-research/recover-tlc-clinical-trials/. Pediatrisk + ung vuxen LDN-RCT planerad (åldrar 6–25, Long COVID + fatigue ≥ 3 mån). Randomiserad placebokontrollerad, 16 v behandling, ~1 300 deltagare på ~100 USA-siter. Enrollment startar sommar 2026. Inga europeiska siter bekräftade.
[S] RECOVER-AUTONOMIC NCT06305780. NIH RECOVER. https://trials.recovercovid.org/autonomic. Adult IVIG vs placebo OR ivabradin vs placebo. n = 381, ≥ 18 år. Resultat förväntade 2026–2027.
[P] Buonsenso D, Munblit D, Pazukhina E, Ricchiuto A, Sinatti D, Zona M, De Matteis A, D'Ilario F, Gentili S, Lanni R, Rongai T, Del Balzo P, Fonte MT, Valenti S, Zampino G, Esposito S, Nicolai T, IP4C Study Group. International Care programs for Pediatric Post-COVID Condition (Long COVID) and the way forward. Eur J Pediatr 2024. PMID: 38287106. International Post-COVID-Condition in Children Collaboration (IP4C). 10 PPCC-vårdprogram + 6 LC follow-up-cohorts kartlagda för real-life management. https://pubmed.ncbi.nlm.nih.gov/38287106/
[G] Equity in research: a global consensus statement on the urgency of including children in long COVID clinical trials. European Respiratory Journal 2025;65(5):2500092. PMC12095905. Konsensusuttalande från ERS + flera barnläkar-organisationer. Kräver explicit pediatrisk inkludering i Long-COVID-RCT. https://pmc.ncbi.nlm.nih.gov/articles/PMC12095905/
[S] CellTrend GmbH (Luckenwalde, Tyskland). GPCR-Antibodies ELISA Kits. https://www.celltrend.de/en/elisa/gpcr-antibodies/. Den enda kommersiella GPCR-autoantikropps-leverantören i EU 2026. Sandwich-ELISA för α1-AR, α2-AR, β1-AR, β2-AR, M1–M5R, AT1R, ETAR. Tar prover från svenska patienter via direkt patient-tjänst eller forskningssamarbete.
[P] Functional Autoantibodies Targeting G-Protein-Coupled Receptors and Their Clinical Phenotype in Patients with Long-COVID. IJMS 2025;26(14):6746. PMID 40724994. Anwar och kollegor — funktionellt bioassay i 194 Long-COVID-patienter. β2-AR-fAAB starkt associerad med yrsel, koncentrationssvårigheter och POTS. https://www.mdpi.com/1422-0067/26/14/6746
[P] Vernino S, Bourne KM, Stiles LE, Grubb BP, Fedorowski A, Stewart JM, Arnold AC, Pace LA, Axelsson J, Boris JR, Moak JP, Goodman BP, Chémali KR, Chung TH, Goldstein DS, Diedrich A, Miglis MG, Cortez MM, Miller AJ, Freeman R, Biaggioni I, Rowe PC, Sheldon RS, Shibao CA, Systrom DM, Cook GA, Doherty TA, Abdallah HI, Darbari A, Raj SR. Postural orthostatic tachycardia syndrome (POTS): State of the science and clinical care from a 2019 NIH Expert Consensus Meeting – Part 1. Auton Neurosci 2021;235:102828. doi:10.1016/j.autneu.2021.102828. PMID 34245985. NIH-konsensusdokument med rekommendation att autoantikroppstest "ska tolkas i kontext" och inte ensam motivera immunterapi. https://pmc.ncbi.nlm.nih.gov/articles/PMC8455420/

Pediatrisk Long-COVID-behandling, sub-klinisk myokardit-screening och forskningsbiomarkörer (kap. 06, 26, 32 — 2026-05-09)#

[P] Yamayoshi S, Sakai-Tagawa Y, Koga M, Akasaka O, Nakachi I, Koh H, Maeda K, Adachi E, Saito M, Nagai H, Ikeuchi K, Ogura T, Baba R, Fujita K, Fukui T, Ito F, Hattori SI, Yamamoto K, Nakamoto T, Furusawa Y, Yasuhara A, Ujie M, Yamada S, Ito M, Mitsuya H, Yotsuyanagi H, Iwatsuki-Horimoto K, Imai M, Kawaoka Y. Anti-SARS-CoV-2 IgG and Neutralizing Antibody Levels in Patients with Past COVID-19 Infection: A Longitudinal Study. mBio 2022. PMID: 35378574. https://pmc.ncbi.nlm.nih.gov/articles/PMC9136548/. Kraftig vaning av anti-N IgG: 87,5 % vid 3 mån → 38,6 % vid 6 mån → 23,7 % vid 9 mån → 26,6 % vid 12 mån. Klinisk implikation: negativ anti-N IgG > 12 mån utesluter inte tidigare COVID. [P]
[P] Mello AT et al. 2024 Sci Rep — Longitudinal analysis of SARS-CoV-2 IgG antibody durability in Puerto Rico. doi:10.1038/s41598-024-80465-4. https://www.nature.com/articles/s41598-024-80465-4. Konfirmerar Yamayoshi-vaningsmönster i ovaccinerad kohort. [P]
[P] Wallukat-typ scoping review Clin Auton Res 2024. Treatments for Long COVID autonomic dysfunction: a scoping review. doi:10.1007/s10286-024-01081-w. Adressar fexofenadin + famotidin, maraviroc + pravastatin, SSRI, nutraceutiska formuleringar (SIM01), HRV-biofeedback, IMT, SGB. SIM01-RCT (Lau 2024) visade förbättring på fatigue/GI. Inga pediatriska RCT inkluderade. [S]
[S] Kell DB, Khan MA, Pretorius E. Fibrinaloid microclots in long COVID: assessing the actual evidence properly. Res Pract Thromb Haemost 2024. doi:10.1016/j.rpth.2024.102566. PMID: 39434957. https://pmc.ncbi.nlm.nih.gov/articles/PMC11491705/. Letter/svar på Hunt et al kritisk opinionsartikel. Beskriver Pretorius-detektionsprotokoll (thioflavin T + Amytracker + flödescytometri). Inte oberoende laboratoriskt replikerat utanför Stellenbosch + Liverpool. Inga pediatriska data. [S]
[P] Kjellberg A et al. 2025 BMJ Open HOT-LoCO trial. Karolinska, Stockholm. RCT n = 80, 10 sessioner HBOT vs sham, 2,4 ATA. Primärt utfall RAND-36 fysisk funktion: ingen signifikant skillnad (HBOT +9,0 vs sham +8,6, p = 0,87). Pediatrisk HBOT vid Long COVID = [EXPERIMENTELL] utan stödande RCT. [P]
[P] Hadanny A et al. 2024 Sci Rep — Long-term outcomes of HBOT 40-sessioner-protokoll vid post-COVID-tillstånd. Sagol-gruppen Tel Aviv. https://www.nature.com/articles/s41598-024-53091-3. Visade signifikant förbättring i kognitiv funktion + fatigue. [P]
[P] Watanabe K et al. 2025 Medicine (Baltimore). EAT (epipharyngeal abrasive therapy) vid pediatrisk Long-COVID-POTS — fallrapport (n = 1). https://pmc.ncbi.nlm.nih.gov/articles/PMC12262939/. [F]
[P] Kim YH et al. 2024 Pediatr Cardiol — Association between hs-cTnT and myocarditis diagnosis in previously healthy pediatric patients. PMID: 39126513. https://pubmed.ncbi.nlm.nih.gov/39126513/. Hs-cTnT-cutoff 90 ng/dL → 100 % sensitivitet, 95 % specificitet för pediatrisk myokardit. [P]
[P] AHA pediatric hs-cTn troponin URL 2023 Circulation. Myocardial Injury Thresholds for 4 High-Sensitivity Troponin Assays in a Population-Based Sample of US Children and Adolescents. doi:10.1161/CIRCULATIONAHA.122.063281. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.063281. Pediatriska 99:e percentil URL är lägre än vuxen-referenser. [P]
[P] Cornicelli MD, Rigsby CK et al. 2019 J Cardiovasc Magn Reson. Diagnostic performance of cardiovascular magnetic resonance native T1 and T2 mapping in pediatric patients with acute myocarditis. doi:10.1186/s12968-019-0550-7. PMID: 31307467. https://pmc.ncbi.nlm.nih.gov/articles/PMC6631973/. n = 23 pediatriska myokardit + 39 friska kontroller. Pediatriska CMR-cutoffs: Global T1 1015,5 ms, T2 48,5 ms, ECV 25,9 %. Sensitivitet 91/91/86 %, specificitet 86/74/89 %. Endast 57 % uppfyllde Lake Louise Criteria. [P]
[G] ACC 2024 Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis. J Am Coll Cardiol. doi:10.1016/j.jacc.2024.10.080. https://www.jacc.org/doi/10.1016/j.jacc.2024.10.080. Inkluderar pediatrisk subgrupp-sektion. [G]
[G] Ferreira VM et al. 2018 J Am Coll Cardiol — uppdaterade Lake Louise Criteria för icke-ischemisk myokardit-diagnos. Kräver minst 1 T2-baserat + 1 T1-baserat kriterium. [G]
[P] Practice patterns of cardiovascular magnetic resonance use in the diagnosis of pediatric myocarditis: A survey-based study. J Cardiovasc Magn Reson 2024. PMC11647491. Endast 11 % av amerikanska centra har scanner-specifika pediatriska normalvärden för T1-mapping; 22 % för T2. [P]
[P] Schultheiß C, Willscher E, Paschold L, Gottschick C, Klee B, Henkes SS, Bosurgi L, Dutzmann J, Sedding D, Frese T, Girndt M, Höll JI, Gekle M, Mikolajczyk R, Binder M. The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med 2022;3(6):100663. doi:10.1016/j.xcrm.2022.100663. PMID: 35732153. https://pmc.ncbi.nlm.nih.gov/articles/PMC9214726/. Etablerad PASC-cytokin-triad-signatur. [P]
[P] Ganesh R et al. 2024 J Prim Care Community Health. Pro-Inflammatory Cytokines Profiles of Patients With Long COVID Differ Between Variant Epochs. doi:10.1177/21501319241254751. https://journals.sagepub.com/doi/10.1177/21501319241254751. Cytokin-triad-signalen förlorad i Omicron-era — variantspecifik. [P]
[P] Cytokine Response to SARS-CoV-2 Infection in Children. PMID: 34578450. https://pmc.ncbi.nlm.nih.gov/articles/PMC8473005/. Pediatrisk IL-6/TNF-α förhöjt vid COVID vs andra infektioner men korrelerar inte med svårighetsgrad. [P]
[P] Wunderle M, Ribeiro A, Lethen I, et al. Serum NfL and GFAP in post-COVID syndrome: minimal evidence of CNS injury after adjusting for confounders. Front Cell Neurosci 2026 (publicerad online 20 mars 2026). doi:10.3389/fncel.2026.1750121. https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2026.1750121/full. Negativt fynd: ingen signifikant gruppskillnad i NfL mellan Long COVID och kontroller efter adjustering för confounders. [P]
[P] Sci Rep 2026 (Stavanger University Hospital-grupp). Long-COVID: assessment of circulating markers suggests no cerebral neuronal damage, neuroinflammation or systemic inflammation – a controlled study. Publicerad mars 2026. doi:10.1038/s41598-026-40142-0. https://www.nature.com/articles/s41598-026-40142-0. NfL + GFAP mätt vid median 69 v post-SARS-CoV-2; ingen signifikant skillnad mot kontroller. Kontrollerad studie utan stöd för CNS-skadehypotesen via NfL/GFAP. [P]
[P] Mol Psychiatry 2024. Long COVID: plasma levels of neurofilament light chain in mild COVID-19 patients with neurocognitive symptoms. doi:10.1038/s41380-024-02554-0. https://www.nature.com/articles/s41380-024-02554-0. Förhöjt plasma-NfL vid mild Long COVID med neurokognitiva symtom (motsatsfynd jämfört med #612 + #613). [P]
[P] Sci Rep 2023. Central nervous system biomarkers GFAp and NfL associate with post-acute cognitive impairment and fatigue following critical COVID-19. PMID: 37527982. doi:10.1038/s41598-023-39698-y. https://www.nature.com/articles/s41598-023-39698-y. Förhöjt GFAP vid 3–6 mån post-ICU-COVID associerat med kognitiv dysfunktion, särskilt hos kvinnor. [P]
[P] Swank Z et al. 2023 Clin Infect Dis. Plasma-based antigen persistence in the post-acute phase of SARS-CoV-2 infection. PMID: 37961239. https://pubmed.ncbi.nlm.nih.gov/37961239/. Ultrasensitiv Simoa-detektion av S/S1/N-protein i ~65 % av Long-COVID-plasma upp till 12 månader. Inte detekterat hos akuta COVID-patienter eller kontroller. [P]
[R] medRxiv 2024.11.11.24317084. Long-term serum spike protein persistence but no correlation with post-COVID syndrome. https://www.medrxiv.org/content/10.1101/2024.11.11.24317084v1. Preprint, ej peer-reviewed. Spike-persistens detekterad även hos asymtomatiska/återställda — ingen korrelation med PCS-symtom. Nyanserar enkel "spike-persistens = sjukdomsdriver"-hypotesen. [R]
[P] Iu DS, Maya J, Vu LT, Fogarty EA, McNairn AJ, Ahmed F, Franconi CJ, Munn PR, Grenier JK, Hanson MR (senior), Grimson A. Transcriptional reprogramming primes CD8+ T cells toward exhaustion in Myalgic encephalomyelitis/chronic fatigue syndrome. PNAS 2024 (publicerad 10 december 2024). doi:10.1073/pnas.2415119121. PMID: 39621903. PMC11648872. https://www.pnas.org/doi/10.1073/pnas.2415119121. Cornell University-grupp; multiomic-analys (single-cell RNA-seq + ATAC-seq + RNA-seq) av CD8+ T-celler från ME/CFS-patienter visade transcriptional reprogramming + altered chromatin landscape + metabolic reprogramming konsistent med exhausted state. (Iwasaki vid Yale har separata Long COVID-studier och är inte författare på denna publikation.) [P]
[P] JCI Insight 2024. Immune exhaustion in ME/CFS and long COVID. PMC11529985. https://pmc.ncbi.nlm.nih.gov/articles/PMC11529985/. Sammanställer evidensen — Tregs och PD-1 främjar kronisk-virus-medierad immununfattning. [P]
[P] Nature Immunology 2025. Identification of soluble biomarkers that associate with distinct manifestations of long COVID. doi:10.1038/s41590-025-02135-5. https://www.nature.com/articles/s41590-025-02135-5. Soluble biomarkers associerade med distinkta LC-fenotyper, inkl. T-cellsexhaustion-signaturer. [P]

Pediatrisk ME/CFS-formalisering, suicidalitet-säkerhetsfarmakologi, kvalitetsgranskning (kap. 05, 19, 33, 38 — 2026-05-09)#

[G] Institute of Medicine. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington, DC: National Academies Press; 2015. PMID: 25695122. ISBN 978-0-309-31689-7. https://www.nationalacademies.org/read/19012/. Pediatrisk modifiering: 3 mån symtomduration vs vuxen 6 mån. [G]
[S] Rowe PC, Underhill RA, Friedman KJ, Gurwitt A, Medow MS, Schwartz MS, Speight N, Stewart JM, Vallings R, Rowe KS. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Diagnosis and Management in Young People: A Primer. Front Pediatr 2017;5:121. PMID: 28674681. https://pubmed.ncbi.nlm.nih.gov/28674681/. International Writing Group for Pediatric ME/CFS. [S]
[P] Jason LA, Sunnquist M. The Development of the DePaul Symptom Questionnaire: Original, Expanded, Brief, and Pediatric Versions. Front Pediatr 2018;6:330. doi:10.3389/fped.2018.00330. PMID: 30460215. https://pmc.ncbi.nlm.nih.gov/articles/PMC6232226/. DSQ-Ped med förälderform + barnform; fritt tillgänglig via REDCap. Pediatriska ME/CFS-kriterier ger 3 % feldiagnos vs Fukuda 24 %. [P]
[P] Sunnquist M, Jason LA. Data-driven ascertainment of the symptom profile of pediatric myalgic encephalomyelitis and chronic fatigue syndrome. Int J Child Adolesc Health 2024;17(2):151–163. [P]
[S] Bell DS. The Doctor's Guide to Chronic Fatigue Syndrome: Understanding, Treating and Living with CFIDS. Reading, MA: Addison-Wesley; 1995. Bell Disability Scale 0–100. [S]
[P] Lansky SB, List MA, Lansky LL, Ritter-Sterr C, Miller DR. The measurement of performance in childhood cancer patients. Cancer 1987;60(7):1651–1656. Lansky Performance Status. [P]
[P] Sommerfelt K, Schei T, Angelsen A, Strand EB. Assessing Functional Capacity in Myalgic Encephalopathy/Chronic Fatigue Syndrome: A Patient-Informed Questionnaire. J Transl Med 2024. PMC11204454. https://pmc.ncbi.nlm.nih.gov/articles/PMC11204454/. FUNCAP-instrument. [P]
[P] Snell CR, Stevens SR, Davenport TE, Van Ness JM. Cardiopulmonary Exercise Test Methodology for Assessing Exertion Intolerance in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Front Pediatr 2018;6:242. doi:10.3389/fped.2018.00242. https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2018.00242/full. Workwell 2-dagars CPET-protokoll. [P]
[G] NICE. Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management (NG206). 2021. https://www.nice.org.uk/guidance/ng206. Brittisk klinisk riktlinje med pediatrisk sektion. [G]
[S] RME (Riksförbundet för ME-patienter). Svensk översättning av Pediatric Primer (Rowe 2017). https://rme.nu/wp-content/uploads/2020/05/Pediatric-Primer-monograph-11-17-2017-for-Website.pdf. [S]
[G] Socialstyrelsen. ICD-10-SE klassifikation: G93.3 Postviralt trötthetssyndrom. https://www.socialstyrelsen.se/. Etablerad svensk ICD-10-kod för ME/CFS — kan dokumenteras parallellt med G90.9 + I95.1. [G]
[P] Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ. The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults. Am J Psychiatry 2011;168(12):1266–1277. PMID: 22193671. doi:10.1176/appi.ajp.2011.10111704. https://cssrs.columbia.edu/. C-SSRS pediatrisk version validerad ≥ 11 år. [P]
[G] FDA. Suicidality in Children and Adolescents Being Treated With Antidepressant Medications. FDA Drug Safety Communication. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/suicidality-children-and-adolescents-being-treated-antidepressant-medications. Black box warning 2003 advisory, 2005 boxed, 2007 utvidgad till unga vuxna. [G]
[P] Intended And Unintended Outcomes After FDA Pediatric Antidepressant Warnings: A Systematic Review. Health Affairs 2024. doi:10.1377/hlthaff.2023.00263. https://www.healthaffairs.org/doi/10.1377/hlthaff.2023.00263. Boxed warning hade delvis negativa nettoeffekter — antidepressivanvändning ↓ 20–50 %, ökad suicid-dödlighet i pediatrisk population. Associationsdata; kausalitet osäker. [P]
[P] March J et al. (TADS Team). Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA 2004;292(7):807–820. Etablerade fluoxetin + CBT som högsta-effekt vid pediatrisk MDD. Fluoxetin = enda SSRI med pediatrisk MDD-godkännande. [P]
[P] Drug-Related Orthostatic Hypotension: Beyond Anti-Hypertensive Medications. Drugs Aging 2020;37(10):725–738. doi:10.1007/s40266-020-00796-5. PMID: 32885462. https://link.springer.com/article/10.1007/s40266-020-00796-5. SSRI 2-faldig OH-risk vid hög dos; vasodilator-effekt via Ca-kanal-inhibition. [P]
[P] Antidepressant Drugs Effects on Blood Pressure. Front Cardiovasc Med 2021;8:704281. PMC8370473. https://www.frontiersin.org/articles/10.3389/fcvm.2021.704281/full. Venlafaxin (SNRI) ökar sympatisk aktivitet → förvärrar hyperadrenerg POTS. [P]
[P] McManimen SL, McClellan D, Stoothoff J, Jason LA. Effects of Unsupportive Social Interactions, Stigma, and Symptoms on Patients with Myalgic Encephalomyelitis and Chronic Fatigue Syndrome. J Community Psychol 2018;46(8):959–971. ME/CFS-suicidalitetsrisk associerad med funktionsnedsättning + isolation. [P]
[S] ClinicalTrials.gov. Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence. NCT01874951. https://classic.clinicaltrials.gov/ct2/show/NCT01874951. [S]
[P] Stanley B, Brown GK. Safety Planning Intervention: A Brief Intervention to Mitigate Suicide Risk. Cogn Behav Pract 2012;19(2):256–264. doi:10.1016/j.cbpra.2011.01.001. Etablerad säkerhetsplan-intervention vid pediatrisk suicidalitet. [P]
[P] Lock J, Le Grange D, Agras WS, Moye A, Bryson SW, Jo B. Randomized clinical trial comparing family-based treatment with adolescent-focused individual therapy for adolescents with anorexia nervosa. Arch Gen Psychiatry 2010;67(10):1025–1032. Familjebaserad terapi (FBT, Lock-modellen). Pediatrisk POTS-extrapolering = [OFF-LABEL]. [P]
[S] AACAP. Suicide and SSRI Medications in Children and Adolescents: An Update. https://www.aacap.org/AACAP/Medical_Students_and_Residents/Mentorship_Matters/DevelopMentor/Suicide_and_SSRI_Medications_in_Children_and_Adolescents_An_Update.aspx. American Academy of Child & Adolescent Psychiatry. [S]
[P] Shannon JR, Flattem NL, Jordan J, Jacob G, Black BK, Biaggioni I, Blakely RD, Robertson D. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med 2000;342(8):541–549. doi:10.1056/NEJM200002243420803. Original SLC6A2 Ala457Pro-mutation. [P]
[P] Hahn MK, Robertson D, Blakely RD. A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters. J Neurosci 2003;23(11):4470–4478. https://www.jneurosci.org/content/23/11/4470. >98 % NET-aktivitetsreduktion. [P]
[P] Esler M, Alvarenga M, Pier C, Richards J, El-Osta A, Barton D, Haikerwal D, Kaye D, Schlaich M, Guo L, Jennings G, Socratous F, Lambert G. The neuronal noradrenaline transporter, anxiety and cardiovascular disease. J Psychopharmacol 2006;20(4 Suppl):60–66. ATVB-relaterad epigenetisk uppföljning. [P]
[S] Bragée ME-center stängd 15 december 2023. Region Stockholm avtals-uppsägning; ~3 000 ME/CFS-patienter överförda till primärvård. Bragée-kliniker fortsätter med smärtrehabilitering. RME-pressmeddelande + Läkartidningen-debattartikel. https://rme.nu/information-angaende-bragee-me-center/ + https://lakartidningen.se/opinion/debatt/me-csf-patienter-overges-nar-brageekliniken-laggs-ned/. Stora Sköndal hotad nedläggning (RME-skrivelse 2024). [S] (patientorganisations-information).

Ivabradin pediatrisk POTS, autoimmun SFN-paneler och IVIG-evidens (kap. 09, 17, 24, 37 — 2026-05-09)#

[P] Taub PR, Zadourian A, Lo HC, Ormiston CK, Golshan S, Hsu JC. Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome. J Am Coll Cardiol 2021;77(7):861–871. doi:10.1016/j.jacc.2020.12.029. PMID: 33602468. https://www.jacc.org/doi/10.1016/j.jacc.2020.12.029. n = 22 RCT crossover, ivabradin 5 mg BID vs placebo. Signifikant HR-reduktion + QoL-förbättring + sänkt plasma-NE. [P]
[P] RECOVER-AUTONOMIC ivabradine arm. NCT06305780. ACC Annual Conference 28 mars 2026. https://recovercovid.org/news/recover-autonomic-clinical-trial-results-shared-2026-acc-conference. n = 181, RCT placebokontrollerad. Primärt utfall NEGATIVT — ivabradin sänkte HR signifikant men förbättrade INTE patient-rapporterade POTS-symtom. Sekundärfynd: koordinerad multidisciplinär vård + ivabradin > ivabradin + standardvård. [P]
[P] Saunders D et al. Comparative cohort study of post-acute COVID-19 infection with a nested, randomized controlled trial of ivabradine for those with postural orthostatic tachycardia syndrome (the COVIVA study). Front Neurol 2025;16:1550636. doi:10.3389/fneur.2025.1550636. PMID: 40692561. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1550636/full. Pågående RCT, åldrar 18–80, ingen pediatrisk data. [P]
[P] Bonnet D, Berger F, Jokinen E, Kantor PF, Daubeney PEF. Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure. J Am Coll Cardiol 2017;70(10):1262–1272. doi:10.1016/j.jacc.2017.07.725. PMID: 28859790. https://www.jacc.org/doi/10.1016/j.jacc.2017.07.725. Pediatrisk RCT som ledde till FDA-godkännande av ivabradin ≥ 6 mån. [P]
[G] FDA Corlanor (ivabradine) Pediatric Label 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209964lbl.pdf. Pediatrisk dosering 0,05 mg/kg BID start, max 0,3 mg/kg BID hos ≥ 1 år, max daglig 7,5 mg. [G]
[P] Ivabradine in treatment of symptomatic heart failure and supraventricular tachycardias in patients under six months of age. Front Pharmacol 2025;16:1502375. doi:10.3389/fphar.2025.1502375. PMC11876114. https://pmc.ncbi.nlm.nih.gov/articles/PMC11876114/. Säkerhet hos spädbarn < 6 mån. [P]
[G] Lauria G, Hsieh ST, Johansson O, Kennedy WR, Leger JM, Mellgren SI, Nolano M, Merkies IS, Polydefkis M, Smith AG, Sommer C, Valls-Solé J. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Eur J Neurol 2010;17(7):903–912. PMID: 20642627. https://pubmed.ncbi.nlm.nih.gov/20642627/. EFNS/PNS guideline — IENFD som guld-standard för SFN-diagnos. [G]
[P] Provost-Olewczynska J, Brusentsov V, Stojanov M, Sallami M, Tournemire T, Lalive A, Schaller K, Devaux J, Borel CO, Tessitore E, Truffert A, Nencha U. Quantitative and qualitative normative dataset for intraepidermal nerve fibers using skin biopsy. PLoS One 2018. PMC5784950. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0191614. IENFD-normativ data — vuxenformel för 5:e percentil. [P]
[P] Levine TD, Saperstein DS. Routine use of punch biopsy to diagnose small fiber neuropathy in fibromyalgia patients. J Neurol Sci 2021. PMID: 33792960. https://pubmed.ncbi.nlm.nih.gov/33792960/. TS-HDS (62 %), FGFR-3 (28 %), Plexin D1 (20 %) av seropositiva kryptogena SFN-fall. Total seropositivitet ~44 %. [P]
[P] Lopate G et al. Small-Vessel Vasculitis in Small Fiber Neuropathy with TS-HDS, FGFR-3, or Plexin D1 antibodies. Neurology 2024 supplement. doi:10.1212/WNL.0000000000204283. https://www.neurology.org/doi/10.1212/WNL.0000000000204283. Histopatologisk evidens för småkärlsvaskulit hos antikroppspositiv SFN. [P]
[P] Lopate G et al. Small-Vessel Vasculitis or Perifolliculitis in Small-Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies. Neurology 2024. PMID: 39590924. https://pubmed.ncbi.nlm.nih.gov/39590924/. [P]
[P] Hsu HC et al. Immune-Mediated Small Fiber Neuropathy With Trisulfated Heparin Disaccharide, Fibroblast Growth Factor Receptor 3, or Plexin D1 Antibodies: Presentation and Treatment With Intravenous Immunoglobulin. Neurology 2022. PMID: 36005471. https://pubmed.ncbi.nlm.nih.gov/36005471/. Open-label IVIG hos antikroppspositiv SFN — 11/12 IENFD-recovery, särskilt Plexin D1. [P]
[F] Liu X et al. Efficacy of rituximab on antibody-positive small fiber neuropathy: A series of 5 cases. J Neurol Sci 2025. https://www.sciencedirect.com/science/article/abs/pii/S0165572825000396. Fallserie n = 5 anti-TS-HDS/anti-FGFR3/anti-Plexin D1 SFN behandlade med rituximab. [F]
[P] Geerts M, de Greef BTA, Sopacua M, van Kuijk SMJ, Hoeijmakers JGJ, Faber CG, Merkies ISJ. Intravenous Immunoglobulin Therapy in Patients With Painful Idiopathic Small Fiber Neuropathy. Neurology 2021. PMID: 33766992. https://pubmed.ncbi.nlm.nih.gov/33766992/. Den första blindade RCT av IVIG vs placebo vid idiopatisk SFN, n = 60. Primärt utfall negativt: 40 % IVIG vs 30 % placebo, p = 0,588. [P]
[G] AAN/AANEM 2024 Consensus Statement: IVIG Treatment of Neuromuscular Disorders. https://www.aanem.org/docs/default-source/documents/practice/consensus-statement--ivig-treatment-nmd.pdf. Avråder IVIG vid idiopatisk SFN och TS-HDS/FGFR-3-positiv SFN. [G]
[P] Bjørnkær K, Holbech JV, Bach FW, Sindrup SH, Lauria G, Tankisi H, Karlsson P. Corneal confocal microscopy in small and mixed fiber neuropathy—Comparison with skin biopsy and cold detection in a large prospective cohort. J Peripher Nerv Syst 2023. doi:10.1111/jns.12595. https://onlinelibrary.wiley.com/doi/10.1111/jns.12595. CCM jämförbar diagnostisk noggrannhet med hudbiopsi. [P]
[S] Patel SV et al. Corneal Confocal Microscopy in the Diagnosis of Small Fiber Neuropathy: Faster, Easier, and More Efficient Than Skin Biopsy? Curr Pain Headache Rep 2022. PMID: 35366285. PMC8954271. https://pmc.ncbi.nlm.nih.gov/articles/PMC8954271/. Review om CCM. [S]
[S] A role for pathogenic autoantibodies in small fiber neuropathy? Front Mol Neurosci 2023. doi:10.3389/fnmol.2023.1254854. https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2023.1254854/full. Review om autoantikropp-medierad SFN. [S]
[P] The effect of high-dose long-term therapy of intravenous immunoglobulins in autoimmune autonomic and sensory small fiber neuropathy: a retrospective open-label controlled study. Sci Rep 2025. https://www.nature.com/articles/s41598-025-33059-7. Retrospektiv kohort hög-dos IVIG vid autoimmun SFN. [P] (open-label, ej RCT)
[G] Mayo Autonomic Function Lab QSART standard. https://www.mayoclinic.org/. Mayo Clinic-protokoll för QSART. [G]
[P] Frontiers Neurology 2024 Oral medications for the treatment of POTS: a systematic review. doi:10.3389/fneur.2024.1515486. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1515486/full. Ivabradin/midodrin/beta-blockerare som mest studerade. [P]
[P] Systematic literature review: treatment of postural orthostatic tachycardia syndrome (POTS). Clin Auton Res 2025. doi:10.1007/s10286-025-01172-2. https://link.springer.com/article/10.1007/s10286-025-01172-2. [P]
[P] The evidence for treatments for postural orthostatic tachycardia syndrome: a systematic review of randomized trials. PubMed 2025. PMID: 40653179. https://pubmed.ncbi.nlm.nih.gov/40653179/. [P]

HPA-axel-biomarkörer, periodiska febersyndrom, ARFID-POTS-EoE-överlapp (kap. 18, 22, 25, 26 — 2026-05-09)#

[P] Woo, Choi, Kim et al. Neuroendocrine signature of ME/CFS: Meta-analytic evidence for bioactive cortisol deficit and exaggerated feedback sensitivity. Mol Psychiatry 2026. doi:10.1038/s41380-026-03608-1. https://www.nature.com/articles/s41380-026-03608-1. n = 46 case-kontroll-studier, 1 388 ME/CFS + 1 349 matchade kontroller (~72 % kvinnor, mean ålder 37 år — vuxendata; pediatrisk extrapolering är inte direkt verifierad). Sänkt salivkortisol (awakening + morgon), attenuerad diurnal variation, förstärkt negativ feedback, trubbigad ACTH-respons. Den största sammanställda evidensen 2026 för HPA-dysfunktion vid ME/CFS. [P]
[S] Cleare AJ, Papadopoulos AS et al. Hypothalamic–pituitary–adrenal axis dysfunction in chronic fatigue syndrome. Nat Rev Endocrinol 2012. PMID: 21946893. https://www.nature.com/articles/nrendo.2011.153. Kanonisk review om HPA-mönstret vid CFS. [S]
[S] Cleare AJ. The HPA axis and the genesis of chronic fatigue syndrome. Trends Endocrinol Metab 2004. PMID: 15036250. https://pubmed.ncbi.nlm.nih.gov/15036250/. Hypocortisolism-hypotesen vid CFS. [S]
[G] Stalder T et al. Assessment of the cortisol awakening response: Expert consensus guidelines. Psychoneuroendocrinology 2016. CAR-protokoll-konsensus — saliv vid awakening + 30 min + 45 min, ≥ 2 mätdagar, actigrafi-validering vid forskningskvalitet. [G]
[P] Newman M, Curran DA, Mayer BR, Olesen TK, Newman LE. Reliability of a dried urine test for comprehensive assessment of urine hormones and metabolites. BMC Chem 2021. PMC7962249. https://pmc.ncbi.nlm.nih.gov/articles/PMC7962249/. DUTCH-test reliability — författare associerade med Precision Analytical (intressekonflikt). [P]
[P] Otte C et al. Effects of mineralocorticoid receptor stimulation on the HPA axis in healthy controls. Psychoneuroendocrinology 2007. https://www.sciencedirect.com/science/article/abs/pii/S0306453007001394. Fludrokortison som MR-agonist supprimerar HPA-axeln. [P]
[P] Pariante CM et al. The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary–adrenal activity in humans with psychotic major depression. Psychoneuroendocrinology 2012. PMC3633490. https://pmc.ncbi.nlm.nih.gov/articles/PMC3633490/. 0,05 mg = neutral dos; 0,075 mg = lägsta aktiva; 0,1 mg = sannolikt suppressiv på HPA-axel. [P]
[P] Stress Management Skills, Cortisol Awakening Response and Post-Exertional Malaise in Chronic Fatigue Syndrome. Cogn Behav Pract 2014. PMID: 25049069. PMC4165790. https://pmc.ncbi.nlm.nih.gov/articles/PMC4165790/. CAR-PEM-koppling. [P]
[S] Chronic stress and cognitive dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome: HPA axis dysregulation and hippocampal plasticity. Front Neurosci 2026;20:1814098. doi:10.3389/fnins.2026.1814098. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2026.1814098/full. HPA-hippocampus-mekanism. [S]
[G] Familial Mediterranean Fever — GeneReviews®. NCBI Bookshelf NBK1227. https://www.ncbi.nlm.nih.gov/books/NBK1227/. FMF MEFV-mutation, kolchicin-behandling, Tel-Hashomer/Eurofever-PRINTO-kriterier. [G]
[G] Familial Mediterranean Fever. StatPearls NBK560754. https://www.ncbi.nlm.nih.gov/books/NBK560754/. [G]
[P] Ben-Chetrit E et al. The significance of carrying MEFV variants in symptomatic and asymptomatic individuals. Clin Genet 2024. doi:10.1111/cge.14566. https://onlinelibrary.wiley.com/doi/10.1111/cge.14566. Heterozygot MEFV-bärare-status. [P]
[S] Familial Mediterranean Fever; Recent Advances, Future Prospectives. Diagnostics (MDPI) 2025;15(7):813. https://www.mdpi.com/2075-4418/15/7/813. [S]
[S] Periodic Fever, Aphthous Stomatitis, Pharyngitis and Adenitis Syndrome (PFAPA): An Update. Children (MDPI) 2025;12(4):446. PMC12025467. https://www.mdpi.com/2227-9067/12/4/446. [S]
[P] Vannucci S et al. Analysis of the genetic basis of periodic fever with aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome. Sci Rep 2015. PMC4437314. https://pmc.ncbi.nlm.nih.gov/articles/PMC4437314/. PFAPA polygenisk arvsgång (NLRP3, MEFV, CARD8). [P]
[P] Utility of a targeted next-generation sequencing-based genetic screening panel in patients with PFAPA syndrome. Arch Rheumatol 2023;38(2). https://archivesofrheumatology.org/full-text/1483. NGS-panel inkluderande ELANE, LPIN2, MEFV, MVK, NLRP3, TNFRSF1A. [P]
[G] EULAR/PRINTO 2015 — Eurofever/PRINTO classification criteria for autoinflammatory periodic fevers. [G]
[P] Performance of Different Diagnostic Criteria for FMF in Children with Periodic Fevers: Multicenter International Registry. J Pediatr 2015. PMID: 26568587. https://pubmed.ncbi.nlm.nih.gov/26568587/. [P]
[P] Clinical Genetic Testing of Periodic Fever Syndromes. PMC3581266. https://pmc.ncbi.nlm.nih.gov/articles/PMC3581266/. [P]
[P] Avoidant/Restrictive Food Intake Disorder: Review and Recent Advances. Focus 2024. PMC11231462. https://pmc.ncbi.nlm.nih.gov/articles/PMC11231462/. ARFID-subtyper + komorbiditeter. [P]
[G] Avoidant Restrictive Food Intake Disorder. StatPearls NBK603710. https://www.ncbi.nlm.nih.gov/books/NBK603710/. [G]
[S] ARFID: A Brief Evidence Review for Eating Disorders Awareness Week 2024. Beat. https://beat.contentfiles.net/media/documents/ARFID_Brief_Evidence_Review_for_EDAW_24_l1oDdT5.pdf. [S]
[S] Avoidant restrictive food intake disorder: recent advances in neurobiology and treatment. PMC11157884. https://pmc.ncbi.nlm.nih.gov/articles/PMC11157884/. [S]
[S] The Suggested Relationships Between Common GI Symptoms and Joint Hypermobility, POTS, and MCAS. PMC11348541. https://pmc.ncbi.nlm.nih.gov/articles/PMC11348541/. hEDS-POTS-MCAS-EoE-trifekta-hypotes. [S]
[P] J Pediatr Gastroenterol Nutr 2024 — Eosinofil esofagit-prevalens vid pediatrisk hEDS/JHS med GI-symtom: 21 %. [P]
[P] Increased Prevalence of Autonomic Dysfunction in Patients with EGID. Am J Gastroenterol 2018. https://journals.lww.com/ajg/fulltext/2018/10001/increased_prevalence_of_autonomic_dysfunction_in.334.aspx. POTS vid EGID 1,25 % vs 0,17 % i allmänpopulationen. [P]
[P] MCAS is not associated with hEDS and/or POTS: A multicenter retrospective review. J Allergy Clin Immunol 2026 (publicerad online februari 2026). Mayo Clinic-multicenter-kohort 2017–2025, n = 110 vuxna med hEDS/POTS/EDS+POTS. Författarnamn ej verifierat per maj 2026 — full text behövs för korrekt citation. Resultat: 95 % hade unconfirmed MCAS-labels; 66 % psykiatrisk komorbiditet; inga uppfyllde etablerade MCAS-diagnostiska kriterier. https://www.jacionline.org/article/S0091-6749(25)01704-X/fulltext. Negativt fynd — ingen klar association efter rigorös diagnostisk klassificering. [P]
[S] Eosinophilic Gastrointestinal Diseases (EGIDs), Connective Tissue Disorders and POTS. EOS Network. https://www.eosnetwork.org/egids-connective-tissue-disorders-pots. [S]
[P] Chishti et al. Mirtazapine Is Associated With Shorter Hospital Stay in Pediatric Avoidant Restrictive Food Intake Disorder—A Retrospective Chart Review. Int J Eat Disord 2025. PMID: 40265508. PMC12232339. https://onlinelibrary.wiley.com/doi/abs/10.1002/eat.24449. n = 87 pediatriska ARFID. Mirtazapin → kortare sjukhusvistelse, lägre NG-behov, snabbare viktuppgång. [P]
[F] Naguy A, Roy S. Mirtazapine and Weight Gain in Avoidant and Restrictive Food Intake Disorder. J Child Adolesc Psychopharmacol 2018. PMID: 29588055. https://pubmed.ncbi.nlm.nih.gov/29588055/. [F]
[S] Food Avoidance: Diagnosis and Treatment of ARFID. Psychopharmacology Institute. https://psychopharmacologyinstitute.com/section/food-avoidance-diagnosis-and-treatment-of-avoidantrestrictive-food-intake-disorder-arfid-2538-4994/. [S]
[G] American Gastroenterological Association / Joint Task Force on Allergy-Immunology — Eosinophilic Esophagitis Guideline 2020 (PPI, lokala steroider, diet-elimination som etablerad behandling). [G]
[S] Avoidant and Restrictive Food Intake Disorder. PMC8185640. https://pmc.ncbi.nlm.nih.gov/articles/PMC8185640/. [S]
[S] NIH researchers uncover genes linked to common recurrent fever in children. https://www.genome.gov/news/news-release/NIH-researchers-uncover-genes-linked-to-common-recurrent-fever-in-children. [S]
[P] Hashkes PJ et al. 2012 Ann Rheum Dis — Anakinra at colchicine-resistant FMF. [P]

Multidisciplinära behandlingsalgoritmer pediatrisk multisystem postinfektiös sjukdom (kap. 12, 23 — 2026-05-09)#

[G] Bateman Horne Center 2025. Clinical Care Guide for Managing ME/CFS, Long COVID, & IACCs. First Edition. Bateman Horne Center of Excellence + Open Medicine Foundation. https://batemanhornecenter.org/wp-content/uploads/2025/05/Clinical-Care-Guide-First-Edition-2025-1.pdf. Den mest omfattande pediatriska + adult ME/CFS-resursen 2026. Severitetsbaserad algoritm + HR-baserad pacing + multidisciplinär team-modell. [G]
[G] NICE 2021 Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management (NG206). https://www.nice.org.uk/guidance/ng206. Pediatrisk: 4 v misstanke, 3 mån diagnos; avråder GET som botande. [G]
[P] NICE guideline on ME/CFS: robust advice based on a thorough review of the evidence. PMID: 38418217. https://pubmed.ncbi.nlm.nih.gov/38418217/. Appraisal av NICE NG206. [P]
[S] Rowe PC et al. 2017 Front Pediatr — IACFS/ME Pediatric Primer. PMID: 28674681. (Tidigare refererad i annan sektion — refererad här för algoritm-syntes.) [S]
[G] EUROMENE 2021 Medicina (Kaunas) — European consensus on diagnosis, service provision, and care of people with ME/CFS in Europe. https://ammes.org/tag/euromene/. Vuxen-fokus med begränsad pediatrisk täckning. [G]
[G] CDC Considerations for Pediatric ME/CFS. https://www.cdc.gov/me-cfs/hcp/clinical-care/pediatric-me-cfs.html. Praktisk pediatrisk klinisk vägledning. [G]
[S] RME (Riksförbundet för ME-patienter) — svensk översättning av Pediatric Primer (Rowe 2017). https://rme.nu/wp-content/uploads/2020/05/Pediatric-Primer-monograph-11-17-2017-for-Website.pdf. Informell svensk pediatrisk standardresurs. [S]
[G] NIH NINDS 2024 Report of the ME/CFS Research Roadmap Working Group of Council. https://www.ninds.nih.gov/sites/default/files/2024-05/Report%20of%20the%20MECFS%20Research%20Roadmap%20Working%20Group%20of%20Council_508C.pdf. Strategisk plan för federalt finansierad ME/CFS-forskning. [G]
[G] Open Medicine Foundation 2025 Clinical Care Guide (samarbetsversion med Bateman Horne Center). https://www.omf.ngo/wp-content/uploads/2025/05/Clinical-Care-Guide-First-Edition-2025.pdf. [G]

Cardioneuroablation (CNA) och Closed-Loop Stimulation (CLS) — invasiv autonom modulering vid svår reflexsynkope (kap. 04, 25, 40.21 — session 48)#

[P] Piotrowski R, Baran J, Sikorska A, et al. Cardioneuroablation for Reflex Syncope: Efficacy and Effects on Autonomic Cardiac Regulation—A Prospective Randomized Trial. JACC: Clin Electrophysiol 2023;9(1):85–95. doi:10.1016/j.jacep.2022.08.011 https://www.jacc.org/doi/10.1016/j.jacep.2022.08.011 — Den första prospektiva randomiserade studien av CNA. n = 48; 8 % vs 54 % synkope-recidiv 2 år. [P]
[P] Piotrowski R, Baran J, Sikorska A, et al. Cardioneuroablation: comparison of acute effects of the right vs. left atrial approach in patients with reflex syncope: the ROMAN2 study. EP Europace 2024;26(2):euae042. PMID 38315895; PMC10873699. doi:10.1093/europace/euae042 https://pmc.ncbi.nlm.nih.gov/articles/PMC10873699/ — Akut RA vs LA approach; LA-only/RA+LA ger bättre vagal denervering än RA-only. [P]
[G] Aksu T, Brignole M, Calò L, ..., Fedorowski A, ..., Pachón JC et al. Cardioneuroablation for the treatment of reflex syncope and functional bradyarrhythmias: A Scientific Statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS) and the Latin American Heart Rhythm Society (LAHRS). EP Europace 2024;26(8):euae206. PMID 39082698; PMC11350289. doi:10.1093/europace/euae206 https://pmc.ncbi.nlm.nih.gov/articles/PMC11350289/ — Internationell konsensus om CNA-indikationer, patientselektion, säkerhetsprofil. Karolinska/Fedorowski-medverkan. [G]
[P] Vandenberk B, Lei LY, Ballantyne B, Vickers D, Liang Z, Sheldon RS, Chew DS, Aksu T, Raj SR, Morillo CA. Cardioneuroablation in patients with vasovagal syncope: An updated systematic review and meta-analysis. Heart Rhythm 2024;21(12):2487–2496. PMID 39067734. doi:10.1016/j.hrthm.2024.07.092 https://www.heartrhythmjournal.com/article/S1547-5271(24)03079-0/abstract — 37 studier, n = 1585, pooled VVS-recidiv 8,9 %. [P]
[P] Aksu T, Yalin K, Gopinathannair R, Kabakcı G, Ribeiro de Sousa MJ, Pachón JC. Inappropriate Sinus Tachycardia Following Cardioneuroablation for Reflex Syncope: A Case Report and Review of the Literature Illustrating this Underappreciated Adverse Effect. Arrhythm Electrophysiol Rev 2025. PMID 40607009. https://www.aerjournal.com/articles/inappropriate-sinus-tachycardia-following-cardioneuroablation-reflex-syncope-case-report — Underrapporterad iatrogen IST/POTS post-CNA; 5–10 % poolad estimat. Direkt POTS-bok-relevans. [P]
[P] Choi NH, Pophal SG, Soriano BD, et al. Cardioneuroablation for pediatric patients with functional sinus node dysfunction and paroxysmal atrioventricular block. J Cardiovasc Electrophysiol 2024;35(2):265–272. PMID 38038245. doi:10.1111/jce.16145 https://pubmed.ncbi.nlm.nih.gov/38038245/ — Pediatrisk retrospektiv n = 6, medianålder 18,9 år. Begränsade data; nervregenerationsrisk hos barn. [P]
[P] Kanjwal K, Shahjouei M, Matthew T, et al. Sinus node sparing novel hybrid approach for treatment of inappropriate sinus tachycardia/postural sinus tachycardia: multicenter experience. J Interv Card Electrophysiol 2021;62(3):679–688. doi:10.1007/s10840-021-01044-5 https://link.springer.com/article/10.1007/s10840-021-01044-5 — Separat teknik från CNA. Endast specialiserade centrum. [EXPERIMENTELL] vid POTS. [P]
[P] Brignole M, Russo V, Arabia F, et al. (BIOSync CLS Investigators). Cardiac pacing in severe recurrent reflex syncope and tilt-induced asystole. Eur Heart J 2021;42(5):508–516. PMID 33186443. doi:10.1093/eurheartj/ehaa936 https://pubmed.ncbi.nlm.nih.gov/33186443/ — Sham-blindad CLS-RCT n = 127. 77 % relativ riskreduktion synkope vid 2 år. Stoppades tidigt för superioritet. Klass I level A i ESC 2021. [P]
[P] Pérez-Vega FJ, Ruíz-Granell R, García-Civera R, et al. Dual-Chamber Pacing With Closed Loop Stimulation in Recurrent Reflex Vasovagal Syncope: The SPAIN Study. J Am Coll Cardiol 2017;70(14):1720–1728. PMID 28958328. doi:10.1016/j.jacc.2017.08.026 https://www.jacc.org/doi/10.1016/j.jacc.2017.08.026 — Den första CLS-RCT:n. Cross-over n = 46; 80 % relativ syncopereduktion. [P]
[P] Khaneja A, Ezekowitz M. The clinical role of closed loop stimulation pacemakers in the treatment of patients with sinus node dysfunction: a review. Future Cardiol 2025. doi:10.1080/14796678.2025.2507464. PMC12150642. https://pmc.ncbi.nlm.nih.gov/articles/PMC12150642/ — Maj 2025-review om CLS-pacemaker-roll vid sinus node-dysfunktion. [P]
[G] Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 2021;42(35):3427–3520. PMID 34455430. https://pubmed.ncbi.nlm.nih.gov/34455430/ — ESC-pacing-guidelines som ger CLS-pacing klass I level A för >40-åringar med dokumenterad asystoli vid VVS. [G]

Inspiratorisk muskelträning (IMST/IMT) som autonom-reparationskandidat — Craighead-axeln, Smith 2015 ITD-RCT, Edgell 2024 PASC/ME-CFS-pilot (kap. 09.8 + 10.1 + 36.Y + 40.22 — session 49)#

[P] Smith ML, Beightol LA, Fritsch-Yelle JM, Ellenbogen KA, Porter TR, Eckberg DL. Inspiratory Resistance Improves Postural Tachycardia: A Randomized Study. Circulation: Arrhythmia and Electrophysiology 2015;8(3):651–658. PMID 25792354; PMC4472504. doi:10.1161/CIRCEP.114.002605 https://www.ahajournals.org/doi/10.1161/CIRCEP.114.002605 — Den enda direkta POTS-RCT:n på inspiratoriskt motstånd. n = 26 POTS-patienter, randomiserad single-blind crossover med ITD ~7 cmH₂O vs sham under HUT. HR signifikant lägre med aktiv ITD efter 10 min (102 vs 109 slag/min, p = 0,003). Akut hemodynamisk åtgärd, inte träning. [P]
[P] Convertino VA, Ratliff DA, Doerr DF, Ludwig DA, Muniz GW, Benedetti E et al. Increased impedance to inspiration ameliorates hemodynamic changes associated with movement to upright posture in orthostatic hypotension: a randomized blinded pilot study. Heart Rhythm 2007;4(4):500–504. PMID 17275744. doi:10.1016/j.hrthm.2006.12.018 https://pubmed.ncbi.nlm.nih.gov/17275744/ — Randomiserad blindad pilot på 18 friska + 22 OH-patienter; aktiv ITD blunted BP-fall under första 100 sek efter stående och reducerade ortostatiska symtom. [P]
[P] Craighead DH, Heinbockel TC, Freeberg KA, Rossman MJ, Jackman RA, Jankowski LR, Hamilton MN et al. Time-Efficient Inspiratory Muscle Strength Training Lowers Blood Pressure and Improves Endothelial Function, NO Bioavailability, and Oxidative Stress in Midlife/Older Adults With Above-Normal Blood Pressure. J Am Heart Assoc 2021;10(13):e020980. PMID 34184544. doi:10.1161/JAHA.121.020980 https://www.ahajournals.org/doi/10.1161/JAHA.121.020980 — Den primära Craighead-axeln-RCT:n. n = 36, 6 veckor 75 % MIP vs sham 15 % MIP, 30 andetag/dag (~5 min). ΔSBP −9 ± 3 mmHg, ΔDBP −4 mmHg, FMD ↑, NO ↑, ROS ↓, adherens 95 %. [P]
[P] Craighead DH, Freeberg KA, McCarty NP, Seals DR. A multi-trial, retrospective analysis of the antihypertensive effects of high-resistance, low-volume inspiratory muscle strength training. J Appl Physiol 2022;133(4):798–807. doi:10.1152/japplphysiol.00425.2022 https://journals.physiology.org/doi/full/10.1152/japplphysiol.00425.2022 — Retrospektiv analys av 5 IMST-trials, n = 128. Pooled ΔSBP −9,1 mmHg, ΔDBP −4,1 mmHg. Effekten oberoende av kön, ålder, BT-läkemedel, OSA-status. [P]
[P] Lee SH et al. Comparison of inspiratory muscle strength and aerobic exercise training and detraining on blood pressure in hypertensive patients. Clinical Hypertension 2025;31:e15. doi:10.5646/ch.2025.31.e15 https://clinicalhypertension.org/DOIx.php?id=10.5646/ch.2025.31.e15 — Direkt jämförelse IMST vs aerobic exercise vid hypertoni. ΔSBP −9,1 mmHg (IMST) vs −6,2 mmHg (aerob); ingen inbördes skillnad. [P]
[P] Edgell H et al. Inspiratory muscle training improves autonomic function in myalgic encephalomyelitis/chronic fatigue syndrome and post-acute sequelae of SARS-CoV-2: A pilot study. Autonomic Neuroscience 2024;256:103205. PMID 39374820. doi:10.1016/j.autneu.2024.103205 https://pubmed.ncbi.nlm.nih.gov/39374820/ — 8-veckors IMT-pilot på 12 friska + 9 PASC + 12 ME/CFS. Alla grupper: MIP ↑, 6MWD ↑, resting HR ↓, HRV ↑, sömn ↓. Endast ME/CFS-armen: COMPASS-31 totalvägd score ↓ (p = 0,005), vaskulär funktion ↑, smärta ↓. Närmaste publicerade träningsdata för postviral dysautonomi. Pilotdesign utan kontrollgrupp. [P]
[P] Pereira RDB, Almeida LB, Oliveira-Sales EB, et al. Inspiratory muscle training improves breathing pattern and sympatho-vagal balance but not spontaneous baroreflex sensitivity in older women. Autonomic Neuroscience 2021;232:102787. PMID 33866039. doi:10.1016/j.autneu.2021.102787 https://pubmed.ncbi.nlm.nih.gov/33866039/ — IMT 8 veckor hos äldre kvinnor: förbättrad sympato-vagal balans (LF/HF), ingen förändring i spontan BRS. Viktigt negativt fynd. [P]
[P] Inspiratory muscle training improves heart rate variability and respiratory muscle strength in obese young adults. PLOS One 2025. PMID 40833943. doi:10.1371/journal.pone.0329623 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0329623 — 8 veckor IMT 80 % MIP hos obesa unga vuxna. SDNN och RMSSD ↑, LF ↓, HF ↑. Tidsdomän-HRV inkonsekvent. [P]
[P] Chittam M et al. The effect of inspiratory muscle training on the inspiratory muscle metaboreflex: A systematic review. Canadian Journal of Respiratory Therapy 2025;61:1–10. PMC11955241. https://pmc.ncbi.nlm.nih.gov/articles/PMC11955241/ — Systematisk review som konfirmerar IMT-medierad attenuering av inspiratorisk metaboreflex. Mekanistiskt relevant för POTS exercise intolerance. [P]
[P] Chan J et al. The effect of inspiratory muscle training and detraining on the respiratory metaboreflex. Experimental Physiology 2023;108(11):1424–1437. doi:10.1113/EP090779 https://physoc.onlinelibrary.wiley.com/doi/10.1113/EP090779 — IMT-effekt på metaboreflex kvarstår veckor efter avslutad träning (detraining-resistens). [P]
[P] Gonçalves AL et al. Effects of inspiratory muscle training on cardiorespiratory network physiology: evidence from cardiac autonomic modulation, respiratory sinus arrhythmia, and baroreflex sensitivity analysis. Frontiers in Network Physiology 2026;6:1761610. doi:10.3389/fnetp.2026.1761610 https://www.frontiersin.org/journals/network-physiology/articles/10.3389/fnetp.2026.1761610/full — 4-veckor IMT 60 % MIP hos friska unga män (n = 22). IMT förbättrade kardiell vagal kontroll och RSA men inte fundamentala nätverksdynamiker (fas-synkronisering, gain) eller BRS. Konfirmerar Pereira-2021-negativfynd för BRS. [P]
[S] POWERbreathe. Precautions & Contraindications. Producentdokumentation, 2024. https://www.powerbreathe.com/contraindications-and-precautions/ — Lista över kontraindikationer för IMST: spontan pneumothorax-anamnes, trummhinneperforation, akut otit, allvarlig okontrollerad astma, akut MI/lungembolism, dekompenserad hjärtsvikt. [S]
[S] Solve ME/CFS Initiative. Inspiratory Muscle Training Reduces Autonomic Symptoms in Patients with ME/CFS or Long Covid. Forskningssammanfattning, 2024. https://solvecfs.org/inspiratory-muscle-training-reduces-autonomic-symptoms-in-patients-with-me-cfs-or-long-covid/ — Patientorganisationssammanfattning av Edgell 2024-pilot. [S]

SGLT2-hämmare och autonom funktion vid POTS — volymförlust vs sympatolys (kap. 09.9, 24.SG, 80 — session 51, 2026-05-12)#

Sektion integrerad från session 50-material (2026-05-11). Källnumrering 596+ enligt etablerad sektionspraxis — sektionsrubriken särskiljer från andra sessioners 596+-numrering.

[P] Wan N, Rahman A, Hitomi H, Nishiyama A. The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity. Front Endocrinol 2018;9:421. https://pmc.ncbi.nlm.nih.gov/articles/PMC9309722/. [P]
[P] Matthews VB, Elliot RH, Rudnicka C, et al. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. J Hypertens 2017;35(10):2059–2068. https://pubmed.ncbi.nlm.nih.gov/28598955/. [P]
[P] Yamazaki D, Hitomi H, Nishiyama A. SGLT2 and SGLT1 inhibitors suppress the activities of the RVLM neurons in newborn Wistar rats. Hypertens Res 2023;46:1652–1661. https://www.nature.com/articles/s41440-023-01417-5. Prekliniskt mekanism för central sympatolys via RVLM-hämning. [P]
[P] Shimizu W, Kubota Y, Hoshika Y, et al. (EMBODY-trial). Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2020;19:148. https://cardiab.biomedcentral.com/articles/10.1186/s12933-020-01127-z. n = 105 T2DM + post-MI; signifikant HRV-förbättring vid 24 v. Inte generaliserbart till POTS. [P]
[P] Cao Y, Bojko M, Lin S, et al. Empagliflozin ameliorates ventricular arrhythmias by inhibiting sympathetic remodeling via nerve growth factor/tyrosine kinase receptor A pathway inhibition. Cardiovasc Diabetol 2024;23:204. https://pubmed.ncbi.nlm.nih.gov/38949125/. Prekliniskt; NGF/TrkA-axeln. [P]
[P] Bardia A, Kabra R, Mahajan R, et al. (SCAN-studien). SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2022;21:120. https://pubmed.ncbi.nlm.nih.gov/35732222/. n = 80 T2DM + CAN + VVS-anamnes; retrospektiv-prospektiv kohort. [P]
[P] Effect of SGLT-2 inhibitors on cardiac autonomic function in type 2 diabetes mellitus: a meta-analysis of RCTs. Acta Diabetol 2022;59:1465–1479. https://link.springer.com/article/10.1007/s00592-022-01958-0. Pooled 7 RCT, n ≈ 1 200 T2DM; signifikant SDNN + RMSSD-förbättring. [P]
[P] Rong X, Li X, Gou Q, Liu K, Chen X. Risk of orthostatic hypotension associated with sodium-glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials. J Renin Angiotensin Aldosterone Syst 2020. https://pubmed.ncbi.nlm.nih.gov/32981346/. Meta-analys 51 RCT, n > 100 000; OH 1,2–1,5 %, ingen signifikant ökning vs placebo. Underrapporteringsrisk noterad av författarna. [P]
[P] Long-term effects of SGLT2 inhibitors on arrhythmias: a systematic review and meta-analysis. Front Pharmacol 2025;16:1558367. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1558367/full. Pooled RCT, n > 100 000; AF ↓ ~17 %, plötslig hjärtdöd ↓ ~22 %, synkope-risk ↑ RR 1,12. [P]
[P] Cardiovascular autonomic neuropathy in diabetes: an update with a focus on management. Diabetologia 2024. https://link.springer.com/article/10.1007/s00125-024-06242-0. CAN-review med SGLT2-positionering. [P]
[P] Dekkers CCJ, Sjöström CD, Greasley PJ, Cain V, Boulton DW, Heerspink HJL. Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. Diabetes Obes Metab 2019;21(12):2667–2673. PMC6899523. https://pmc.ncbi.nlm.nih.gov/articles/PMC6899523/ — Dapagliflozin sänker estimerad plasmavolym (ePV); effekten fullt utvecklad vid 8–12 veckor och bibehållen till v. 24, validerad mot ¹²⁵I-humant serumalbumin-mätt plasmavolym. Korrigerar tidigare felaktig "Tang H et al. Circulation 2018"-attribution för SGLT2-plasmavolymdata (det citerade Tang-arbetet handlade om cancerrisk, inte plasmavolym). [P]
[G] Metra M, Tomasoni D, Adamo M, et al. SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the Heart Failure Association and the Heart Failure-Associated Investigators. ESC Heart Fail 2025. https://onlinelibrary.wiley.com/doi/full/10.1002/ehf2.15408. Klass IA HFrEF. [G]
[G] American Diabetes Association. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes — 2025. Diabetes Care 2025;48(Suppl 1):S207. https://diabetesjournals.org/care/article/48/Supplement_1/S207/157549/10-Cardiovascular-Disease-and-Risk-Management. [G]
[S] Cleveland Clinic Journal of Medicine. Managing the side effects of sodium-glucose cotransporter-2 inhibitors. CCJM 2024;92(8):503. https://www.ccjm.org/content/92/8/503. Klinisk vägledning. [S]
[S] Interaction between SGLT2 and the sympathetic nervous system in normal and various cardiovascular metabolic disease states. Hypertens Res 2025. https://www.nature.com/articles/s41440-025-02216-w. [S]
[S] A decade of progress in T2DM and CVD: advances in SGLT2 inhibitors and GLP-1 receptor agonists — a comprehensive review. Front Endocrinol 2025. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1605746/full. [S]

Rotorsaksdiagnostik vid OH — bedside-differentiering neurogen vs icke-neurogen (kap. 04.5, 04.6, 04.7, diagnostisk-guide Del A/B — session 53)#

[P] Norcliffe-Kaufmann L, Kaufmann H, Palma JA, et al. Orthostatic heart rate changes in patients with autonomic failure caused by neurodegenerative synucleinopathies. Ann Neurol 2018;83(3):522–531. doi:10.1002/ana.25170. PMID 29405350; PMC5867255. https://pmc.ncbi.nlm.nih.gov/articles/PMC5867255/ — Cutoff ΔHR/ΔSBP <0,492 bpm/mmHg, sensitivitet 91,3 % / specificitet 88,4 %, AUC 0,96. n = 402 efter exklusion av 42 AF/non-sinus-patienter; obalanserad kohort (378 nOH vs 24 icke-nOH); diabetiker exkluderade. Kritisk bedside-referens — begränsningar måste flaggas vid klinisk användning. [P]
[P] Goldstein DS. All orthostatic hypotension is neurogenic. Clin Auton Res 2023;33(2):105–106. doi:10.1007/s10286-023-00966-6. PMID 37160542. https://pubmed.ncbi.nlm.nih.gov/37160542/ — Kort kommentar/perspektivartikel. Argumenterar att OH per definition kräver autonom impairment; "icke-neurogen" OH bör läsas som autonom impairment + aggraverande faktor. Påverkar tolkningen av binär nOH/icke-nOH-dikotomi. [P]
[P] Kim HA, Yi HA, Lee H. Utility of the Valsalva maneuver in the diagnosis of orthostatic disorders. Auton Neurosci 2016. PMID 26491102. https://pubmed.ncbi.nlm.nih.gov/26491102/ — Diagnostisk yield av Valsalva-mönstren vid ortostatiska syndrom. [P]
[P] Sandroni P, Benarroch EE, Low PA. Pharmacological dissection of components of the Valsalva maneuver in adrenergic failure. J Appl Physiol 1991;71(4):1563–1567. PMID 1757382. https://pubmed.ncbi.nlm.nih.gov/1757382/ — Originalbeskrivningen av Valsalva-fasmönstren vid adrenerg svikt: utebliven fas IV-overshoot och reducerad sen fas II vid sympatisk neurocirculatorisk svikt. [P]
[G] Cheshire WP, Goldstein DS. Autonomic uprising: the tilt table test in autonomic medicine. Clin Auton Res 2019;29:215–230. doi:10.1007/s10286-019-00598-9. PMID 30838497. https://pubmed.ncbi.nlm.nih.gov/30838497/ — Metodologisk översikt av HUTT inom autonom medicin (protokoll, tolkning, begränsningar). [G]
[G] Shibao C, Lipsitz LA, Biaggioni I. ASH position paper: evaluation and treatment of orthostatic hypotension. J Am Soc Hypertens 2013;7(4):317–324. doi:10.1016/j.jash.2013.04.006. PMID 23791471. https://pubmed.ncbi.nlm.nih.gov/23791471/ — ASH-positionsdokument om OH-bedömning och behandling, inklusive icke-neurogena bidragande faktorer. [G]
[P] Singer W, Berini SE, Sandroni P, et al. Pure autonomic failure: predictors of conversion to clinical CNS involvement. Neurology 2017;88(12):1129–1136. doi:10.1212/WNL.0000000000003737. PMID 28202694. https://pubmed.ncbi.nlm.nih.gov/28202694/ — Fenokonversion PAF → MSA/PD/LBD; en betydande andel konverterar inom 4 år. Stöd för MSA-misstanke som driver neurologremiss vid utebliven NE-ökning. [P]
[P] Coon EA, Singer W, Low PA. Pure autonomic failure. Mayo Clin Proc 2019;94(10):2087–2098. doi:10.1016/j.mayocp.2019.03.009. PMID 31543254. https://pubmed.ncbi.nlm.nih.gov/31543254/ — Modern översikt över PAF-diagnostik och fenokonversionsrisk. [P]
[P] Vernino S, Hopkins S, Wang Z. Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy. Auton Neurosci 2009;146(1–2):3–7. doi:10.1016/j.autneu.2008.09.005. PMID 18951069. https://pubmed.ncbi.nlm.nih.gov/18951069/ — gAChR-antikroppsdiagnostik vid AAG; behandlingsbar OH-orsak som inte får missas. [P]
[G] Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol 2017;264(8):1567–1582. doi:10.1007/s00415-016-8375-x. PMID 28050656. https://pubmed.ncbi.nlm.nih.gov/28050656/ — Konsensuspanel för nOH-screening, diagnostik och behandling, inklusive samtidig supin hypertoni. [G]

Subtypisering inom neurogen OH — Singer/Coon/Kaufmann/Koay-fenokonversion + Syn-One + MIBG + QSART (kap. 04.6.2, planerade kap. 30 + 26 + 80 — session 54, 2026-05-14)#

Sektionsbaserad numrering enligt etablerad design — sektionsrubriken särskiljer kollisionerna med tidigare 596+-sektioner.

[P] Singer W, Berini SE, Sandroni P, et al. Pure autonomic failure: predictors of conversion to clinical CNS involvement. Neurology 2017;88(12):1129–1136. doi:10.1212/WNL.0000000000003737. PMID 28202694. https://pubmed.ncbi.nlm.nih.gov/28202694/ — Mayo-kohort n = 318; 41 stabil PAF, 37 (12 %) konverterare (22 MSA, 11 PD/DLB, 4 indeterminata). Multivariabla MSA-prediktorer: (1) mild kardiovagal funktionsnedsättning, (2) preganglionärt anhidrosismönster (TST anhidrosis + bevarad QSART), (3) allvarlig blåsstörning, (4) supin plasma-NE ≥100 pg/mL, (5) subtila motoriska tecken. Singer 2017-paradoxen: bevarade autonoma funktioner i PAF = red flag för MSA-konversion. [P]
[P] Coon EA, Singer W, Low PA, et al. Predicting phenoconversion in pure autonomic failure. Neurology 2020. doi:10.1212/WNL.0000000000010002. https://www.neurology.org/doi/10.1212/WNL.0000000000010002 — Mayo-utökad kohort n = 275; 67 (24 %) fenokonverterade (34 MSA, 33 PD/DLB). Längre uppföljningstid + striktare PAF-stringens jämfört med 2017. Mayo-kohorten visar ≈ 1:1 MSA/Lewy-body-fördelning. [P]
[P] Phenoconversion in pure autonomic failure: a multicentre prospective longitudinal cohort study. Brain 2024;147(7):2440–2448. doi:10.1093/brain/awae033. PMID 38366572. PMC11224600. https://pubmed.ncbi.nlm.nih.gov/38366572/ — Multicenter (8 centra, 7 USA + 1 Europa), prospektiv (NCT01799915), n = 209 PAF, median sjukdomsduration 6 år vid inklusion. 48 (33 %) fenokonverterade vid 3 år — 42 % PD, 35 % DLB, 23 % MSA. Lewy-body-dominans (77 % PD+DLB). Starkaste prediktor: urin- och sexuell dysfunktion (Onuf's nucleus). Andra prediktorer: subtila motoriska tecken, sväljsvårigheter, försämrad handstil → PD, svårighet att hantera bestick → DLB. [P]
[P] Koay S, et al. Multimodal Autonomic Biomarkers Predict Phenoconversion in Pure Autonomic Failure. Ann Clin Transl Neurol 2025;12(11):2170–2180. doi:10.1002/acn3.70140. PMID 40696849. https://pubmed.ncbi.nlm.nih.gov/40696849/ — Observationell n = 391 α-synukleinopati (varav 194 PAF). 50/194 (26 %) PAF → MSA/LBD efter median 13 år. Prediktorer: normala pupiller (intakt sympatisk pupillrespons), HR-respons-djupandning ≥10 bpm, supin NE ≥200 pg/mL. Yngre debutålder + högre supin NE → MSA-konversion. Bekräftar Singer 2017-paradoxen. [P]
[P] Gibbons CH, Levine T, Adler C, et al. Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies. JAMA 2024;331(15):1298–1306. doi:10.1001/jama.2024.0792. PMID 38497740. PMC10955354. https://jamanetwork.com/journals/jama/fullarticle/2816441 — Synuclein-One-studien. Blindad multicenter, n = 428. 3 mm hudbiopsi från nacke/axel, lår, ankel; immunhistokemi för P-SYN. Sensitivitet: PD 92,7 %, MSA 98,2 %, DLB 96,0 %, PAF 100 %. NIH Top Medical Findings 2024. Intressekonflikt: Syn-One Test är kommersiell produkt från CND Life Sciences (Scottsdale, AZ); författarkoppling deklarerad. Replikation vid europeiska centra pågår; inte rutin i svensk vård 2026. [P]
[P] Donadio V, Incensi A, Rizzo G, et al. Synuclein-One study: skin biopsy detection of phosphorylated α-synuclein for diagnosis of synucleinopathies. J Neurol Neurosurg Psychiatry 2022. PMID 35272481. PMC9169016. https://pmc.ncbi.nlm.nih.gov/articles/PMC9169016/ — Föregångare-/replikationsstudie till JAMA 2024. Bekräftar P-SYN-detektion i hudbiopsi som biomarkör för synukleinopati. [P]
[P] Clinical utility of synuclein skin biopsy in the diagnosis and evaluation of synucleinopathies. Front Neurol 2024;15:1510796. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1510796/full — Klinisk utvärdering av P-SYN-biopsi. Bekräftar hög sensitivitet; diskuterar diagnosförändring i kliniskt material. [P]
[P] Phosphorylated alpha-synuclein skin biopsy alters diagnosis in two out of three patients: Initial findings in a tertiary center. J Neurol Sci 2026. https://www.sciencedirect.com/science/article/pii/S135380202600060X — Tertiärcenterdata: P-SYN-resultat förändrade klinisk diagnos i 2/3 patienter vid oklar parkinsonism/dysautonomi. Stort kliniskt avtryck — fortfarande tertiärcenter, replikation pågår. [P]
[P] Catalan M et al. 123I-Metaiodobenzylguanidine Myocardial Scintigraphy in Discriminating Degenerative Parkinsonisms. Mov Disord Clin Pract 2021. doi:10.1002/mdc3.13227. PMC8287155. https://movementdisorders.onlinelibrary.wiley.com/doi/full/10.1002/mdc3.13227 — Kardiell MIBG, sens 89,7 % / spec 94,6 % för PD vs MSA-diskriminering. Aggregerade prestanda håller. [P]
[P] Jagusch et al. Cardiac MIBG Scintigraphy in Neurodegenerative Parkinsonism: Limitations in Clinical Practice. Mov Disord Clin Pract 2025. doi:10.1002/mdc3.70656. https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mdc3.70656 — Negativt/cautionary fynd: frekventa "oväntade" MIBG-resultat i klinisk praxis. False-negativa vid läkemedel som påverkar NE-upptag (tricykliska, SSRI, opioider, labetalol); false-positiva vid samtidig DAN/hjärtsvikt. Begränsar rutinmässig användning. [P]
[P] Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson's Disease: A Comprehensive Review. Brain Sci 2023;13(10):1471. doi:10.3390/brainsci13101471 https://www.mdpi.com/2076-3425/13/10/1471 — Sammanställande review av MIBG vid PD-diagnostik. [P]
[P] Treglia G, et al. Cardiac 123I-MIBG Scintigraphy in Neurodegenerative Parkinson Syndromes: Performance and Pitfalls in Clinical Practice. Front Neurol 2019;10:152. PMC6399127. https://pmc.ncbi.nlm.nih.gov/articles/PMC6399127/ — Sensitivitet 0,81 (tidig fas) / 0,83 (sen fas); specificitet 0,86 / 0,80. MSA bevarar H/M-ratio; PD/PAF/DLB reducerar den. [P]
[P] Kim SW, Chung SJ, Lee S, et al. Postganglionic Sudomotor Dysfunction and Brain Glucose Hypometabolism in Patients with Multiple System Atrophy. J Parkinsons Dis 2021. doi:10.3233/JPD-202524. https://journals.sagepub.com/doi/10.3233/JPD-202524 — MSA-postganglionär sudomotordysfunktion vid avancerad sjukdom; preganglionärt mönster (TST anhidrosis + normal QSART) finns vid tidig MSA — postganglionära fibrer påverkas senare. Nyans kring "MSA bevarar QSART"-bilden. [P]
[P] Association of Cardiovascular Autonomic Failure With Progression and Phenoconversion in Isolated REM Sleep Behavior Disorder. Neurology 2024. doi:10.1212/WNL.0000000000213470. PMID 38366544. https://www.neurology.org/doi/10.1212/WNL.0000000000213470 — Isolerad RBD-kohort: 4-faldigt ökad risk för fenokonversion till synukleinopati när kardiovaskulär autonom svikt detekteras inom 5 år efter RBD-debut. Stöder RBD + autonom svikt som hög-risk-konstellation. [P]
[G] REM Sleep Behavior Disorder as a Prodromal Synucleinopathy: Updates on Clinical and Laboratory Biomarkers, and Implications for Neuroprotective Trials. Curr Neurol Neurosci Rep 2025. PMID 41134495. https://pubmed.ncbi.nlm.nih.gov/41134495/ — RBD-biomarkör-konsensusöversikt; seed amplification assays för α-synuklein lyfts som lovande antemortem-diagnostik. [G]
[S] CND Life Sciences. Syn-One Test. Produktinformation, 2024. https://cndlifesciences.com/syn-one-test/ — Tillverkardokumentation; provtagning, klinisk indikation, kostnad. Sekundärkälla — använd som komplement till Gibbons 2024 JAMA (#600). [S]

Differentiell droxidopa-respons PAF/PD vs MSA (kap. 30 — session 55, 2026-05-15)#

Sektionsbaserad numrering enligt etablerad design — sektionsrubriken särskiljer kollisionen med tidigare 596+-sektioner.

[P] Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension. BMC Neurol 2017;17:90. https://pmc.ncbi.nlm.nih.gov/articles/PMC5427571/ — Poolad subgruppsanalys av fas 3-studierna NOH301/302/306. Droxidopa förbättrade nOH-symtom signifikant vs placebo i hela materialet, men MSA-subgruppen (n = 55) var inte statistiskt skild från placebo — författarna betonar att subgruppen var liten och hade ovanligt stor placeboeffekt (underpowered, ej bevis för utebliven effekt). Effekt tydligast vid PD och PAF. Mekanistisk förklaring: nOH vid PD/PAF beror på postganglionär denervering, vid MSA på centralt fel med bevarade postganglionära fibrer. Stöder subtyps-styrt behandlingsval i kap. 30.1. [P]

Strukturerad uteslutning av icke-neurogen OH — STOPPFall + Bhanu/Mol + AHA 2024 + Gillmore-amyloidos + endokrint + PPH (kap. 04.7 steg N1–N5, kap. 04.8, kap. 10.0/10.1.1/10.5, diagnostisk-guide Del A/F/G — session 57, 2026-05-17)#

Sektionsbaserad numrering enligt etablerad design — sektionsrubriken särskiljer kollisioner med tidigare 596+-sektioner.

[P] Bhanu C, Nimmons D, Petersen I, et al. Drug-induced orthostatic hypotension: A systematic review and meta-analysis of randomised controlled trials. PLoS Med 2021;18(11):e1003821. doi:10.1371/journal.pmed.1003821. PMID 34752479. PMC8577726. https://pubmed.ncbi.nlm.nih.gov/34752479/ — Meta-analys av 69 RCT:er; centralt verkande antihypertensiva (klonidin, metyldopa, moxonidin) OR 2,4 (95 % KI 1,55–3,74) för OH — högst i analysen. α₁-BPH-blockerare, tricykliska, dopaminagonister, antipsykotika, opioider, diuretika klassrankade. Polyfarmaci är additiv — kumulativ risk över klasser. [P]
[P] Seppala LJ, Petrovic M, Ryg J, et al. STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk): a Delphi study by the EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs. Age Ageing 2021;50(4):1189–1199. doi:10.1093/ageing/afaa249. PMID 33543764. https://pubmed.ncbi.nlm.nih.gov/33543764/ — EuGMS-Delphi-konsensus, 14 läkemedelsklasser identifierade som fallriskdrivare hos äldre. Operativ algoritm per klass: när överväga utsättning, titreringsstrategi, monitoreringsfynd som motiverar avbrytande. STOPPFall-listan är översatt och tillgänglig i Sverige via Janusinfo. [P]
[P] Briggs R, Donoghue O, Lima-Costa MF, et al. The association between STOPPFall medication use and orthostatic hypotension in community-dwelling older people. Age Ageing 2025;54(12):afaf347. doi:10.1093/ageing/afaf347. https://academic.oup.com/ageing/article/54/12/afaf347/8374023 — Populationsbaserad valideringsstudie >65 år: ≥2 STOPPFall-mediciner är oberoende associerade med klassisk OH, fördröjd BP-återhämtning och signifikant lägre SBP vid 30, 60, 90 och 120 sek efter uppresning. Dosberoende på antal klasser. [P]
[G] Juraschek SP, Cluett JL, Belanger MJ, et al. Orthostatic Hypotension in Adults With Hypertension: A Scientific Statement From the American Heart Association. Hypertension 2024;81(3):e16–e30. doi:10.1161/HYP.0000000000000236. PMID 38205630. https://pubmed.ncbi.nlm.nih.gov/38205630/ — Selektiv deprescribing-strategi: utsätt klasser med högst OH-bidrag (centralt verkande, α₁-BPH-blockerare, tricykliska, opioider) före klasser med stor mortalitetsvinst (ACE/ARB, β-blockerare vid HFrEF, SGLT2-hämmare). Tidsanpassad dosering ("nightly antihypertensives"). AHA noterar själv att deprescribing-strategin saknar randomiserad utfallsevidens — konsensus-baserad. [G]
[P] Raj SR, Biaggioni I, Yamhure PC, et al. Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. Circulation 2005;111(13):1574–1582. doi:10.1161/01.CIR.0000160356.97313.5d. PMID 15781744. https://pubmed.ncbi.nlm.nih.gov/15781744/ — Raj-paradoxen. POTS-kohort med låg plasmavolym (¹³¹I-albumin) visade oförändrad PRA (0,79 vs 0,79 ng·mL⁻¹·h⁻¹) och lägre aldosteron (190 vs 380 pmol/L, p=0,017) jämfört med kontroller — inappropriat RAAS-suppression vid hypovolemi. Relevant för OH med hypovolem fenotyp. [P]
[P] Mar PL, Raj V, Black BK, et al. Impaired Renin Activity in Postural Orthostatic Tachycardia Syndrome. J Pers Med 2023;13(7). PMC10380257. https://pmc.ncbi.nlm.nih.gov/articles/PMC10380257/ — Bekräftar Raj-paradoxen: renin-aktiviteten är funktionellt nedsatt vid POTS, inte binjurefunktionen i sig. [P]
[P] Stewart JM, Medow MS, Visintainer P, et al. Adrenal Gland Response to Adrenocorticotropic Hormone is Intact in Patients with Postural Orthostatic Tachycardia Syndrome. J Endocr Soc 2024;8(10):bvae142. PMC11409324. https://pmc.ncbi.nlm.nih.gov/articles/PMC11409324/ — ACTH-test visar intakt binjurefunktion vid POTS — bekräftar att Raj-paradoxen ligger på renin-/RAAS-nivå, inte i binjuren. [P]
[G] Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016;101(2):364–389. doi:10.1210/jc.2015-1710. PMID 26760044. https://pubmed.ncbi.nlm.nih.gov/26760044/ — Endocrine Society-konsensus. Cosyntropin-test 250 µg, peak <500 nmol/L vid 30–60 min talar för insufficiens. Plasma-ACTH särskiljer primär från sekundär. Anti-21-hydroxylas vid autoimmun etiologi. [G]
[P] Husebye ES, Pearce SH, Krone NP, Kämpe O. Adrenal insufficiency. Lancet 2021;397(10274):613–629. PMID 33484633. https://pubmed.ncbi.nlm.nih.gov/33484633/ — Modern översikt över primär binjurebarksinsufficiens (Addisons sjukdom). Klassisk presentation med OH + hyponatremi + hyperkalemi + hyperpigmentering + saltbegär. [P]
[G] Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99(6):1915–1942. doi:10.1210/jc.2014-1498. PMID 24893135. https://pubmed.ncbi.nlm.nih.gov/24893135/ — Endocrine Society-konsensus. Plasma fria metanefriner sens ≈99 % / spec ≈89 % — förstahandsval. Provtagningsfallgropar: levodopa, tricykliska, klozapin, paracetamol, MAO-hämmare → falskt förhöjda värden. [G]
[P] Manger WM, Gifford RW. Pheochromocytoma. J Clin Hypertens 2002;4(1):62–72. PMID 11821644. https://pubmed.ncbi.nlm.nih.gov/11821644/ — Klassisk översikt; 30–40 % av epinefrin-dominanta tumörer presenterar med ortostatisk hypotension mellan attacker — paradoxal presentation. Mekanism: kronisk katekolamin-medierad hypovolemi, baroreflex-desensitisering, adrenerg receptor-nedreglering. [P]
[P] Tomkins M, Lawless S, Martin-Grace J, et al. Central and nephrogenic diabetes insipidus: updates on diagnosis and management. Front Endocrinol 2024;15:1479764. PMC11750692. https://pmc.ncbi.nlm.nih.gov/articles/PMC11750692/ — DI som sen orsak till OH via volymförlust och hypernatremi vid nedsatt törstrespons. Kopeptin (direkt vasopressin-mått) byter ut det klassiska vattendeprivationstestet vid flera centra. Central DI → desmopressin (snabb effekt på OH). [P]
[P] Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133(24):2404–2412. doi:10.1161/CIRCULATIONAHA.116.021612. PMID 27143678. https://pubmed.ncbi.nlm.nih.gov/27143678/ — Gillmore-algoritmen. 1217 patienter från 7 amyloidos-center, 5 länder. Eko + obligatorisk FLC/SPEP/UPEP-uteslutning av AL före ⁹⁹ᵐTc-PYP-skintigrafi. Grad 2–3 + negativt monoklonalt protein → ATTR-CM (specificitet och PPV 100 %, 95 % KI 98,0–100). TTR-genetik särskiljer h-ATTR från wt-ATTR. Operativ standard 2026. [P]
[P] Eapen S, Edwards M, McCall L, et al. False positive technetium-99m pyrophosphate scintigraphy in a patient with cardiac amyloidosis light chain. J Nucl Cardiol 2021. PMID 33907108. https://pubmed.ncbi.nlm.nih.gov/33907108/ — Falskt positiv PYP vid AL-amyloidos förekommer. Understryker varför FLC/SPEP-uteslutning är obligatorisk före PYP-tolkning — AL kräver akut hematologisk behandling, feltypning som ATTR förvärrar prognosen katastrofalt. [P]
[G] Kittleson MM, Ruberg FL, Ambardekar AV, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis. J Am Coll Cardiol 2023;81(11):1076–1126. PMID 36697135. https://pubmed.ncbi.nlm.nih.gov/36697135/ — ACC-konsensus om multidisciplinär amyloidos-vård (kardiologi + hematologi + neurologi + amyloidos-center). [G]
[P] Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-ACT). N Engl J Med 2018;379(11):1007–1016. doi:10.1056/NEJMoa1805689. PMID 30145929. https://pubmed.ncbi.nlm.nih.gov/30145929/ — Pivotal RCT för tafamidis vid ATTR-CM (wild-type och hereditär). Förlängd överlevnad och minskad sjukhusinläggning. [ETABLERAD]. [P]
[P] Pelliccia F, Cecchi F, Olivotto I, Camici PG. Syncope in Aortic Stenosis: Not Always What It Seems. J Clin Med 2023;12(8). PMC10129862. https://pmc.ncbi.nlm.nih.gov/articles/PMC10129862/ — AS-OH-mekanism: fixerad CO + baroreflex-hyperaktivering. Midodrin/fludrokortison kan förvärra AS-OH (ökat afterload + preload) — eko före farmakologisk OH-behandling vid äldre med systoliskt blåsljud. [P]
[P] Levine BD, Zuckerman JH, Pawelczyk JA. Cardiac atrophy after bed-rest deconditioning: a nonneural mechanism for orthostatic intolerance. Circulation 1997;96(2):517–525. PMID 9244220. https://pubmed.ncbi.nlm.nih.gov/9244220/ — Levine/Fu-paradigmet. 6 veckors sängläge → kardiell atrofi + försämrad ortostatisk tolerans utan primär autonom dysfunktion. Strukturerat reträningsprogram ("Dallas-protokollet") reverserar både kardiell storlek och ortostatisk tolerans. Basen för CHOP-protokollet vid pediatrisk POTS. [P]
[P] Goldstein DS, Cheshire WP. Orthostatic hypotension and anemia. CMAJ 2025;197(5):E135. https://www.cmaj.ca/content/197/5/E135 — Klinisk översikt: anemi → OH via reducerad viskositet + NO-medierad vasodilatation. Hb-korrektion bör övervägas innan symtomatisk OH-behandling vid Hb <105/115 g/L. [P]
[P] Jian Z, Li H. Acarbose for Postprandial Hypotension With Glucose Metabolism Disorders: A Systematic Review and Meta-Analysis. Front Cardiovasc Med 2021;8:663635. PMC8172613. https://pmc.ncbi.nlm.nih.gov/articles/PMC8172613/ — Meta-analys av små RCT:er; SBP-stegring 15–20 mmHg postprandialt med acarbose 50–100 mg före måltid. Konsistent positiv riktning; långtidseffekt på fallrisk och funktionellt utfall otestat. [ETABLERAD] för PPH-indikation. [P]
[P] Shibao C, Gamboa A, Diedrich A, et al. Acarbose, an α-Glucosidase Inhibitor, Attenuates Postprandial Hypotension in Autonomic Failure. Hypertension 2007;50(1):54–61. doi:10.1161/HYPERTENSIONAHA.107.091355. https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.107.091355 — Klassisk mekanistisk studie av acarbose vid PPH hos autonom svikt. [P]
[P] Mejilla A et al. Acarbose Unveiled: A Breakthrough in Postprandial Hypotension Treatment. Cureus 2024;16(6). PMC11246765. https://pubmed.ncbi.nlm.nih.gov/39006592/ — Modern översikt över PPH-prevalens (upp till 46 % slutenvård äldre), patofysiologi och acarbose-behandling. [P]

Behandlingsprediktiva biomarkörer vid nOH — Palma 2018 supin-NE-tröskel, Ramirez 2021 atomoxetin, Goldstein 2024 triad-biomarkör, Goldstein 2025 DHPG-axeln, AAG-screening, PMNFD/SGNFD (kap. 04.6.3, 10.0.1, 26.3, 30 — session 59, 2026-05-19)#

Sektionsbaserad numrering enligt etablerad design — sektionsrubriken särskiljer kollisioner med tidigare 596+-sektioner.

[P] Palma JA, Norcliffe-Kaufmann L, Martinez J, Kaufmann H. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension. Neurology 2018;91(16):e1539–e1544. doi:10.1212/WNL.0000000000006369. PMID 30232253. PMC6202942. https://pubmed.ncbi.nlm.nih.gov/30232253/ — Class I-evidens för behandlingsprediktiv biomarkör vid nOH. Prospektiv blindad observationsstudie n = 20, Vanderbilt/NYU. Supin plasma-NE <219,5 pg/mL predikterar droxidopa-pressor-respons (≥10 mmHg SBP-ökning) med sens 83 %, spec 93 %. Mekanism: denervations-supersensitivitet av α-adrenerga receptorer vid postganglionär lesion. Begränsningar: liten kohort, studiespecifik tröskel, ingen svensk validering. [P]
[P] Ramirez CE, Okamoto LE, Arnold AC, Gamboa A, Diedrich A, Choi L, Raj SR, Robertson D, Biaggioni I. Predictors of the Pressor Response to the Norepinephrine Transporter Inhibitor, Atomoxetine, in Neurogenic Orthostatic Hypotension. Hypertension 2021. PMID 34176285. PMC9192331. https://pubmed.ncbi.nlm.nih.gov/34176285/ — Atomoxetin (NET-inhibitor) ger signifikant pressor-effekt vid nOH särskilt i MSA-subgruppen. Högre plasma-NE modest associerat med större pressor-respons (motsatt mönster jämfört med droxidopa). Författarna konkluderar att varken plasma-NE eller kardiell sympatisk bevarande är tillräckligt robust som enskild prediktor — kombination med klinisk fenotypning krävs. [P]
[P] Okamoto LE, Shibao CA, Gamboa A, Diedrich A, Raj SR, Black BK, Robertson D, Biaggioni I. Synergistic Pressor Effect of Atomoxetine and Pyridostigmine in Patients With Neurogenic Orthostatic Hypotension. Hypertension 2018. https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.118.11790 — Kombinationen atomoxetin + pyridostigmin ger synergistisk pressor-effekt utan supin BP-förvärring vid behandlingsrefraktär nOH. Klinisk relevans vid samtidig supin hypertoni. [P]
[P] Kaufmann H, Norcliffe-Kaufmann L, Palma JA. Norepinephrine Reuptake Inhibition, an Emergent Treatment for Neurogenic Orthostatic Hypotension. Hypertension 2024. PMC11168875. https://pmc.ncbi.nlm.nih.gov/articles/PMC11168875/ — Review om NET-inhibitor-strategin; introducerar konceptet behandlingsprediktiv vs diagnostisk biomarkör explicit. [P]
[P] Goldstein DS, Sullivan P, Cooney A, et al. A pathophysiological biomarker combination separates Lewy body from non-Lewy body neurogenic orthostatic hypotension. Clin Auton Res 2024. PMID 38844644. doi:10.1007/s10286-024-01035-2. https://pubmed.ncbi.nlm.nih.gov/38844644/ — Triad-biomarkör: ¹⁸F-dopamin myokardiell radioaktivitet + UPSIT (lukttest) + α-syn–TH-kolokaliseringsindex i hudbiopsi (arrector pili). Separerar fullständigt Lewy-body-nOH från icke-Lewy-body-nOH (MSA) med p < 0,0001 för var och en. n = 44 (31 LB, 13 icke-LB). Replikation i bredare kohorter saknas. [P]
[P] Goldstein DS, Sullivan P, Cooney A, Holmes C, Sharabi Y. 3,4-Dihydroxyphenylglycol levels separate multiple system atrophy from Parkinson disease with orthostatic hypotension. Clin Auton Res 2025. doi:10.1007/s10286-025-01150-8. https://link.springer.com/article/10.1007/s10286-025-01150-8 — DHPG-axeln. CSF-DHPG ↓ vid MSA; plasma-DHPG ↓ vid PD+OH. CSF/plasma-DHPG-ratio "respektabel" ROC-separation. Retrospektiv NIH-kohort 1995–2024; specifika AUC-värden ej i abstract. [P]
[P] Goldstein DS, Holmes C, Sharabi Y. Plasma biomarkers of decreased vesicular storage distinguish Parkinson disease with orthostatic hypotension from the parkinsonian form of multiple system atrophy. Clin Auton Res 2015. PMC5248558. https://pmc.ncbi.nlm.nih.gov/articles/PMC5248558/ — Tidigare F-DOPAC- och F-DOPAC:DHPG-kvot-evidens via vesikulär lagringsdefekt. Förelöpare till Goldstein 2025-DHPG-axeln. [P]
[P] Frontiers Cell Infect Microbiol 2025 — Immunotherapies for postural orthostatic tachycardia syndrome, other common autonomic disorders, and Long COVID: current state and future direction. PMC12515974. https://pmc.ncbi.nlm.nih.gov/articles/PMC12515974/ — Review som konstaterar att AAG-initiala symtom är "lätta att förbise"; uppskattar 2–5 % AAG-prevalens i kronisk OH-kohort vid systematisk gAChR-screening. [P]
[P] Sandroni P, Vernino S, Klein CM, et al. Idiopathic autonomic neuropathy: comparison of cases seropositive and seronegative for ganglionic acetylcholine receptor antibody. Arch Neurol 2004 / PMC2837591. https://pmc.ncbi.nlm.nih.gov/articles/PMC2837591/ — Seropositiv vs seronegativ AAG-respondens: ~80+ % seropositiva svarar på immunterapi vs ~50–60 % seronegativa. [P]
[P] Hineno A et al. (japansk multicenter, 2022) — Diagnostic significance and clinical features of AAG. PMC9364197. https://pmc.ncbi.nlm.nih.gov/articles/PMC9364197/ — Multicenter n = 31 seropositiv AAG; 87 % rapporterade någon klinisk förbättring efter kombinerad IVIG/plasmaferes/steroider. Observationell evidens utan RCT. [P]
[P] Frontiers Hum Neurosci 2025 — Autonomic nerve fiber markers PMNFD (piloerector muscle nerve fiber density) and SGNFD (sweat gland nerve fiber density) beyond standard IENFD. PMC12847426. https://pmc.ncbi.nlm.nih.gov/articles/PMC12847426/ — Hudbiopsi-baserade autonom-specifika fiber-markörer. Autonom fiberskada kan förekomma vid normal somatisk IENFD. Inte rutin i svensk klinisk vård 2026. [P]
[R] Larsen NW, Hill A, Stiles LE, et al. Deep phenotyping in Long COVID with POTS. medRxiv 2025-04-28 preprint (ej peer-reviewed). https://www.medrxiv.org/content/10.1101/2025.04.28.25326508v1 — Standard-IENFD-utmaningen: 22 % LC-POTS hade "låg IENFD" med standardcutoffs men 38 % friska kontroller hade också det (n = 24 LC-POTS, en center). Replikation behövs. [R]
[P] Vernino S, Hopkins S, Wang Z. Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy. Auton Neurosci 2009;146(1–2):3–7. PMID 19129027. https://pubmed.ncbi.nlm.nih.gov/19129027/ — gAChR-axeln vid AAG; titer-svårighetsgradskorrelation. [P]
[P] Front Neurol 2024 (Tao L et al.) — Relapsed gAChR-positive AAG treated by plasma exchange and mycophenolate mofetil — case report. PMC11757093. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1533840/full — Fallrapport: plasmaferes-induktion + MMF-underhåll → 18 mån remission, antikroppar negativiserade. Hypotesgenererande. [P]

Behandlingsbara sällsynta OH-orsaker — DBH-brist, paraneoplastisk autonom, hereditära neuropatier (kap. 04.7 steg 4 + kap. 26.6 + kap. 30.2.5 + diagnostisk-guide Del G10 — session 60, 2026-05-20)#

[P] Biaggioni I. Dopamine Beta-Hydroxylase Deficiency. GeneReviews® (NCBI Bookshelf NBK1474; ursprunglig publikation 2003-09-04, senaste uppdatering 2024-09-26). https://www.ncbi.nlm.nih.gov/books/NBK1474/ — Auktoritativ klinisk översikt vid DBH-brist; <25 publicerade fall globalt; ultra-sällsynt autosomalt recessiv. Droxidopa 100–500 mg × 2–3 dagligen som biokemisk ersättningsterapi. Diagnos: plasma-NE och adrenalin omätbara + plasma-dopamin mätbart/förhöjt + DBH-sekvensering. (Obs: en separat översikt av Senard JM & Rouet P finns publicerad i Orphanet J Rare Dis 2006;1:7 (PMC1459119); det är en annan artikel än GeneReviews-kapitlet.) [P]
[P] Robertson D, Goldberg MR, Onrot J, et al. Isolated failure of autonomic noradrenergic neurotransmission. Evidence for impaired beta-hydroxylation of dopamine. N Engl J Med 1986;314:1494–1497. https://pubmed.ncbi.nlm.nih.gov/3713750/ — Första fallbeskrivningar av DBH-brist; etablerade biokemiska diagnoskriterier. [P]
[P] Biaggioni I, Robertson D. Endogenous restoration of noradrenaline by precursor therapy in dopamine-beta-hydroxylase deficiency. Lancet 1987;2(8569):1170–1172. https://pubmed.ncbi.nlm.nih.gov/2890806/ — Ursprunglig demonstration av droxidopa-ersättningsprincipen; mekanistisk grund för "kringgår DBH-blocket". [P]
[P] Robertson D, Haile V, Perry SE, Robertson RM, Phillips JA 3rd, Biaggioni I. Dopamine beta-hydroxylase deficiency. A genetic disorder of cardiovascular regulation. Hypertension 1991;18(1):1–8. https://www.ahajournals.org/doi/abs/10.1161/01.hyp.18.1.1 — Patofysiologisk grundläggning; longitudinella data med droxidopa-effekt över år. [P]
[P] Repetitive syncope in a newborn leading to pacemaker implantation: Evidence for dopamine beta-hydroxylase deficiency. Case report 2025. PMC12432978. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432978/ — Illustrerar diagnostisk fallgrop hos spädbarn — synkope vid uppresning misstas för primärt arytmiproblem, pacemaker-implantation utförd innan korrekt DBH-diagnos ställdes. [P]
[S] Orphanet. Dopamine beta-hydroxylase deficiency. Orpha number 230. https://www.orpha.net/en/disease/detail/230 — Orphan disease-databas med epidemiologiska och diagnostiska data. [S]
[S] Mayo Clinic Laboratories test catalog. Paraneoplastic Autoantibody Evaluation, Serum (PAVAL). https://neurology.testcatalog.org/show/PAVAL — Mayo:s testbeskrivning. Mayo flaggar att PAVAL inte längre är deras rekommenderade förstascreen vid misstänkt autoimmun neurologisk sjukdom (testet finns kvar men rekommenderas inte); fenotyp-specifika paneler (autonomic, encephalopathy, movement disorders, myelopathy, axonal neuropathy m.fl.) rekommenderas i stället eftersom PAVAL inte uppdaterats med alla kliniskt relevanta antikroppar och bred screening utan klinisk fenotyp ger för stor andel falska positiva (31 % av seror med ≥2 antikroppar utan klinisk konsekvens). [S]
[P] Li et al. Detection of paraneoplastic antibodies and their significance in paraneoplastic neurologic syndromes: a narrative review. Ann Transl Med 2024. https://atm.amegroups.org/article/view/106731/html — Översikt över paneluppdelning; rekommendation om fenotyp-specifik testning. Beskriver klinisk-pragmatisk distinktion cellytan vs intracellulär antigen för behandlingsrespons-prediktion. [P]
[P] Vernino S, Lennon VA. Paraneoplastic neurological autoimmunity associated with ANNA-1 autoantibody and thymoma. Neurology 2002;59:929–932. https://www.neurology.org/doi/10.1212/WNL.59.6.929 — ANNA-1 + thymom-associationen; cancerassociationsstatistik för anti-Hu (>85 % SCLC). [P]
[P] HLA-DR3∼DQ2 associates with sensory neuropathy in paraneoplastic neurological syndromes with Hu antibodies. PMC11377461 (2024). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11377461/ — HLA-association; bidrar till genetiska riskfaktorer för paraneoplastisk fenotyp. [P]
[P] Peringassery Sateesh I et al. Hereditary sensory autonomic neuropathy type VI in the age of genetic testing. Annals of the Child Neurology Society 2024. https://onlinelibrary.wiley.com/doi/full/10.1002/cns3.20085 — HSAN-VI-uppdatering; klassifikationsram för HSAN typ I–VIII med distinkta gener (modern molekylärgenetisk klassifikation). [P]
[P] Auer-Grumbach M. Hereditary sensory and autonomic neuropathies: types II, III, and IV. Orphanet J Rare Dis 2008 — PMC2098750. https://pmc.ncbi.nlm.nih.gov/articles/PMC2098750/ — Klinisk genomgång typ II–IV; diagnostiska kriterier och biokemiska evalueringar. [P]
[P] Hereditary Sensory and Autonomic Neuropathy — Report of Two Cases in Siblings and Review of Literature. PMC11407555 (2024). https://pmc.ncbi.nlm.nih.gov/articles/PMC11407555/ — Översikt med fallserie i syskon; illustrerar genotyp-fenotypvariabilitet. [P]
[S] What is Familial Dysautonomia? Helen Journal of Human Exceptionality 2025. https://helenjournal.org/february-2025/what-is-familial-dysautonomia — Sammanfattning av aktuellt 2025-läge för HSAN-III/Riley-Day; ASO-prövning startad 2024 (Tikun Therapeutics). [S]
[P] Norcliffe-Kaufmann L et al. Advances in the treatment of familial dysautonomia: what does the future hold? Expert Rev Neurother 2025. https://www.tandfonline.com/doi/full/10.1080/14737175.2025.2525400 — Aktuell terapeutisk pipeline för familjär dysautonomi; gen-/ASO-terapi-program. [P]
[P] Biegstraaten M, van Schaik IN, Wieling W, Hollak CEM, Linthorst GE. Autonomic neuropathy in Fabry disease: a prospective study using the Autonomic Symptom Profile and cardiovascular autonomic function tests. BMC Neurology 2010;10:38. PMID 20529242. PMC2892441. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2892441/ — Prospektiv autonom Fabry-data; ASP-instrument. Negativt fynd för ERT-effekt på etablerad autonom skada — ERT-behandlade kohort utan signifikant mindre autonom dysfunktion än obehandlade. [P]
[P] Hilz MJ et al. Enzyme replacement therapy improves cardiovascular responses to orthostatic challenge in Fabry patients. J Hypertens 2010. PubMed 20125036. https://pubmed.ncbi.nlm.nih.gov/20125036/ — Normaliserad kardiovaskulär respons efter 18–23 mån ERT — motstridigt fynd mot Cable 2010 (PMC2892441); illustrerar att tidig start vid mild sjukdom troligen ger bättre autonomt utfall än vid etablerad nervskada. [P]
[P] 2024 Update of the TSOC Expert Consensus of Fabry Disease. PMC11413953 (2024). https://pmc.ncbi.nlm.nih.gov/articles/PMC11413953/ — Uppdaterat 2024-konsensus från Taiwan Society of Cardiology; multidisciplinär hantering inklusive autonom påverkan. [P]
[P] Red flags in patients with hereditary transthyretin amyloidosis at diagnosis in a non-endemic area of Spain. Neurología 2024. https://www.sciencedirect.com/science/article/pii/S2173580822001705 — Operativ red-flag-checklista i icke-endemisk kontext (bilateral karpaltunnel, spinalstenos, EKG-LVH-diskordans, GI-dysmotilitet). Relevant för svensk vård utanför Skellefteå-trakten. [P]
[P] Genetic Screening for Hereditary Transthyretin Amyloidosis in the Population of Cammarata and San Giovanni Gemini Through Red Flags and Registry Archives. PMC12025942 (2025). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12025942/ — Populationsbaserad screening i italiensk endemisk klusterregion. Metodologisk parallell till svensk Skellefteå-amyloidos-utredning. [P]
[G] Diagnosis and Screening of Patients with Hereditary Transthyretin Amyloidosis (hATTR): Current Strategies and Guidelines. PMC7434568. https://pmc.ncbi.nlm.nih.gov/articles/PMC7434568/ — Översikt diagnostiska strategier och guidelines; standardalgoritm för h-ATTR-utredning. [G]
[P] Fontana M, Berk JL, Gillmore JD, et al. Vutrisiran in Patients with TTR Amyloidosis with Cardiomyopathy (HELIOS-B). N Engl J Med 2024. doi:10.1056/NEJMoa2409134. https://www.nejm.org/doi/abs/10.1056/NEJMoa2409134 — Fas 3 RCT (n = 655) av vutrisiran vs placebo vid ATTR-CM; HR 0,72 (95 % KI 0,56–0,93; p = 0,016) för kompositutfall. Tillsammans med HELIOS-A (ATTR-PN) etablerar vutrisiran sc var 3:e månad som [ETABLERAD] vid ATTRv-PN och ATTR-CM. [P]

Natriuretiska peptidsystemet och NPR1-antagonism vid POTS — REGN7544, prövningsstatus och den metabola baksidan (kap. 24.NP + kap. 25 + kap. 17.4d — session 63, 2026-05-23)#

[P] Jordan J, Pesta D, Moro C. Natriuretic peptide signaling as a therapeutic target in POTS: physiological opportunities and caveats. Clin Auton Res 2026;36(2):311–313. doi:10.1007/s10286-026-01194-4 (Correction: doi:10.1007/s10286-026-01200-9). https://link.springer.com/article/10.1007/s10286-026-01194-4 — Letter to the Editor/expertkommentar (ej originalstudie). Argumenterar att NPR1-antagonism är mekanistiskt sammanhängande mot hypovolemin vid POTS men att natriuretiska peptider även är metabola hormoner — kronisk NPR1-hämning kan teoretiskt försämra skelettmuskelenergetik, ansträngningsintolerans och långsiktig metabol hälsa. Efterlyser metabola/funktionella effektmått i framtida prövningar. [P]
[P] Kulapatana S, Urechie V, Rigo S, et al. Blood volume deficit in postural orthostatic tachycardia syndrome assessed by semiautomated carbon monoxide rebreathing. Clin Auton Res 2025;35(2):267–276. doi:10.1007/s10286-024-01091-8. https://pubmed.ncbi.nlm.nih.gov/39614968/ — Metodologiskt modern bekräftelse av reducerad blodvolym vid POTS. [P]
[P] Jacob G, Robertson D, Mosqueda-Garcia R, Ertl AC, Robertson RM, Biaggioni I. Hypovolemia in syncope and orthostatic intolerance — role of the renin-angiotensin system. Am J Med 1997;103(2):128–133. https://pubmed.ncbi.nlm.nih.gov/9274896/ — Klassisk dokumentation av hypovolemi vid ortostatisk intolerans. [P]
[P] Fu Q, VanGundy TB, Galbreath MM, et al. Cardiac origins of the postural orthostatic tachycardia syndrome. J Am Coll Cardiol 2010;55(25):2858–2868. doi:10.1016/j.jacc.2010.02.043. https://pmc.ncbi.nlm.nih.gov/articles/PMC2914315/ — Liten hjärtkammarstorlek och låg slagvolym vid POTS — låga fyllnadstryck. [P]
[P] Garland EM, Gamboa A, Nwazue VC, et al. Effect of High Dietary Sodium Intake in Patients With Postural Tachycardia Syndrome. J Am Coll Cardiol 2021;77(17):2174–2184. doi:10.1016/j.jacc.2021.03.005. https://pmc.ncbi.nlm.nih.gov/articles/PMC8103825/ — Högt saltintag ökar plasmavolym och dämpar ståtakykardi på gruppnivå; symtomeffekten är måttlig och individuellt variabel. [P]
[P] Jacob G, Shannon JR, Black B, et al. Effects of volume loading and pressor agents in idiopathic orthostatic tachycardia. Circulation 1997;96(2):575–580. https://pubmed.ncbi.nlm.nih.gov/9244228/ — Volymexpansion (iv koksalt) förbättrar ortostatisk takykardi. [P]
[P] Shibata S, Fu Q, Bivens TB, Hastings JL, Wang W, Levine BD. Short-term exercise training improves the cardiovascular response to exercise in the postural orthostatic tachycardia syndrome. J Physiol 2012;590(15):3495–3505. doi:10.1113/jphysiol.2012.233858. https://pmc.ncbi.nlm.nih.gov/articles/PMC3547265/ — Träningseffekten vid POTS kan delvis förmedlas via plasmavolymexpansion. [P]
[P] Pandey KN. Guanylyl cyclase/natriuretic peptide receptor-A: identification, molecular characterization, and physiological genomics. Front Mol Neurosci 2022;15:1076799. doi:10.3389/fnmol.2022.1076799. https://pmc.ncbi.nlm.nih.gov/articles/PMC9852736/ — Översikt över NPR1/GC-A:s molekylära och fysiologiska roll. [P]
[P] Raj SR, Biaggioni I, Yamhure PC, et al. Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. Circulation 2005;111(13):1574–1582. https://www.ahajournals.org/doi/10.1161/01.cir.0000160356.97313.5d — Renin-aldosteron-paradoxen: lågt aldosteron och otillräcklig natriumretention trots hypovolemi. [P]
[P] Jordan J, Birkenfeld AL, Melander O, Moro C. Natriuretic peptides in cardiovascular and metabolic crosstalk: implications for hypertension management. Hypertension 2018;72(2):270–276. doi:10.1161/hypertensionaha.118.11081. https://pubmed.ncbi.nlm.nih.gov/29941512/ — Natriuretiska peptider som metabola hormoner. [P]
[P] Engeli S, Birkenfeld AL, Badin PM, et al. Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. J Clin Invest 2012;122(12):4675–4679. doi:10.1172/JCI64526. https://pmc.ncbi.nlm.nih.gov/articles/PMC3533552/ — Humanstudie: natriuretiska peptider ökar skelettmuskelns oxidativa kapacitet. [P]
[P] Birkenfeld AL, Boschmann M, Moro C, et al. Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J Clin Endocrinol Metab 2005;90:3622–3628. doi:10.1210/jc.2004-1953. https://pubmed.ncbi.nlm.nih.gov/15741263/ — Humanstudie: ANP främjar lipolys vid fysiologiska koncentrationer. [P]
[P] Sujana C, Salomaa V, Kee F, et al. Natriuretic peptides and risk of type 2 diabetes: results from the BiomarCaRE consortium. Diabetes Care 2021;44(11):2527–2535. doi:10.2337/dc21-0811. https://pubmed.ncbi.nlm.nih.gov/34588210/ — Stor human kohort: låga natriuretiska peptidnivåer associerade med ökad typ 2-diabetesrisk (association, ej bevisad kausalitet). [P]
[P] Coue M, Badin PM, Vila IK, et al. Defective natriuretic peptide receptor signaling in skeletal muscle links obesity to type 2 diabetes. Diabetes 2015;64(12):4033–4045. doi:10.2337/db15-0305. https://pubmed.ncbi.nlm.nih.gov/26253614/ — Nedsatt NPR-signalering i skelettmuskel kopplar fetma till typ 2-diabetes. [P]
[P] Carper D, Lac M, Coue M, et al. Loss of atrial natriuretic peptide signaling causes insulin resistance, mitochondrial dysfunction, and low endurance capacity. Sci Adv 2024;10(41):eadl4374. doi:10.1126/sciadv.adl4374. https://pubmed.ncbi.nlm.nih.gov/39392880/ — Mekanistisk studie; det kausala påståendet vilar på experimentella modeller och ska ej i sig extrapoleras till människa. [P]
[R] Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS) (REGN7544 fas 2; protokoll R7544-POTS-2429). ClinicalTrials.gov NCT06593600. https://clinicaltrials.gov/study/NCT06593600 — Fas 2, dubbelblind, placebokontrollerad, enkeldos; n = 81; ålder 18–55; start 2024-11-13, beräknat slut 2026-06-11. [R]
[R] A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult Participants (REGN7544 fas 1, single ascending dose). ClinicalTrials.gov NCT05970718. https://clinicaltrials.gov/study/NCT05970718 — Fas 1 hos friska frivilliga; start 2023-08, primärt slutförd 2024-07. [R]
[R] A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension. ClinicalTrials.gov NCT06608901. https://clinicaltrials.gov/study/NCT06608901 — REGN7544 prövas även vid sepsisinducerad hypotoni — en andra hypotoni-indikation. [R]
[S] Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With POTS — clinical trial listing (study summary, eligibility criteria, study design; senast uppdaterad 2026-02-06). CenterWatch / WCG. https://www.centerwatch.com/clinical-trials/listings/NCT06593600/study-of-natriuretic-peptide-receptor-1-npr1-antagonist-in-adult-patients-with-postural-orthostatic-tachycardia-syndrome-pots — Prövningslistning med design-, inklusions- och exklusionsdetaljer; sponsorhärledd patientriktad beskrivning (fas 1: blodtrycksstegring som stabiliserades). [S]
[S] Safety Outcomes From a First-in-Human Study of a Novel Investigational Monoclonal Antibody, REGN5381, an Agonist to the Natriuretic Peptide Receptor 1. Circulation 2023;148(suppl_1):Abstract 13840. https://www.ahajournals.org/doi/10.1161/circ.148.suppl_1.13840 — Konferensabstrakt (ej fullständig peer-review). REGN5381 är en NPR1-agonist (motsatt verkningsriktning mot REGN7544) — illustrerar bidirektionell farmakologi mot samma receptor. [S]

Prognostiska prediktorer och återhämtning vid pediatrisk POTS (kap. 05.6, 31.6.1, 31.7, 36.5 — session 62, 2026-05-22)#

[P] Tao C, Lu W, Lin J, Li H, Li X, Tang C, Du J, Jin H. Long-Term Outcomes of Children and Adolescents With Postural Tachycardia Syndrome After Conventional Treatment. Front Pediatr 2019;7:261. doi:10.3389/fped.2019.00261. PMID 31316954; PMC6610301. Retrospektiv kohort, Peking University First Hospital; n = 121 (6 bortfall, 5,0 %), mean uppföljning 18,7 mån. Kumulativ symtomfri andel 48,4 % vid 1 år → 85,6 % vid 6 år. Två oberoende prediktorer (Cox): symtomduration före behandling (varje månad → −1,2 procentenheter kumulativ symtomfri andel) och maximal upprätt HR i ståtest (varje bpm → +2,1 procentenheter — kontraintuitivt, ej replikerat). Encenter, Kina; ingen extern validering. Motsvarar tidigare källa #107 (samma studie, nu med kvantitativa prediktordata integrerade). [P]
[P] Wang Y, Du J, Li X, Liu P, Wang Y, Liao Y, Jin H. Impact of Comorbidities on the Prognosis of Pediatric Postural Tachycardia Syndrome. Int J Gen Med 2021;14:8945–8954. doi:10.2147/IJGM.S339805. PMID 34866935; PMC8636694. Retrospektiv kohort, Peking University First Hospital; n = 275 (S-POTS 156, Co-POTS 119), 2016–2019, median uppföljning 24 mån, 21 bortfall (7,6 %). Mediantid till symtomremission 9 mån (S-POTS) vs 30 mån (Co-POTS); CSRR 1,748× högre utan komorbiditet; varje +1 kg/m² BMI → −5,1 % CSRR. Vanligaste komorbiditet: allergiska tillstånd (>1/3). Komorbiditet och BMI oberoende ogynnsamma faktorer. Encenter, Kina. [P]
[P] Yanagimoto Y, Ishizaki Y, et al. Exercise training improves circulatory dynamics in adolescents with postural orthostatic tachycardia syndrome. Front Pediatr 2025;13:1573842. doi:10.3389/fped.2025.1573842. PMC12176885. Kvasi-experimentell studie (allokering efter inläggningsmånad, ej randomiserad), Kansai Medical University, Japan; n = 28 (12–15 år, 19 pojkar), 17 träning / 11 kontroll, inneliggande recumbent ergometer 30 min/dag × 5/v × 4 v. Upprätt slagvolym 61,7→73,1 ml (P = 0,009), hjärtminutvolym 6,6→7,7 L/min (P = 0,001), peak VO₂ 30,3→33,2 (P = 0,005). Negativt fynd: ortostatiska testresultat (BP-fall, HR-ökning, max HR) oförändrade i båda grupperna. Liten kohort (n < 30 → begränsad power), pojkdominerad, japansk encenter. [P]

Kompenserande ortostatisk takykardi och mekanistisk fenotypning (kap. 3.6 + kap. 25 + kap. 13 + kap. 9.4 — session 61, 2026-05-21)#

[P] Chopra P. Postural orthostatic tachycardia syndrome: when dysautonomia misleads — a mechanistic argument for compensatory orthostatic tachycardia. Front Neurol 2026;17:1806502. doi:10.3389/fneur.2026.1806502. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2026.1806502/full — Narrativ, hypotesdriven enförfattar-review (Warren Alpert Medical School, Brown University) som argumenterar för att den ortostatiska takykardin vid POTS i många fall är ett kompenserande svar på en hemodynamisk stressor snarare än primär autonom svikt, och att etiketten "dysautonomi" rutinmässigt övertolkas. Föreslår femkategorisk mekanistisk fenotypning. Ingen finansiering, inga intressekonflikter deklarerade. Evidenstyngd: expertperspektiv, ej ny mätdata — ingen RCT har testat mekanism-styrd vs etikett-styrd vård. [P]
[P] Wei L, Cheng H, Chen S, Dai J, Li G, Ding D, Zhang X, Zhang K, Li J, Hou J. Pathophysiological mechanisms of Postural Orthostatic Tachycardia Syndrome analyzed by means of hemodynamics. PLOS One 2025;20(7):e0327236. doi:10.1371/journal.pone.0327236. PMID 40601666. https://pubmed.ncbi.nlm.nih.gov/40601666/ — Hemodynamisk fluid-structure interaction-modell (Kunming University of Science and Technology, Kina; Tokai University, Japan). Modellen förutsåg att 30 % minskad blodvolym sänker cerebralt blodflöde ~100 mL/min och att 50–100 % ökad arteriell styvhet ytterligare försämrar hjärtminutvolym/cerebral perfusion. Beräkningsmodell (in silico) — ej klinisk studie; modellresultat får inte extrapoleras direkt till klinisk rekommendation. [P]
[P] Characterisation of Postural Orthostatic Tachycardia Syndrome (POTS): Findings from a physician chart-audit pre- and post-COVID-19. Auton Neurosci 2026;263. PMID 41483737. https://pubmed.ncbi.nlm.nih.gov/41483737/ — Multinationell, webbaserad tvärsnitts-chart-audit; 153 läkare (77 % kardiologer) rapporterade data för 599 patienter (361 icke-COVID-utlöst + 238 COVID-utlöst POTS). ~80 % feldiagnostiserade innan POTS-diagnos, 25 % väntade ≥1 år, 5–8 undersökningar. COVID-utlöst POTS äldre med färre komorbiditeter. Metodologisk reservation: läkarrapporterad chart-audit — selektions-/rapporteringsbias möjlig; finansieringskälla ej verifierad i denna sammanställning. [P]
[P] Garland EM, Robertson D. Chiari I malformation as a cause of orthostatic intolerance symptoms: a media myth? Am J Med 2001;111:546–552. doi:10.1016/S0002-9343(01)00922-6. PMID 11705431. https://pubmed.ncbi.nlm.nih.gov/11705431/ — Kritisk analys som ifrågasätter Chiari I som etablerad orsak till ortostatisk intolerans; pekar på selektionsbias i remisskohorter. Motstridig mot kirurgiska serier (#600). [P]
[P] Henderson FC Sr, Francomano CA, Koby M, Tuchman K, Adcock J, Patel S. Cervical medullary syndrome secondary to craniocervical instability and ventral brainstem compression in hereditary connective tissue disorders: 5-year follow-up after craniocervical reduction, fusion, and stabilization. Neurosurg Rev 2019;42:915–936. doi:10.1007/s10143-018-01070-4 — Kirurgisk uppföljningsserie som rapporterar förbättring efter kraniocervikal stabilisering; observationell, selekterad remisskohort. Motstridig mot Garland & Robertson (#599); motsättningen olöst. [P]

LC-autonom dysfunktion — objektiv vs subjektiv evidensspricka 2025 (kap. 06, 12, 31, 32, 80 — session 64, 2026-05-26)#

[P] Bryarly M, Robbins NM, Roberts M, Cabrera J, Parsonnet J, Martin C, Hernandez RS, Barshikar S, Vernino S. Minimal Objective Autonomic Dysfunction in Long COVID. J Am Coll Cardiol 2025;86:2068–2070. doi:10.1016/j.jacc.2025.04.038. https://www.jacc.org/doi/10.1016/j.jacc.2025.04.038 — UT Southwestern Autonomic Disorders Clinic. Den största enskilda LC-autonomtestningskohorten publicerad t.o.m. 2025. 86 % av LC-patienter hade normala eller endast lätt avvikande objektiva tester (CASS, tilt, Valsalva, QSART); endast 12 % uppfyllde POTS-kriterier; 2 % signifikant autonom svikt. Negativ-resultats-referens. [P]
[P] Keller C, Mascarenhas L, Reyes J, et al. Association of autonomic dysfunction with long COVID: evaluation using quantitative autonomic testing. J Am Coll Cardiol 2025 (Dec 10). doi:10.1016/j.jacc.2025.09.1608. https://www.jacc.org/doi/10.1016/j.jacc.2025.09.1608 — M Health Fairview University Medical Center retrospektiv kohort 2019–2023. n = 341 (78 LC, 25 kontroller, 38 PAF). LC-patienter hade signifikant större HR-stegring/BP-fall vid tilt och lägre RSA/Valsalva-kvoter än kontroller; efter ålders-/könsjustering jämförbara med PAF-gruppen. Avvikelser kvarstod upp till 40 månader. Selektionsbias möjlig (specialistklinik, liten kontrollgrupp). [P]
[P] Long COVID as Intermediate Physiology: Rethinking Autonomic Dysfunction and Medical Uncertainty. J Am Coll Cardiol 2025. doi:10.1016/j.jacc.2025.10.083. https://www.jacc.org/doi/abs/10.1016/j.jacc.2025.10.083 — Editorial som introducerar intermediate physiology-begreppet för att beskriva fall där fysiologisk störning är kvantitativt mätbar på gruppnivå men subklinisk på individnivå. Användbar tolkningsram för Bryarly-vs-Keller-motsättningen. [P]
[P] Eastin EF, Machnik JV, Stiles LE, Larsen NW, Seliger J, Geng LN, Bonilla H, Yang PC, Miglis MG. Chronic autonomic symptom burden in long-COVID: a follow-up cohort study. Clin Auton Res 2025;35(3):453–464. doi:10.1007/s10286-025-01111-1. PMID 39907931. https://pubmed.ncbi.nlm.nih.gov/39907931/ — Stanford Autonomic Disorders Program-uppföljning av internationell online-LC-kohort. n = 526; median symtomduration 36 [30–40] mån. 71,9 % COMPASS-31 ≥ 20, 33 % nydiagnostiserad POTS, 37,5 % arbets-/studieavbrott. Etablerad referens för flerårig persistens av subjektiv autonom symtombörda vid LC. Intressekonflikt rapporterad: seniorförfattare Miglis har erhållit forskningsstöd från Argenx (ALPHA-sponsorn) — påverkar inte den observationella studiens slutsatser men ska redovisas vid citering. [P]
[P] Erratum: Correction: Chronic autonomic symptom burden in long-COVID: a follow-up cohort study. Clin Auton Res 2025;35(3):543. doi:10.1007/s10286-025-01123-x. PMID 40272628. — Publicerad korrigering till Eastin/Miglis 2025 (#599); en korrigering, ingen retraction. [P]
[P] Zadeh A et al. Letter to the editor regarding "Chronic autonomic symptom burden in long-COVID." Clin Auton Res 2025. doi:10.1007/s10286-025-01161-5. https://link.springer.com/article/10.1007/s10286-025-01161-5 — Ifrågasätter Eastin/Miglis-tolkningen. Författarsvar (#602) publicerat. Normal vetenskaplig diskussion. [P]
[P] Eastin EF et al. Response to letter by Zadeh et al. Clin Auton Res 2025. doi:10.1007/s10286-025-01174-0. https://link.springer.com/article/10.1007/s10286-025-01174-0 — Författarsvar till Zadeh-letter (#601). [P]
[P] Bhargava A, Geetha D, et al. Characterization of Postural Orthostatic Tachycardia Syndrome in Long COVID: Self-reported Data From the LISTEN Study. JACC Adv 2025;4(8):101873. doi:10.1016/j.jacadv.2025.101873. PMID 40883051. https://www.jacc.org/doi/10.1016/j.jacadv.2025.101873 — Yale LISTEN-kohort, n = 578; 28,9 % rapporterade nytillkommen POTS-diagnos. 78 % kvinnor. Signifikant högre hälsobörda hos LC-POTS-grupp. Begränsning: allt självrapporterat, ingen formell POTS-diagnostik. [P]
[P] Hira R, Baker JR, Siddiqui T, et al. Attenuated cardiac autonomic function in patients with long-COVID with impaired orthostatic hemodynamics. Clin Auton Res 2025. doi:10.1007/s10286-025-01107-x. https://link.springer.com/article/10.1007/s10286-025-01107-x — Calgary/Toronto-gruppen (Sheldon, Raj). Subgruppsuppdelning: LC-patienter med objektiva ortostatiska avvikelser har också attenuerad HRV och kardiovagal funktion. Stödjer stratifierad framställning. [P]
[P] Blitshteyn S, Funez-dePagnier G, Szombathy A, Hutchinson M. Immunotherapies for postural orthostatic tachycardia syndrome, other common autonomic disorders, and Long COVID: current state and future direction. Front Cell Infect Microbiol 2025;15:1647203 (publicerad 29 sept 2025). doi:10.3389/fcimb.2025.1647203. PMID 41089328. PMC12515974. https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2025.1647203/full — Officiell syntesreview som bekräftar ALPHA-negativt utfall ("no clinically meaningful improvement when compared to placebo for the MaPS score and COMPASS-31"). Auktoritativ kritisk översikt över immunterapier vid POTS/LC. Återanvändning av redan-existerande post (#568) — denna post inkluderar full kontext för session 64 + 65-användning. [P]
[S] American College of Cardiology Journal Scan: "Is Long COVID Associated With Autonomic Dysfunction?" 17 Dec 2025. https://www.acc.org/Latest-in-Cardiology/Journal-Scans/2025/12/17/15/00/Is-Long-COVID — Sekundärsammanfattning av Keller-studien (#597). Inte primärkälla. [S]
[S] The Sick Times (Oct 2025): "Vyvgart brought us back to life, but the Long COVID trial was canceled." https://thesicktimes.org/2025/10/10/vyvgart-brought-us-back-to-life-but-the-long-covid-trial-was-canceled-we-are-calling-on-the-nih-and-hhs-to-study-the-drug/ — Patientföreningssida som dokumenterar ALPHA-studiens stängning. Användbar som kontext för efgartigimod-pipeline-stängning hos argenx. [S]

Pediatrisk Long COVID och autonom dysfunktion (kap. 5.5, 6.1, 32 — session 65, 2026-05-28)#

[P] Morrow AK, Villatoro C, Kokorelis C, Rowe PC, Malone LA. Orthostatic Intolerance in Children With Long COVID Utilizing a 10-Minute Passive Standing Test. Clinical Pediatrics 2025;64(3). doi:10.1177/00099228241272053. PMID 39123312. https://journals.sagepub.com/doi/10.1177/00099228241272053 — Kennedy Krieger Pediatric Post-COVID-19 Rehabilitation Clinic (Baltimore). Retrospektiv genomgång av 92 barn med Long COVID, bedside 10-min passivt stå-test. 71 % uppfyllde kriterier för något ortostatiskt tillstånd (POTS, OT, klassisk OH, fördröjd OH, ortostatisk hypertension). Vanligaste symtom yrsel (67 %), trötthet (25 %), kroppssmärta (23 %). Selektionsbias mot remisspopulation noteras. Primärreferens för pediatrisk LC-OI-screening. [P]
[P] Mancuso T, et al. Autonomic cardiac function in children and adolescents with long COVID: a case-controlled study. European Journal of Pediatrics 2024. doi:10.1007/s00431-024-05503-9. PMC11035407. https://pmc.ncbi.nlm.nih.gov/articles/PMC11035407/ — Italiensk encenterstudie. 56 barn med LC (medelålder 10,3 ± 3,8 år) vs 27 friska kontroller; 12-avlednings-EKG + 24-h Holter. Signifikant lägre r-MSSD och högre VLF/LF/HF hos LC-barn — tolkat som relativ predominans av parasympatisk tonus. Skiljer sig från klassisk hyperadrenerg POTS-bild. Liten kohort, encenter, italiensk — replikering i annan population saknas. [P]
[P] Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study. Lancet Infect Dis 2025. doi:10.1016/S1473-3099(25)00476-1. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00476-1/fulltext — NIH RECOVER-Initiative. >460 000 barn vid 40 amerikanska pediatriska sjukhus under omikron-eran. Reinfektion var associerad med signifikant ökad risk för dysautonomi (inklusive POTS), myokardit (>3× högre), trombotiska händelser (>2× högre), trötthet, kognitiv nedsättning. Visar samband — inte bevisad kausalitet; retrospektiv journalbaserad design med selektionsbias. [P]
[R] Preprint-version: Reinfection with SARS-CoV-2 in the Omicron Era is Associated with Increased Risk of Post-Acute Sequelae of SARS-CoV-2 Infection: A RECOVER-EHR Cohort Study. medRxiv 2025-03-28. doi:10.1101/2025.03.28.25324858. https://www.medrxiv.org/content/10.1101/2025.03.28.25324858v1 — Preprint-version av #598 (mars 2025). Rapporterar bl.a. RR 1,59 (95 % KI 1,45–1,74) för arytmier vid reinfektion. Ej peer-reviewed i preprint-stadium; den definitiva versionen är #598. [R]
[P] Long COVID is here to stay—even in children. Lancet Infect Dis 2025 (editorial till #598). doi:10.1016/S1473-3099(25)00496-7. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00496-7/fulltext — Editorial-syntes som understryker behovet av långsiktig övervakning och vaccinationsstöd. [P]
[P] Individualized online exercise therapy aids recovery in pediatric long-COVID—findings from an exploratory randomized controlled trial. European Journal of Pediatrics 2026. doi:10.1007/s00431-025-06705-5. PMC12774993. https://pmc.ncbi.nlm.nih.gov/articles/PMC12774993/ — Encenter prospektiv exploratorisk RCT. n = 14, 9–17 år, median symtomduration 21 mån. 12-veckors-IOET: 6MWT 396,0 → 616,3 m; sit-to-stand 25,4 → 32,6. Liten kohort, ingen PESE-screening, hypotesgenererande. Internationell pediatrisk fysioterapikonsensus rekommenderar PESE-screening först. [P]
[P] Diagnosis and Management of Long COVID in Children and Adolescents: An Update after 5 Years of Clinical and Research Experience. Current Pediatrics Reports 2025. doi:10.1007/s40124-025-00352-y. https://link.springer.com/article/10.1007/s40124-025-00352-y — Strukturerad 5-årsuppdatering. Använder 2024 NASEM-kriterierna. Multimodal rehabilitering + KBT anpassad för kronisk sjukdom har visat förbättring; riktade läkemedelsbehandlingar för autonom dysfunktion appliceras fall-för-fall med begränsad högkvalitativ evidens. [P]
[P] A perfect storm: the immunological and pathophysiological landscape of pediatric post-COVID-19 condition. Frontiers in Immunology 2026. doi:10.3389/fimmu.2026.1794596. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1794596/full — Översikt över samverkande immunmekanismer vid pediatrisk LC: viruspersistens, latent virus-reaktivering (EBV), molekylär mimikry, mastcellsdysreglering, mikrobiomförskjutning. Pediatrisk immunsystemutveckling modulerar dessa mekanismer på sätt som skiljer från vuxen LC. Kontextram, inte ny mätdata. [P]
[F] Successful treatment of long-COVID postural tachycardia syndrome with epipharyngeal abrasive therapy in an adolescent patient: A case report. 2025. PMC12262939. https://pmc.ncbi.nlm.nih.gov/articles/PMC12262939/ — Fallrapport (n = 1). Beskriver adolescent med LC-POTS som genomgick veckovisa EAT-sessioner under 120 dagar med rapporterad förbättring. Får inte ensam utgöra grund för klinisk rekommendation — en enskild fallrapport [F] kan i bokens evidenshierarki inte etablera behandlingseffekt. Procedureffekten kan vara icke-specifik (regression mot medelvärdet, naturlig förloppsförbättring, placebo, terapeutisk allians). Nämns för fullständighet, inte som rekommendation. [F]
[S] Kennedy Krieger Institute press release (Sept 2024): "New Study Reveals Majority of Pediatric Long COVID Patients Develop a Dizziness Known as Orthostatic Intolerance." https://www.kennedykrieger.org/stories/news-and-updates/research-news-releases/new-study-reveals-majority-pediatric-long-covid-patients-develop-dizziness-known-orthostatic-intolerance — Institutionellt pressmeddelande som sammanfattar Morrow/Malone 2025-fyndet (#596). [S]
[S] EurekAlert/Lancet Infect Dis press release (sept 2025): "New study suggests risk of long COVID in children may be twice as high after a second infection." https://www.eurekalert.org/news-releases/1100133 — Pressmeddelande för #598. Sekundärsammanfattning. [S]
[S] Long COVID Physio: Post-Exertional Symptom Exacerbation (PESE). https://longcovid.physio/post-exertional-symptom-exacerbation — Internationell fysioterapikonsensus om PESE-screening innan träningsrehabilitering. Inte primärlitteratur; redovisar nuvarande praxisstandard från klinikergrupp specialiserad på LC-rehabilitering. [S]